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Mast cells (MCs) are long living cells widely distributed in mucosal and connective tissues, in close 
contact with blood vessels and the external environment. They are known for their predisposition 
to cross-talk with many cell types and in this work the mutual interplay between MCs and B cells 
has been object of interest. We focused our attention on the different MCs’ and B cells’ subsets that 
can communicate in the peritoneal cavity and the intestine: serosal and mucosal subtypes of MCs 
and B-1 and B-2 lineages of B lymphocytes. We uncovered that B-2 cells require MCs’ contribution 
for their activation but fail to significantly impact MC’s behaviour. On the other hand, B-1 cells do 
not need MCs to survive and achieve their functions, but exert an intriguing effect exacerbating the 
activation of MCs. Specifically, B-1 cells induce an increase in the synthesis and release of pro-
inflammatory mediators from IgE/Ag activated MCs and enhance their membrane expression of ST2, 
the receptor for the IL-33. This cytokine is an early danger-sensing molecule important in the 
activation of MCs in the pathological contexts studied in this work: the intestinal acute inflammation 
and colorectal cancer (CRC).  
MC-B cell interaction was then followed through in vivo analyses: the distribution of MCs was 
investigated in a B-1-deficient mouse model while B cells were characterized in MCs-lacking mouse 
models both in physiological condition and in the DSS-induced acute intestinal inflammation. The 
density of MCs resulted to be increased in the lungs and in the small intestine of the bumble B-1-
deficient mouse model studied in physiological conditions. On the contrary, the distribution of B cell 
subsets and B cells’ markers of activation were not altered in MCs-deficient mice. Differently, we 
were able to prove that the presence of MCs is important for the regulation of IgA responses in 
homeostasis and that MCs support the IgA skewing during the intestinal inflammation.  
Since chronic gut inflammation predisposes to the onset of CRC, and that the distribution and 
activation of both MCs and B cells are dramatically altered in this pathology, we explored whether 
MCs could influence the behaviour of B lymphocytes also in this context. In the subcutaneous CRC 
mouse model studied in this work, B cells infiltrate the tumor and accumulate in the tumor-draining 
lymph nodes (dLNs). We ascribe this observation to an increase of chemotactic factors among which 
CCL20 and CXCL13. Interestingly, in MC-deficient tumor-bearing mice, reduced tumor-infiltrating B 
cells and no increase of CCL20 and CXCL13 in dLNs, were observed; moreover in MC-reconstituted 
tumor-mice the wild type conditions were restored. In light of our data, we propose a model in 
which MCs’ direct interaction with cancer cells promotes the exacerbation of a milieu enriched in 
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pro-inflammatory factors; among these mediators, the MCs-derived TNF-α turned out to be 
responsible for the increased induction of CCL20 in cancer cells. This chemotactic factor is of great 
relevance since it is known both to enhance tumor spreading and to attract immune cell types in 
inflammatory sites. 
 
Collectively, our results provide novel insights in the MC-B cell cross-talk, emphasising that B-1 cells 
can support the allergic and inflammatory functions of MCs and, furthermore, for the first time 
trough in vivo experiments, we are able to show that MCs provide valuable support for IgA-
dependent humoral functions. During carcinogenesis, instead, the chemotaxis of B lymphocytes into 
CRC sites is indirectly promoted by the activation of  MCs. In conclusion, the specific signals that 
modify the microenvironment in these pathologies must be carefully considered when analysing 
MC/B cell interplay in order to design targeted therapies.   
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DCs: dendritic cells 
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EFG: epidermal growth factor 
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Flt3L: Fms-like tyrosine kinase 3 ligand 
FO: follicular (B cells) 
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GC: germinal center 
GM-CSF: granulocyte–macrophage colony-
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GMPs: granulocyte/monocyte progenitors 




IBD: inflammatory bowel disease  
ICAM-1: intracellular adhesion molecule 
ICS: intracellular staining 
IECs: intestinal epithelial cells 
Ig(s): immunoglobulin(s) 
ILC(2)s: (type 2) innate lymphoid cells 
iNKT: invariant natural killer T cells 
InsP3: inositol-1,4,5-trisphosphate 
ITAMs: tyrosine-based activation motifs 
K.I.: Knock-in 
K.O.: knock-out 
LFA-1: lymphocyte function-associated antigen  
LNs: lymph nodes 
LP: (intestinal) lamina propria 
LPS: lipopolysaccharide  
LT α1β2: lymphotaxin α1β2  
LTs: leukotrienes 
MAPKs: activation of the mitogen-activated protein 
kinases 
MC(s): mast cell(s) 
MCC: chymase-positive MCs  
MCCT: tryptase- and chymase-positive MCs 
MCp: MCs precursors 
MCPT: mast cell protease 
MCT: tryptase-positive MCs  
MHC: major histocompatibility complex 
MLNs: mesenteric LNs 
MMC(s): mucosal mast cell(s) 
MPPs : multipotent progenitor precursors 
mTORC1/2: rapamycin-sensitive mTOR complex1/2 
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NF: newly formed (B cells) 
NFAT: nuclear factor of activated T cells 
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PAF: platelet activating factor 
Pax5: paired box protein 5 
PC(s): plasma cell(s) 
PDMCs: peritoneal cell-derived MCs 
PG: prostaglandin 
PI3K: phosphatidylinositol 3-kinase  
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PIP3: phosphatidylinositol 3,4,5-triphosphate 




PKC: protein kinase C 
PLC: phospholipase C 
PMCs: peritoneal MCs 
RA: rheumatoid arthritis 
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RMB: Red Mast Cell and Basophil 
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SCF: stem cell factor 
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TLRs: through toll-like receptors 
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3.1. THE MAST CELL: A PECULIAR CELL IN THE IMMUNE SYSTEM 
 
Mast cells (MCs) belong to a unique cell population within the immune system with an ancient 
evolutionary history, in fact it is estimated that they appeared 450-500 million years ago in the first 
vertebrates. The presence of this innate  immune cell throughout the evolution leads to believe in 
the existence of a selective pressure favouring their survival and infers that MCs have beneficial and 
important roles1. In 1878 Paul Ehrlich was the first to characterize this cell in humans in close 
proximity to nerves and blood vessels. Great efforts have been made subsequently towards the 
understanding of the origin of MCs until the discovery of its hematopoietic multipotent progenitors 
in the bone marrow2. It is currently known that MCs can virtually be found in any body tissue, and 
that they are more abundant at tissues’ barriers where they can exert a role of immune “sentinels” 
not only in acute but also in chronic infections3. Activated MCs undergo a process defined 
degranulation that is a compound exocytosis that enables MCs to discharge their content very 
rapidly and efficiently4. MCs have been traditionally classified into subtypes according to their 
granular content and body distribution: chymase- and tryptase-positive MCs or only tryptase-
positive MCs and connective tissue- or mucosal-MCs, in humans and rodents respectively. However, 
more recent considerations overcome this paradigm: MC’s phenotype and functions are in fact 
largely shaped by the microenvironment and there are suggestions that a new classification of MCs 
is required5. Indeed, it is increasingly clear that these cells are characterized by a great phenotypical 
heterogeneity and functional plasticity6. 
 
3.1.1. MC’s origin, tissue maturation and in vitro studies  
One atypical feature concerning the development of the MC is that although this hematopoietic cell 
is produced and committed in the bone marrow, it accomplishes its maturation only in peripheral 
tissues. MCs origin has been long debated until, bi-potent progenitor cells capable of giving rise to 
both basophils and MCs precursors (MCp) inside the granulocyte/monocyte progenitors (GMPs), 
have been described and isolated in mouse spleen7 as showed in figure1. For this process a fine 
tuning of different transcription factors is required: GMPs expresses C/EBPα and give rise to a 
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progenitor with MC and basophil-forming capacity, when it downregulates C/EBPα and upregulates 
of GATA-2, GATA-3 and Hes-1. The switch off of C/EBPα and the upregulation of MIFT are essential 
for the commitment of MCp8. 
 
 
Figure 1: MCp development from the HSC. According to the illustrated model, hematopoietic stem 
cells (HSCs) originated in the bone marrow differentiate into multipotent progenitors (MPPs),  then 
into common myeloid progenitors (CMPs) and granulocyte/monocyte progenitors (GMPs). The 
GMPs population give rise to both MCs and basophils not only from an FCεRI+ subset but also from 
an FCεRI- population. Also MCs’ precursors (MCp) can express or not the FCεRI both in the bone 
marrow and in the blood. In tissues of C57BL/6 mice, MCp express low level of this receptor8. 
 
In vitro, MCp have a great capacity to undergo cell division9 but in situ proliferation is still a matter 
of debate. MCs are long-lived cells and, in the periphery precursors acquire, in a microenvironment-
driven way, the phenotype of mature cells capable of multiple degranulation during time10. MCs are 
greatly influenced by the modifications of the local environment (figure 3), for example, in several 
diseases, an altered accumulation of MCs is reported. This mastocytosis is likely due to an increased 
recruitment of immature precursors8 but mediators such as the stem cell factor (SCF) can also 
induce the proliferation of on-site MCs during the progression of the pathology11.  
MCs can be found in many different organs12, with a major representation in  the gastrointestinal 
tract13, the peritoneum (especially in the murine setting)14 the skin15 and the lungs. Rare MCs 
localized also in organs such as the spleen, lymph nodes (LNs), brain, pancreas and kidney, their 
numbers can increase with the development of inflammation or cancer16. Recently, Gentek 
et collaborators, with very elegant demonstrations, were able to segregate the hematopoietic 
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output of the yolk sac and the HSCs produced in the aorta-gonado-mesonephros. They utilized the 
Cdh5-CreERT2 mice and took advantage of the Cdh5 expression by all endothelial cells and its 
downregulation upon hematopoietic transition, and applied the temporally defined activation of 
Cdh5-CreERT2. The authors uncovered that MCs have dual developmental origins in primitive and 
definitive hematopoiesis: a first wave from the endothelium of the yolk sac that is dilute with a 
second wave of definitive MCs. Moreover, they observed that adult MC maintenance is generally 
bone marrow independent, supporting the idea that homeostatic maintenance and replenishment 
of MCs could be supported by in situ expansion of MCp or mature MCs17. 
 
 
Figure 2: Model of dual developmental origin of mouse skin MCs. This pattern shows that MCs 
can originate not only via primitive haematopoiesis but they are also generated with the definitive 
adult haematopoiesis. During embryogenesis, skin MCs would derive from the yolk sac vascular 
endothelium, on the contrary after birth MCs derive from HSCs. Surprisingly, in adult mice MCs 
homeostasis is independent from the bone marrow and it is suggested that there is a reservoir of 
tissue-resident MC precursors produced by HSCs during embryogenesis that is able to proliferate. 
Primitive MCs in adult skin look like adult MCs of definitive origin rather that embryonic primitive 
MCs (taken from commentary by Anja A. Wolf and Helen S. Goodridg17). 
 
The characteristic tissue residency of MCs makes their in vitro studies very difficult:  processes of 
direct isolation from tissues or differentiation protocols from MMPs in culture media are required. 
Murine fetal tissues such as the liver or the spleen are good sources of MCs progenitors. However, 
the bone marrow of young animals is the most easily accessible source of precursors and allows, 
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after addition of IL-3 or/and SCF, to induce the differentiation and the maintenance of bone-marrow 
derived MCs (BMMCs)18. Form the peritoneal cavity of rodents, and from a lesser amount the skin, 
instead, mature connective tissue MCs can be isolated and separated (these cells ex vivo are called 
peritoneal cell-derived mast cells (PDMCs)) 19. PDMCs need both IL-3 and SCF to survive and amplify 
in vitro after peritoneal cells collection and culture. 
 
 
Figure 3: MCp, by effect of different microenvironments, give rise to heterogeneous MCs 
populations. MCp (MCP in the figure), subject to genetic and epigenetic regulations, originate from 
the bone marrow and migrate in several  tissues. In periphery, they mature under the effect of 
different microenvironments (cytokines, growth factors, resident cells) acquiring very diverse 
phenotypes. Moreover, microenvironmental alterations (mediators of inflammation, pathologies 
etc.) can induce a further change in MCs’ phenotype and behaviour20. 
 
 
3.1.2. Main categories of MCs’ subsets 
In mouse mature MCs are subdivided in two main groups based on their anatomical location and 
granule composition: connective-tissue MCs (CTMCs), mainly localized in serosal cavities, around 
venules and nerves21, and mucosal MCs (MMCs). Both categories respond to IgE-mediated 
activation with signalling, degranulation, and inflammatory cytokines release but differ for 
biochemical and functional properties. In human the classification is based mostly on protease 
content. In brief, three main subsets of human MCs can be distinguished: tryptase-positive MCs 
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(MCT), chymase-positive MCs (MCC) and tryptase- and chymase-positive MCs (MCCT). MCT are more 
abundant in the alveolar wall and gastric mucosa, resemble MMCs in rodents and are predominantly 
present in the mucosal tissues of the gut and in the respiratory tract mucosa. MCC do not have 
specific localization nor abundancy in tissues, while MCCT are located predominantly in the skin and 
intestinal submucosa; both are similar to CTMCs in rodents and contain heparin and chondroitin 
sulphate A and E22.  
Concerning rodents, MMCs differ from the CTMCs for tissue localization and also for morphological 
and functional properties that are reflected in different histochemical properties and content of 
granule proteinases (Enerback L., 1987). MMCs express in basal conditions the transcripts for the 
MC protease-1 (MCPT1) and MCPT2 chymases and contain serotonin but low levels of histamine. 
CTMCs contain instead both serotonin and high levels of histamine; they express MCPT4 chymase, 
MCPT5 elastase, MCPT6 and MCPT7 tryptases and carboxypeptidase A3 (CPA3)23. The protease 
content however differs also for anatomical localization and inflammation state: MMCs in the 
intestine of T. spiralis infected mice expresses only MCPT1, while CTMCs expresses both MCPT4, 
MCPT5, MCPT6, MCPT7 and CPA324. In an allergic inflammation model both tracheal MMC and 
CTMC expressed all the six proteases, while in the proximal bronchi MMC expressed only MCPT1, 
MCPT6 and MCPT7 while CTMCs were still positive for all the six proteases25. In 2016 Dwyer et 
collaborators showed that MCs have tissue specific gene expression and among the most 
differentially expressed genes proteases, G protein-coupled receptors and integrins have been 
found26. To distinguish between MMCs and CTMCs proteoglycan content of the granules are widely 
used. Two different glycosaminoglycans (GAGs) are contained into MCs, heparin and chondroitin 
sulphates; MMCs contain mainly chondroitin sulphate A, B and E while CTMCs hold both chondroitin 
sulphate E and high amounts of heparin27. The Safranin dye is indeed known to stain with more 
intensity CTMCs28. 
This heterogeneity can be reproduced also in vitro: BMMCs cultured in the presence of the only IL-
3 cytokine can be considered as immature MCs with a phenotype that is intermediate between 
mucosal and connective MCs; indeed they express MCPT5, MCPT6 and CPA3 (which is a CTMC-like 
phenotype) but the proteoglycan content is more similar to those of MMCs (low levels of histamine 
and heparin). If BMMCs are instead grown on a monolayer of fibroblast and in presence of IL-3 or 
the presence of both IL-3 and SCF,  the granule content of heparin and histamine are augmented 
hence these cells become similar to CTMCs. Moreover, the addition of factors such as IL-9, IL-10 or 
IL-33 induces higher expression of MCPT1, MCPT2 and MCPT6 respectively29,30. 
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All these aspects emphasize the great plasticity of MCs, their maturation depends on 
microenvironmental status and tissue specificity, making reductive the classification based only on 
granules content. 
 
3.1.3. MC’S biology: activation and mediators  
MCs are able to respond to a plethora of different stimuli and the high density of receptors on their 
membranes makes them particularly sensitive to the microenvironment. Moreover, the great 
abundance of pre-stored and newly synthesized mediators makes these cells also powerful 
modulators of the tissue microenvironment. MCs recognise pathogens through toll-like receptors 
(TLRs), C-type lectin receptors (CLRs), complement receptors and respond to soluble mediators 
released in the context of infection through several cytokine- and chemokine-receptors31. MCs 
degranulation can occur in response to various external stimuli among which IgE receptor cross-
linking is the most known, but they can also rapidly release their mediators in response to 
complement activation, neuropeptides and certain toxins. Depending on the type of the stimulus 
they can be activated by the binding of the IgE to the FcεRI in the cross-linking of bi- or multivalent 
antigens (Ags), or by the binding of the FcγRs by immune complexes (this last receptor in human 
MCs); but their activation can also be inhibited by the binding of receptors such as the FcγRIIb32.  
 
3.1.3.1. FcεRI dependent activation 
 
This type of MC’s activation is the best characterized and the most studied since, traditionally, MCs 
have been mostly considered as essential components of IgE-mediated class type I hypersensitivity 
reactions. The signal begins with the cross-linking of IgE/Ag complexes on MCs’ surface FcεRI 
receptor. This is a tetrameric receptor which contains the IgE-binding a-chain, a membrane-tetra 
spanning b-chain and a disulphite-linked homodimer of the g-chain. The Ag is recognized by the 
FcεRIα-bound IgE that induces the receptor aggregation, the activation of SRC family kinases (SFKs) 
and tyrosine phosphorylation of the receptor subunits. Four main SRC kinases have been described 
in FcεRI activation: LYN, SYK, FYN and HRC. These SFKs simultaneously initiate independent cascades 
that induce a complex intracellular signalling that controls MC’s activation. This process is tightly 
regulated: two main complementary pathways are described, the first comprises LYN and SYK and 
activates the phospholipase Cγ (PLCγ), the second one depends on FYN and activates the 
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phosphatidylinositol 3-kinase (PI3K)33. All these events are key factors during allergic inflammatory 
responses and the two pathways are briefly illustrated in figure 4. 
  
The canonical signalling of the FcεRI 
 
The highest activation is guaranteed by the presence of LYN kinase in lipid raft domains at the 
plasma membrane. LYN is responsible for the phosphorylation of tyrosine residues in the FcεRI β-
chain and γ-chain that are present in the immune receptor tyrosine-based activation motifs (ITAMs). 
When phosphorylated, the β- and γ-chain ITAMs provide high-affinity docking sites for the SH2 
domains of LYN22 and for the SH2 domains of the ZAP70 (ζ-chain-associated protein kinase of 70 
kDa)- related tyrosine kinase SYK (spleen tyrosine kinase), respectively. This allows trans- and 
autophosphorylation of its catalytic domain, as well as phosphorylation by LYN, hence increasing its 
catalytic activity34. SYK and LYN promote the tyrosine phosphorylation of the transmembrane 
adaptor molecule LAT that is fundamental for the initiation of the downstream signalling pathways 
and serve as scaffold for recruitment of other proteins35. Its four terminal tyrosine residues (Y132, 
Y171,Y191 and Y226) are reported to be crucial and sufficient for the ability of LAT to regulate 
degranulation signalling in MCs36. The most important protein that is recruited by LAT, is PLCγ which 
catalyses the hydrolysis of phosphatidylinositol-4,5- bisphosphate (PtdIns(4,5)P2) in the plasma 
membrane inducing the formation of two products inositol-1,4,5-trisphosphate (InsP3) and 
diacylglycerol (DAG). The InsP3 induces a transient but sustained mobilization of cytosolic calcium 
and DAG induces the activation of protein kinase C (PKC). These two signals are essential for the 
induction of the degranulation33. In the final steps of this process, the guanine-nucleotide-exchange 
factors VAV56 and SOS57 are needed to induce cytokine production: they induce the shift to the 
GTP bound-active state of RAS. RAS in turns regulates the RAF-dependent pathway that leads to 
phosphorylation and activation of the mitogen-activated protein kinases (MAPKs) extracellular-
signal-regulated kinase 1 (ERK1) and ERK2, JUN amino terminal kinase (JNK) and p3837. Finally, 
together with the calcium influx and the subsequent nuclear translocation of nuclear factor of 
activated T cells (NFAT), these pathways lead to the activation of NF-kB, the activator protein 1 (AP1) 
members JUN and FOS and therefore cytokine expression is induced38. 
 




Figure 4: Main and complementary signalling from the FcεRI in MCs: (a) The canonical FcεRI pathway 
includes a series of consecutive stages from the FcεRI aggregation starting from LYN that associates with 
ITAM domains and induces SYK. Finally LAT is phosphorylated and it accommodates the signalling 
required for the production of the different pro-inflammatory mediators: the activation of PLCγ and PKC 
and the increase of calcium mobilization are essential for the degranulation, at the other side the 
mitogen MAPK pathway is fundamental for cytokines production. (b) In the alternative pathway FYN- 
and GAB2-dependent phosphorylation of PI3K catalyses a further calcium influx which sustains the initial 
PLCγ-dependent calcium mobilization and the activation of the AKT/mTOR pathway. NTAL might 
regulate these processes by binding GRB2 following phosphorylation of NTAL in a LYN- and SYK-
dependent manner. Adapted from33. 
 
 
The complementary activation pathway of the FcεRI 
 
The discovery of the IgE/Ag complementary activatory pathway arose with the discovery that in 
addition to LYN, FYN, another SRC-kinase, was essential for degranulation and cytokine production 
in MCs39. LAT, in this pathway, is not essential and PLCγ, on the contrary, is not activated. PI3K is 
activated through the phosphorylation of the cytosolic adaptor molecule GAB2 (GRB2-associated 
binding protein 2)40. In this process PI3K phosphorylates membrane-bound PIP2 to 
phosphatidylinositol 3,4,5-triphosphate (PIP3) that works as a  docking site for other molecules such 
as PLCγ, VAV, the Burton’s tyrosine kinase (BTK) and AKT. PLCγ phosphorylation induces the calcium 
influx and PKC activation, AKT is instead fundamental for the activation of  the mammalian target of 
rapamycin (mTOR) pathway by inactivating its negative regulator mTOR tuberin41. Active mTOR 
forms two complexes, the rapamycin-sensitive mTOR complex 1 (mTORC1) and the rapamycin-
insensitive mTORC2.  
Animal studies showed that PI3K seems to be mainly responsible for the maintenance, but not for 
the initiation, of the calcium signal that is required for an optimal degranulation. It is not well 
a b 
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defined whether for calcium mobilization and degranulation, an adaptor transmembrane molecule 
is required, it has however been proposed that NTAL, known also as LAT2, can have similar functions 
covered by LAT in the assembly of the macromolecular complex necessary for FYN signalling42. 
 
3.1.3.2. Other ways of activations 
 
As mentioned above, the IgE/Ag-dependent activation of MCs is the best known activation process 
but cannot be considered the most important since in different types of inflammatory diseases or 
tumors, where MCs’ accumulation has been proposed as a prognostic role, they are reported to be 
activated independently from an IgE stimulation43,44. 
Different products of pathogens, such as the lipopolysaccharide (LPS), the peptidoglycan (PGN), poly 
(I:C) and some viruses are able to directly interact with MCs through the TLRs expressed on their 
membranes: TLR-1, 2, and 4–6 on the cell surface while TLR-3, and 7–9 intracellularly45. TLR 
signalling includes a complex network of signalling molecules and, among others, the MyD88-
dependent and MyD88-independent pathways are highly relevant. The type of cytokine produced 
after a TLR activation in some cases is redundant, nevertheless some differences can be found, TLR-
2 activation induces the production of TNF-α, IL-6, IL-13, IL-4, and IL-5, while TLR-4 leads to the 
synthesis of TNF-α, IL-6, IL-13, and IL-1β. One interesting aspect is that if murine MCs are pre-
exposed to TLR ligands, the following IgE-induced activation is suppressed because of the temporary 
reduced FcεRI expression46. Oppositely, in human MCs it has been shown that a simultaneous 
exposure to various TLR ligands and FcεRI stimulation produces an increased cytokine secretion 
without affecting degranulation47. 
MCs can also be activated by IgG immune complexes binding pro-inflammatory FcγRI, FcγRIIA, or 
FcγRIII and many works have reported a role for FcγR-induced mast cell activation in pathologies 
like rheumatoid arthritis (RA), Sjögren’s syndrome, multiple sclerosis, or glomerulonephritis48. 
Moreover, degranulation is induced also by activation of the complement fragments C3a and C5a 
that are also called anaphylatoxins. C3a sustains MCs’ degranulation in the presence of FcγRI 
signalling and C5a is able to induce migration and adhesion aside from cytokine synthesis49,50. 
On their surface MCs present a wide range of cytokine and chemokine receptors. Chemokines are 
important in directing MCs to the anatomical compartment where they will accomplish their 
differentiation, in inflammatory conditions their receptors respond to chemokine gradients 
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favouring a specific and localized activation. Chemokine receptors that are constitutively expressed 
in MCs include CCR1, CCR3,4 and 5, CXCR1–4, and CX3CR151. 
Cytokines instead are essential meditators that control many homeostatic functions such as growth 
and proliferation but also promote activation or silencing of specific signalling. Among the ones that 
drive homeostatic activities, and besides the already cited importance of IL-3 and SCF that activate 
several antiapoptotic pathways, IL-4, IL-10, and TGF-β are very relevant52. 
 
 
The IL-33/ST2 axis in MCs 
 
IL-33 cytokine is acquiring more and more importance in MC biology since it acts as a potent 
activator. ST2 and IL-1RAcP on MCs form a transmembrane protein complex that is the only known 
receptor for IL-33. This interleukin triggers a MyD88-dependent NF-kB signal similar to the TLR 
cascade and promote survival, maturation, cytokine production and adhesion. More specifically, IL-
33 binding to ST2 leads to the recruitment of MyD88 adapter protein along with IL-1R-associated 
kinase1 (IRAK1), IRAK4 and TNFR-associated factor 6 (TRAF6)53 then NF-ĸB and MAP kinases 
transcription factors become activated; as well as ERK1/2, p38MAPK, and JNK kinases are activated 
and inflammatory mediators are produced54. The first report about cytokine polarization concerning 
an IL-33 stimulation of MCs concern a Th2-cytokine polarization54, however the  impact of IL-33 on 
mast cell biology has also been extended at the single cell level. It has been demonstrated that IL-
33 potentiates most of the IgE-mediated MC responses both by increasing the number of 
responding cells and by enhancing the responses of individual MCs55. Additionally, it enhances 
cytokine production amplifying the IgG signals56. In table 1 are listed the main effector mediators 
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Table1: Functional effects of IL-33 on MCs. The principal effects of the downstream signalling 
cascade of IL-33 binding on ST2 on BMMCs, human LAD2 cell line, human umbilical cord blood-
derived MCs and murine intestine and lungs. MCs upon effect of IL-33 are supported in their 
survival, cytokine and chemokine production. 
 
 
Historically MCs were among the first cell types to be identified to express the ST2 receptor. IL-
33/ST2 activation of MCs is growing in importance since more and more implications of this axis in 
pathological conditions such as asthma, anaphylaxis, arthritis, or tumours are discovered57,58,59,60. 
An important aspect to note is that MCs are not only activated by IL-33, they are also among the 
cells that are able to actually produce the cytokine. IL-33, that is stored in the nucleus, is also 
considered an “alarmin” since it is released after necrosis or tissue damage, instead when apoptosis 
occurs it is inactivated by caspases cleavage. It is mainly expressed by structural cells as oblasts, 
osteoblasts, endothelial cells, epithelial cells but also in MCs, dendritic cells (DCs) and 
macrophages61. It is furthermore reported that chymase and tryptase, the two major serine 
proteases released by activated human MCs, are involved in the processing of IL-33. The mature 
forms of  IL-33 generated resulted to be potent activators on  type 2 innate lymphoid cells (ILC2s), 
and this suggests that both MMCs and CTMCs in their different microenvironment, might be able to 
generate highly active mature forms of IL-3362.  
The MC’s involvement in the production of IL-33 in in vivo pathological setting has been inquired. 
The first findings demonstrated a mechanism by which MCs influence the recruitment and 
activation of inflammatory cells into sites of IgE-dependent activation pointing out a functional 
effect of endogenous IL-33 in inflammation. Nevertheless, deciphering the mechanisms through 
which IL-33 becomes extracellular is still an unexplored area of study, indeed experiments have 
failed to detect IL-33 release from MCs in vitro63. It has been suggested that failure to detect IL-33 
release in vitro lies in the limitations of the existing cytokine detection techniques enzyme-linked 
IL-33 
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immunosorbent assay (ELISA), and a modified method to allow detection of IL-33 from the cell 
supernatant has been suggested64. 
 
3.1.3.3. MC’s derived mediators 
 
The most common identified morphological feature of MCs is their high cytoplasmic content of 
electron-dense lysosome-like secretory granules. Indeed a great abundance of pro-inflammatory 
mediators is stored and released from these cells when appropriately activated. For this reason MCs 
have been defined as “cells armed for a battle”65.  
In response to some stimuli, beyond the classical degranulation process, MCs also display a 
“piecemeal” degranulation characterized by gradual loss of granule contents without detectable 
granule fusion to the membrane. Thus, piecemeal degranulation allows release of discrete packets 
of granule-associated components without granule exocytosis66. Mediators released from MCs are 
divided into two groups: pre-formed mediators, such as histamine, that are stored in the cytoplasm 
in granules, and de novo synthesized mediators that comprise lipid mediators, cytokines, and 
chemokines. Very different roles are played by this bioactive molecules, not only in allergic settings, 
but also in physiological and pathophysiological conditions67. In the granules vaso- and neuro-active 
molecules such as histamine, serotonin, β-exosaminidase, tryptase, chymase are stocked. Growth 
factor such as epidermal growth factor (EGF), fibroblastic growth factor 2 (FGF2), granulocyte-
macrophage colony stimulating factor (GM-CSF), transforming growth factor type-β (TGF- β), 
vascular endothelial growth factor (VEGF) and lipid mediators, including  leukotriene (LT) C4, 
prostaglandin (PG) D2, and platelet activating factor (PAF) are neo-synthesized and are good 
example of how diverse is the MCs contribution in modulating biological processes68. A deeper 
description of MCs’ derived cytokine, bioactive molecule that are mainly involved in the regulation 
of other immune cell types is done below. 
 
TNF-α (tumor necrosis factor-alpha) 
 
This mediator has been historically discovered to be expressed in MC lines (e.g. C57.1, 2D4, RBL-
2H3), IL-3 maintained BMMCs, rat and mouse peritoneal MCs (PMCs), rat CTMCs and also human 
bone marrow-derived “basophils/MCs” and PMCs (stored preformed)69. The mRNA expression and 
production of this mediator has been shown to increase upon an IgE-dependent stimulation70. 
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Moreover IL-33 together with substance P (SP) has been shown to enhance  the TNF-α synthesis and 
secretion in LAD2 human mast cell line71. In addition, IL-33, through the signalling induced by the 
binding of its receptor ST2, is reported to be critical for the late-phase inflammation occurring during 
FcεRI anaphylactic activation of BMMCs63.  
The evidence of preformed TNF-α in MCs has been demonstrated in MC-deficient KitW/W-v mice 
where rapid secreted TNF-α helped the initiation of local inflammation by recruiting neutrophils into 
the peritoneal cavity72.  
As mentioned above, one of the first roles uncovered for MC-derived TNF-α is the recruitment of 
other leukocytes during an inflammatory process, not only neutrophils during hypersensitivity 
reactions73, but also the migration of skin or airway DCs74. Also adaptive immune cells can be 
affected by IgE-activated MCs through the release of TNF-α, as reported in a work in which T cells 
activation was increased through the expression of OX4075. It is important to note that not only 
immune cells respond to the TNF-α molecule, keratinocytes for instance are induced to produce 
nerve growth factor in response to MC-released TNF-α that in turns induce nerve elongation76.  
The results section of this thesis will show a novel and important role that MCs-derived TNF has in 
a context of intestinal tumorigenesis. 
 
Other pro-inflammatory cytokines 
 
IL-6 is a pro-inflammatory cytokine that is produces by many immune cells and well-studied in MCs 
because is largely released from this cell type. MCs are able to produce IL-6 in response to an IgE-
dependent stimulation, a TLR4-dependent activation, after SP, IL-1 or IL-33 encounter. In addition, 
IL-6 can act also in an autocrine way since human MCs growth is supported by its anti-suppressive 
signalling77. Similar stimulations are needed for the release of IL-1β that is shown to be implicated 
in arthritis or skin inflammation57. MC-derived IL-6, together with INF-γ, a Th1 cytokine, are shown 
to be relevant in promoting atherogenesis78. 
Among the Th2-type cytokines, IL-4, IL-5 and IL-13 are the most counted and their functions partially 
overlap. These cytokines are released upon an FcεRI stimulation or under LPS, IL-33, PGN stimuli. IL-
13 plays an important role in host defence to infection against parasites and together with the other 
cytokines participates in the pathogenesis of type-2 immune responses that are usually associated 
with high antibody (Ab) responses79,80. 
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IL-10 is an anti-inflammatory cytokine secreted mostly by regulatory T and B lymphocytes, 
macrophages, DCs, Natural Killer (NK) lymphocytes and others. MCs release and production of IL-10 
is increased by LPS, IgE-crosslinking and via FcγRIII81. Reports indicate a role of MC-derived IL-10 in 
the suppression of adaptive responses ameliorating the detrimental effect contact hypersensitivity, 





Chemokines are a particular class of cytokines with a generally low molecular weight, ranging from 
7 to 15kDa and a chemotactic activity on immune cells. Chemotaxis is a key process in homeostasis, 
it allows migration and compartmentalization of cells in specific body sites, and is also extremely 
relevant during the onset of inflammatory processes including infections, allergy, autoimmune 
diseases and tumors84,85. For this reason one type of classification is the division into homeostatic 
and inflammatory chemokines. Moreover two main families of chemokines can be identified based 
upon cysteine residues position: CXC and CC (even though historically they have been known with 
different names). In 1888 Leber was the first to describe chemotaxis reporting the movement of 
leukocytes towards inflammation sites. This phenomenon is induced by the formation of an 
extracellular gradient of chemicals. Cells that express on the membrane the corresponding 
chemokine receptor (or more than one receptor), become polarized and migrate towards the higher 
chemoattractant concentration. Chemokine receptors are differentially expressed by immune cells 
and can be divided into two groups: G protein-coupled chemokine receptors (GPCRs) and atypical 
chemokine receptors, which seem to form chemokine gradients and reduce inflammation by 
scavenging chemokines in a G protein independent manner86. 
It is known indeed that among the newly synthesised mediators, MCs are source of a wide plethora 
of chemokines. Some of them are expressed both in mouse and human such as CCL1, CCL2, CCL3, 
CCL7, CCL17, CXCL4, CXCL5, some have been detected only in mouse studies such as CCL21 and 
CCL25, and others are described only in human MCs: CCL4, CCL5, CCL19, CCL20, CXCL1087. 
In this work, chemokines and the ability of MCs in regulating chemotactic properties of B cells in 
physiology and during cancer development is of great interest. 
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3.1.4. Animal models for studying MCs in vivo 
To date, Abs-based methods or stabilizers able to specifically inhibit MCs activity are not available, 
therefore genetically modified animals are the most used and suitable. Indeed, over the past 
decades many efforts have been put in generating MCs-deficient animal models to study specific 
functions of MCs. However, each approach has revealed limitations that need to be taken into 
account in the interpretation of the results.  
The first MCs deficient mice harboured naturally occurring a loss-of-function mutations at the Kit-
encoding locus (also known as white spotting locus W). Differently from the majority of the 
hematopoietic cells that lose Kit expression upon differentiation, MCs express Kit all over their 
lifetime and binding the SCF participate in the survival, differentiation, self-renewal, proliferation 
and migration88. In the in vivo studies, WBB6F1-KitW/W−v and C57BL/6-KitW−sh/W−sh  mice are the most 
used Kit mutant mice.  
The first mice carry one allele (W) with a point mutation which encodes a truncated version of Kit, 
and one allele (W-v) with a point mutation in the tyrosine kinase domain of Kit. The second model, 
C57BL/6-KitW−sh/W−sh, instead presents an abnormal Kit expression due to an inversion mutation that 
affects the transcriptional regulatory elements upstream of the c-kit transcription site on 
chromosome 5. As a result, in these mice all MCs subsets are depleted. Unfortunately,  the loss of 
Kit causes other major defects: both mice are greatly deficient in melanocytes, conferring the white 
coloured fur. In addition, WBB6F1-KitW/W−v mice are anaemic and sterile and have reduced numbers 
of neutrophils and basophils; C57BL/6- KitW−sh/W−sh  mice instead are not anaemic nor sterile, but 
have increased numbers of neutrophils and basophils and exhibit splenomegaly89. 
From the work  of Nakano T. and collaborators in 1985, many anatomical sites of these Kit-mutant 
mice are engrafted with genetically compatible in vitro-derived Wt or mutant MCs (such as BMMCs). 
This allows  to attribute to MCs specific effects observed in these mice that carry strong non-MCs 
related abnormalities. The principal routes for the administration of MCs, in order  to generate this 
sort of “MC knock-in mice”, are intraperitoneal (i.p.), intravenous (i.v.) and intradermal (i.d.). 
However it has been demonstrated that upon reconstitution different body compartments are 
differently engrafted with MCs compared to normal tissue distribution. For example, using i.p or i.v. 
reconstitutions native levels of skin MCs are not restored; on the other side, an i.v. injection is not 
able to refurbished peritoneal cavity MCs number as well as in the spleen, an organ in which the 
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density of MCs is particularly low, collectively, this type of reconstitution leads to a non-physiological 
accumulation of MCs90. 
More recently, new strains of MC-deficient lacking abnormalities related to c-kit structure or 
expression mice have been created. The most common transgenic mice carry Cre recombinase (Cre) 
expressed under the control of MC-specific or MC-associated promoters. Mcpt5 gene is the target 
gene of the Mcpt5-Cre;R-DTA mice. To generate these mice Cre has been crossed with Mcpt5 and 
Cre-specific ablation is specific in cells expressing the diphtheria toxin alpha (DTA)91. There is a 
constitutive lack of peritoneal and ear skin MCs, an almost complete reduction in the number of 
abdominal and back skin MCs, but numbers of MMCs that do not express Mcpt5 are not affected. 
In the Cpa3Cre/+ - “Cre-Master” mice92 the mice are extremely depleted of MCs and this seem to be 
due to Cre-induced genotoxicity. A limit of this model is the reduction of some other populations 
that express various levels of Cre such as other  hematopoietic progenitors, basophils and tymic T 
cells89. 
A third mouse model, derived from the previous one is the Cpa3-Cre;Mcl-1fl/fl called “Hello Kitty” 
mice since the phenotype of MCs deficiency occurs in the absence of mutations of the c-Kit. These 
mice, in addition to have almost 100% of MCs depletion in all anatomical sites, have a great 
reduction in basophils numbers93. 
The principal goal in studying MC-deficient animal models is to validate the role and the contribution 
of MCs in certain pathologies and to assess them as therapeutic targets. The ideal in vivo model 
should be the one in which MCs depletion is both highly selective and inducible. Current promising 
approaches, make use of the injection of diphtheria toxin (DT) into transgenic bearing DT receptor 
(DTR) adult mice into selected cell types.  
Below the B6; B6.Ms4a2tm1Mal also called RMB (Red Mast Cell and Basophil) mice is described; 
this model was generated by the group of Pierre Launay in 201494 and is also used in the present 
thesis work. In this mouse model the 3′-UTR of the FcεRI β-chain, encoded by the Ms4a2 gene, holds 
a cassette composed of an internal ribosomal entry site, a sequence coding for the bright red td-
Tomato (tdT) fluorescent protein, a 2A cleavage sequence, and the human diphtheria toxin receptor 
(hDTR). This construct allows the tracking of both MCs and basophils thanks to the red fluorescence 
and makes these cells sensitive to DT. In figure 5 the whole strategy used to create the RMB mice is 
shown. Two i.p. injections of DT (within 48h) are needed to obtain a complete depletion of MCs in 
the peritoneal cavity and other compartments, and of basophils in the blood. The analysis of the 
repopulation kinetics demonstrated the adequacy of the model: basophils started to reappear 6 
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days after the DT treatment and reached their normal levels by day 12. Differently, MCs were not 
detected within 12 days nor 2 months after DT treatment the numbers of MCs remained low (about 
6% of the physiological conditions); their half repopulation was seen at 6 months after the depletion. 
 
Figure 5: Strategy used for the generation of RMB knock-in mice. (1) The Wt Ms4a2 gene that 
encodes for the FcERI β-chain has been partially restricted. Exons are represented as grey boxes. 
Two BamH1 sites are used for digestion and the 5’ and 3’of  single-copy probes used to verify 
proper homologous recombination are shown. (2) An IRES-tdTomato-2A-hDTR cassette in the 3’ 
untranslated region of the gene is introduced: this cassette is flanked at its 3’ end by an auto-
deleting loxP-Cre-NeoR-loxP cassette. TK: thymidine kinase expression cassette bordered onto the 
3’ end of the right homology arm. I: IRES, T: tdTomato, p: peptide 2A, D: hDTR. (3) This is how the 
structure of the targeted allele following homologous recombination and preceding Cre-mediated 
self-excision of the neoR cassette appears. (4) Final structure of the target site after auto-deletion 
of the Cre-NeoR cassette in male gametes.94 
 
By investigating the RMB derived BMMCs’ properties, the authors determined that B6 BMMCs 
characteristics where comparable with them. Moreover, the numbers of other leukocyte 
populations (neutrophils, eosinophils, monocytes, B and T lymphocytes) were not affected in this 
knock-in RMB mouse proposing this as an ideal model to study the homeostatic and pathological 
role of MCs. In their work, Dahdah A. and collaborators were able to prove a detrimental role for 
peritoneal MCs in a model of severe sepsis since IL-4 produced by this MC subset by effect of E. coli 
was responsible for inhibiting resident macrophages phagocytosis. This model can be therefore 
considered better compared to Kit mutant mice (even if different, since these mice are MC-
competent until their induced depletion), it is however important to keep in mind that in humans 
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there is no report of any MCs deficiency and it is likely to consider that any lack of MCs does not 
provoke severe immunodeficiency95.  
 
3.1.5. The MC as an highly social immune cell 
MCs are known to give a high contribution in the regulation of innate and adaptive immune 
responses. They can be considered highly promiscuous cells, indeed their broad array of cell surface 
receptors, co-stimulatory molecules, and ligands involved in cell–cell contact (and also in cell-
extracellular-matrix adhesion) make them important modulators of other immune and non-immune 
cell types, reflecting in very complex bi-directional interactions87. We can consider MCs as highly 
specialized cells in creating communication with other cells and many reports have shown the 
clinical relevancy that this modulation of other cell responses produce in the overall improvement 
of the disease96 . 
Eosinophils are closely related to MCs since both of them are key effectors in allergies, in this light 
their interaction is important in the frame of the regulation of allergic responses. Human cord blood 
derived MCs and human peripheral blood eosinophils are able to mutually increase the survival and 
activation ex vivo in the presence of SCF97. 
MCs and basophils cooperate in worsening or modulating inflammation as well as in facilitating 
tissue repair. Human basophils chemotaxis is induced by the binding of PDG2 released by MCs to 
the transmembrane receptor CRTH2, expressed on basophils98. During lung inflammation, CCL2 
secreted by MCs can induce histamine and leukotrienes release from human basophils99. MC-
derived VEGF concurs with basophil recruitment at inflammatory sites and then promoting 
angiogenesis. Moreover basophils can be activated by a wide plethora of receptors for growth 
factors released by MCs such as IL-2, IL-3, IL-4, IL-5, GM-CSF, NGF and IL-8100. 
The involvement of MCs in the activation of neutrophils became clear with the first study of 
reconstitution of MC-deficient mice87. In a model of immune complex-mediated peritonitis both the 
rapid and the late phase recruitment of neutrophils appeared to be promoted respectively by LTs 
and TNF-α produced by MCs72, also CXCL2 and mMCP-6 cover a role in neutrophils chemotaxis 
induced by MCs facilitating host defence101,102. Recently a close morphological association between 
MCs and neutrophils was documented in a series of human gastric cancer. The ultrastructural 
analysis allowed to uncover degranulating MCs with a mechanism called kiss-and-run fusion that is 
different from the classical massive anaphylaxis or the piecemeal degranulation103. 
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In the modulation of innate immune responses, MCs release factors that are able to affect DCs such 
as histamine, prostaglandins and TNF-α that are known to facilitate their migration, maturation and 
antigen processing 74,104,105. More recently it has been shown that, beyond soluble mediators, also 
the cell-cell contact is established between these two cells,  a synapse allows the transfer of antigens 
that in turns leads to T cell activation106. In addition, the formation of direct contact between these 
two cell type depends on, the axis between lymphocyte function-associated antigen (LFA-1) on DCs 
and intracellular adhesion molecule (ICAM-1) on MCs 107. 
The interactions with monocytes and macrophages are extensively studied in the context of 
infectious conditions, however monocytes and MCs have been shown to accumulate also in several 
inflammatory states, for example interaction of the two cells have been proposed in cardiovascular 
and metabolic diseases108. The Th2 cytokine IL-4 is one of the reported factors derived from MCs 
that are able to affect macrophage activity in the context of infections. However opposite roles have 
been shown: promotion of an efficient phagosomal activity by macrophages109, and downregulation 
in a septic model instead94. 
MCs are not only modulators of innate immunity, many studies indeed show their ability to finely 
tune the activities of effector T, B and regulatory lymphocytes bridging innate with adaptive 
immunity. MCs-B cells interplay is of main interest for the purpose of this work and is extensively 
discussed in the section 3.3.1 “MC-B cell cross-talk: what is known and what is missing”. 
In T cell-mediated inflammatory processes, a physical proximity and an increased number of MCs 
are described. Recruitment, activation, proliferation and cytokine production are modulated by 
effect of MCs in several T cell subsets110. MCs expressing  CD80/CD86, PD-L1, ICOS-L, OX40L co-
stimulatory molecules, together with the induction of MHC-II expression (primed by a combination 
of inflammatory stimuli such as INF-γ, LPS and IL-4) are able to act as antigen presenting cells75. It is 
interesting to note that a role for MCs-derived exosomes are able to induce antigen specific 
responses of T cells111. The sustained T cells’ activation and cytokine synthesis and a polarization 
towards a Th2 CD4+ cells is induced by TNF-α and by other important mediators (IL-4, IL-6, IL-13) 
release by MCs112. Interesting positive and negative activation of CD4+CD25+Foxp3+ regulatory T 
cells (Treg) roles are played by MCs. MC-derived IL-6 and interactions through OX40 on T cells and 
MC-expressing OX40L have suppressive role in Treg functions113; also histamine, released during a  
microbial activation of MCs has been proposed to have a negative effect of Treg activity114. There 
are reports in which  a greater MCs recruitment is observed into the peritoneum in mice with Treg 
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transfer suggesting a MC contribute in Treg activity115. Moreover, Treg, differently from effector T 
cells, inhibit MC activation and release of mediators  (illustrated in  figure 6). 
 
 
Figure 6: Molecules and soluble mediators involved in MC-T cell crosstalk: (A) Effector T cells are 
shown in their crosstalk with MCs. Different membrane axis promote a mutual sustain in cytokine 
secretions and activation of the cells. (B) MCs interaction with Treg downmodulates MC 
degranulation. Modified from113. 
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3.2. THE B CELL ARM OF THE IMMUNE SYSTEM  
 
3.2.1. B cell development: B-1 and B-2 cells the main subsets 
B cells are an important component of the adaptive immune system. Differently from the cells of 
innate immunity, defence against pathogens is achieved by a mature compartment of long lived 
lymphocytes that underwent differentiation capable of providing Ag presentation and production 
of Abs. This mature compartment, made of different subtypes of B cells with complementary 
functions, is supplied by a continuous production of immature cells from the bone marrow. In 
mouse, two main categories of B cells can be identified, B-1 and B-2 lineages that are distinguished 
by their developmental origin, anatomical localization and functional properties116. In general, B-2 
cells are “conventional” B lymphocytes, that participate in adaptive immune response undergoing 
germinal centre (GC) reactions, mainly  in the spleen and LNs. After migration in the spleen, B-2 cells 
can further mature into follicular (FO) or marginal zone (MZ) B cells117. B-1 cells instead can be 
considered as “innate” B lymphocytes that reside mainly in the body cavities. The origin of the B-1 
and B-2 main subsets has been long debated, but the majority of the studies suggests the existence 
of different progenitors118. 
 
3.2.1.1. B-1 B cells 
 
Historically this murine B cell subset has been identified as CD5+ B cells sharing similarities with 
human chronic lymphocytic B-cell leukemia119. Later B-1 cells were identified as the dominant B cell 
population in the peritoneal and pleural cavities and extremely rare cells in spleen or LNs. 
Phenotypically they express high levels of surface IgM, low levels of B220 and IgD and are CD23- 
cells. Moreover,  B-1 cells can be further divided on the base of CD5 expression into B-1a (CD5+) and 
B-1b (CD5-). B-1 cells residing in the peritoneal cavity express in addition intermediate levels of Mac-
1. B-1 cells express at high levels different type of integrins (α4, α6, β1 and β7) and the CD9 
tetraspanin120. In addition, in the body cavities, they are defined as cells having a 
CD11b+sIgMhisIgDlow phenotype while the rare B-1 cells of the spleen are CD11b- cells121. 
In mice, B-1 cells represent up to the 5% of the total B cells and represent a pool of long-living and 
self-renewing B cells that contribute to the production of the majority of circulating IgM122. Indeed, 
they are defined as “innate” B cells for their ability to produce most of the natural polyreactive Abs 
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against self- and foreign-Ags. These Abs have a low affinity and broad specificities and provide the 
first line of defence against infections. The restriction in the repertoire reflects the fact that specific 
Ag stimulation and somatic hypermutation are not required. For all these reasons, together with 
the functionally linked splenic MZ B cells, they represent a bridge between innate and adaptive 
immunity. These two B cells subset are indeed ontologically evolved to deliver responses for gut or 
peritoneal and blood-borne Ags, in a T-independent manner favouring the development of rapid 
responses to a restricted number of conserved Ags123.  
Even if they share many phenotypical characteristics, B-1a and B-1b are also functionally separate. 
For example, concerning humoral functions, B-1a cells are reported to constitutively release natural 
IgM Abs against S. pneumoniae while B-1b are able to make Abs specific to S. pneumoniae 
(producing a so-called “memory IgM”)124. Moreover B-1a cell development is strongly influenced by 
B cell Ag receptor (BCR) specificity and strength of signalling as well as by the presence of an intact 
CD19. To date, robust BCR signalling in B-1 cells has been shown to be dependent on the positive 
regulation through the CD148-Lyn axis, while in B-2 cells CD148 covers a redundant role125. 
The definition of the developmental phases of the B-1 cells is intriguing and it is still a matter of 
debate. With elegant experiments, in 2006, the existence of a B-1 cell-specific progenitor in the Lin-
CD45low-negCD19+ population was identified. This progenitor was indeed able to reconstitute only B-
1 cells in SCID mice recipients. Previously the maturation of B-1 cells was reported to derive from 
fetal or neonatal precursors existing in mouse liver and omentum126. These authors, instead, also 
showed the presence of the B-1 progenitor in the adult bone marrow, suggesting the possibility that 
B-1 cell numbers during adult life can be supplemented by progenitor cell differentiation besides 
self-renewal potential127. The two existing models concerning B-1 cell development were reviewed 
by the authors in the same year, and shown in the figure 7. 
 




Figure 7: Models of B-1 cell development from an HSC. B-1 cells, alike all other blood cell type, 
derive from the HSC. The lineage model of B-1 cell development proposes the existence of a Lin-
CD45-/lowCD19+ progenitor with the developmental potential to the production of B-1a and B-1b 
cells. The selection model instead proposes that B-1 and B-2 cells develop through a single 
developmental pathway, by a common B-cell progenitor, and that Ag-binding to cells at the sIgM-
expressing stage of development determines whether a cell will acquire the characteristics of B-1 
or B-2 cells121. 
 
Their finding of the Lin-CD45low-negCD19+ population in the fetal liver and fetal and adult bone 
marrow from which B-1 cells develop support the lineage model. 
More recently, in 2011, the same authors investigated the nature of B-1 transition elements. They 
discovered the existence of a common B-1 lymphoid progenitor and that B-1 cells can derive from 
sIgM+CD93+CD23+/– transitional cell intermediates that predominate in neonatal spleen during the 
first two weeks after birth, proposing a new model for peripheral B-1 (and B-2) cells maturation128,128 
(Figure 8). In addition, they demonstrated that, both the inactivation of the classical pathway and 
the alternative NF-kB pathway block the appearance of B-1 and B-2 transitional cells. While the B-2 
transitional cell maturation resulted to be dependent on the alternative NF-kB signalling, mature B-
1 cells are reduced in mice carrying defects in the classical NF-kB signalling without affecting the 
maturation of transitional B-1 cells. On the contrary, the classical pathway is necessary for the 
maintenance of mature B-1 cells and in particular for B-1a cells.     
 




Figure 8: Model of layered B-1 and B-2 development. In a first neonatal wave, B-1 CLPs generate 
B-1 progenitors that differentiate into immature B-1 cells. These immature cells migrate to the 
spleen and there, after a B-1 transitional cell intermediates they mature into B-1a and B-1b cells. 
In a second wave, B-2 CLPs generate B-2 progenitors and then immature B-2 cells that form splenic 
B-2 transitional cells. This B-2 transitional cell wave is the predominant one in adults129. 
 
These results were afterwards confirmed and extended with the identification of phenotypical 
characteristics that are useful to discriminate transitional cells with B-1a potential from the B-2 
counterpart. The transitional B-1a element is unique for the co-expression of CD93, IgM, CD43 and 
low levels of CD45R. Transitional B-1a cells are, in addition, CD5+ and the majority of mature 
peritoneal cavity B-1 cells generated from these precursors are B-1a cells. Differently, neonatal Wt 
CD93+IgM+CD5- transitional cells predominantly mature into B-2 cells. This population also gives rise 
to some B-1b cells and even B-1a cells, showing an unappreciated heterogeneity of the neonatal 
transitional-cell population. The CD5+ transitional B-1a cells derives directly from the CD5- 
progenitor. Moreover, the presence of an intact NFkB signalling via IkBNS in the transitional B-1a 
subset ,was essential for the development of B-1 cells130. These experiments were conducted in the 
bumble mice, a mutagenic mouse in which there is a complete disruption of the gene encoding the 
IκBNS protein belonging to the nuclear IκB-like family of proteins131. Indeed, previously, an impaired 
B cell development and function were shown in the absence of IkBNS132. This bumble mouse 
assumes, therefore, the phenotype of a B-1 deficient mouse model (having in addition also a severe 
reduction of the numbers of splenic MZ B cells). The heterozygous mice for the IkBNS mutation have 
instead a mild phenotype with reduced levels of circulating IgM Abs and responses to TI-2 Ags but 
normal frequencies of B-1 and MZ-B cells133. 
                                                                                                                                                           Introduction 
29 
 
A de novo influx of B-1 cells in adult mice seems to be severely restricted under steady state 
conditions. The maintenance of the B-1 lymphocytes is favoured by their self-renewal capability, 
this process relies on cyclin D2. The constitutive release of high amounts of cytokines such as IL-10, 
IL-6, IL-5 and IL-9. IL-10 is mainly carried out by B-1a cells, that have also been identified as a 
regulatory B cell population; IL-5 instead is mainly produced by the B-1b subset134. 
Very recently the group of Karlsson Hedestam G.B. further investigated the possibility that neonatal 
spleen is required for B-1a cell development. They observed that neonatal splenectomized mice had 
similar peritoneal cavity B-1a cell frequencies to those observed in control mice until 6 weeks after 
surgery. They propose that an intact spleen is essential for B-1a cell maintenance rather than 
generation. They used a model in which fetal liver cells were transferred from pre-splenic embryos 
into splenectomized recipient mice. Moderately lower numbers of B-1a cells developed in asplenic 
mice. B-1a cells were then generated in the absence of the spleen but the neonatal spleen was 
instead essential for the maintenance of the B-1a compartment135. 
In B-1 cells, whose BCRs are cross-reactive to self-Ags, inhibitory mechanisms were developed in 
order to prevent their activation in the absence of infection and autoimmunity. Differently from B-
2 cells, BCR ligation induces modest calcium mobilization, little or no proliferation, and increased 
apoptosis. CD5, that is in the complex with IgM, negatively regulates the BCR signalling in peritoneal 
cavity B-1 cells. Experiments conducted in Wt and CD5 K.O. mice showed that the proliferation of 
both mice derived B-1 cells was similar in response to anti-CD40 and LPS stimulations. Instead, 
proliferation to anti-IgM was effective only in CD5 K.O. B-1 cells and the blocking of CD5 association 
with mIgM recovered the proliferative defect upon BCR ligation136. Later, Lyn, and SFK were 
reported to negatively regulate the BCR signalling by phosphorylating the ITIM motifs in B cell co-
receptors137. The high calcium mobilization after co-cross-linking of BCR and CD19 that occurs in B-
2 cells, is defective in both B-1a and B-1b cells that are equally hypo-responsive to synergistic 
stimulation138. The mobilization of mainly extracellular calcium reflects these defects in calcium 
response. Finally, autocrine IL-10 production mediates also autoregulation in controlling the 
expansion of self-reactive B-1 cells139. 
 
3.2.1.2. B-2 B cells 
 
B-2 cells in the mouse are the predominant population of B cells in the spleen, LNs, and peripheral 
blood. After birth B-2 cells are continuously replenished by bone marrow hematopoiesis and stroma 
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cells, provides all the necessary signals for the commitment of the progenitors. Functionally 
different from B-1 cells, B-2 conventional lymphocytes participate strongly in adaptive immune 
responses providing support to Ag-specific T cell activation and generating memory cells and plasma 
cells (PCs) able to recognize ad attack more efficiently previously encountered pathogens. 
In the differentiation process, pluripotent HSCs originate naïve FO or MZ B cells through a complex 
and highly regulated process. Soluble signals and cell-to-cell contacts such as IL-7 and Fms-like 
tyrosine kinase 3 ligand (Flt3L) derive from bone marrow stroma cells. The differentiation process 
involves intermediate developmental stages identified by the expression of specific transcription 
factors and surface molecules, Ig heavy and light chain rearrangement and expression of B cell 
receptor complexes140. Multipotent progenitors lose their self-renewal capacity and express Flt3, 
that is fundamental for the growth and survival of the progenitors141. According to the classical view, 
the MPP generate two lineage-restricted populations, named CMPs and CLPs. In 2010 an alternative 
myeloid-based model of hematopoiesis has been proposed: it was suggested that myeloid potential 
persists in the T and B cell branches, even after the divergence of the two lineages142. PU.1 and 
Ikaros are the two transcription factors expressed in MMPs that control Flt3, c-Kit and IL-7R alpha 
signalling; PU.1 is determinant in the commitment of the myeloid or lymphoid fate143. CLP 
commitment to the B cell lineage depends again on specific transcription factors: the absence of  
E2A, early B cell factor 1 (EBF1), and paired box protein 5 (Pax5) blocks B cell maturation (also shown 
in picture 9).  
The pre-pro B phase is characterized by the expression of CD45R, the lack of CD19 a no Ig 
rearrangement. In the pro-B stage recombination-activating gene-1 (RAG-1) and RAG-2 
recombinases are up-regulated and the process called V(D)J recombination, that allows 
rearrangement and recombination of the Ig genes, can take place144. During the gene 
rearrangement of the receptor the variable (V), diversity (D) and joining (J) gene segments an huge 
repertoire of different Ag receptors is generated. In the early phase of pro-B stage DH-to-JH genes 
are rearranged, in the late phase of pro-B, the joining of a VH segment to the pre-arranged DHJH 
complex occurs. A successful rearrangement of the heavy chain gene on one chromosome represses 
the rearrangement of genetic material from the second chromosome. Afterwards, a mechanism 
called allelic exclusion guarantees the monoallelic expression of the IgH gene and monospecific Ag 
recognition145. After heavy-chain rearrangement the cell expresses the pre-BCR in which the 
rearranged μ heavy chain is combined with the surrogate light chains λ5 and VpreB; moreover, the 
pre-BCR associates with the Igα/Igβ dimer (CD79a/CD79b dimer), this cell is now called the pre-B 
                                                                                                                                                           Introduction 
31 
 
cell. The expression of a functional pre-BCR is a critical step, it initiates cell cycling and light chain 
rearrangement in the small pre-B cells that undergo V-J joining on one light chain chromosome; the 
resulting light chain must be able to pair with the µ heavy chain in order to form a functional BCR. 
It is important to note that alterations of its functionality have been associated with cancer and 
immunodeficiencies. Cells expressing functional BRC have acquired Ag specificity and have reached 
the stage of immature B cells. 
 
 
Figure 9: B cell developmental stages from the pro-B to the immature B cell stage. Each stage of B cell 
maturation is defined by the rearrangement status of the IgH and IgL chains. The X indicates the stages in 
which the absence of the E2A, EBF and Pax-5 induce arrest of the development. Each stage is also defined by 
the expression of surface markers and status of V(D)J recombination. Adapted from146. 
 
If from one side this reflects the ability of B cells to respond with several different Ab specificities, 
on the other  these receptors can react against self-Ags. To prevent this risk, the immune system 
developed two important mechanisms: the negative selection of lymphocytes that express high 
affinity receptors for self-Ags triggering these cells to apoptosis, and the receptor editing, i.e. the 
capacity to reactivate the Ab recombination process in order to express a receptor no longer specific 
for a self-Ag. There is also an intrinsically regulated mechanism that brings these auto-reactive 
clones to a state of anergy. Moreover, extrinsic controls can inhibit cells that evaded upon itemized 
mechanisms limiting the supply of essential growth factors, co-stimuli, pro-inflammatory 
mediators147. Immature B cells that survive negative selections egress from the bone marrow and 
specifically home the spleen where a transitional developmental stage takes place in order to 
become mature naïve B cells. B cells are naïve until the encounter with an Ag, that induce the 
maturation into FO or MZ B cell. 
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Two main types of transitional cells can be identified: transitional 1 (T1) or newly formed (NF) B cells 
that express IgM, very low levels of the complement receptors CD21 (that is part of the CD19-CD21-
CD81 co-receptor complex) and do not express follicular markers such as IgD and the low affinity 
receptors for IgE, the CD23. T1 cells mature into transitional 2 (T2) B cells that form follicles and are 
able to recirculate; moreover they acquire the expression of surface IgD and CD23 and express 
intermediate levels of CD21148. The next fate of a transitional cell is to mature into either FO or MZ 
B cell: the strength of the BCR signalling and the participation of Notch2 lead to one or the other B 
cell splenic subset. If the BCR reacts with an intermediate affinity with a self-Ag it is induced to 
differentiate into a FO B cell while if it reacts weakly to the self-Ag signals drives it to an MZ B cell 
fate149. These phases of splenic FO maturation are regulated by the presence of specific factors such 
as B cell activating factor (BAFF). This is a member of the TNF superfamily that through BAFF-
receptor (BAFF-R) mediates survival of B cells involving mainly non-canonical NF-κB activation. 
However, canonical NF-κB signalling is also required for MZ B cell development and survival149. The 
transitional developmental phase is shown in the figure 10.  
 
 
Figure 10: Model for transitional B cells maturation. In the spleen transitional (T1 and T2) B cells 
can mature in either follicular (FO) or marginal zone (MZ) B cells. This cell fate decision depends both 
on the strength of BCR signalling and the involvement of Notch2 signals. It is probable that T2 B cells 
mature into FO B cells if they recognize self-Ag with a high affinity, whereas self-reactive B cells with 
a lower affinity can mature into MZ B cells. BAFF survival signals are also important in this process149. 
 
FO B cells are the main splenic B cell population and they are appropriately located to perform T 
cell-dependent immune responses in the secondary lymphoid organs. MZ B cells represent a sessile 
5% of B cells and after maturation migrate to the white pulp of the spleen, a definite anatomic 
location between the marginal sinus and the red pulp. The MZ B resemble for many aspect B-1 cells: 
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they have potential to self-renew and can survive indefinitely, express polyreactive BCRs and high 
densities of TLRs and are able to initiate rapid T cell independent and T cell dependent Ab responses 
against blood-borne bacterial Ags. Phenotypically FO B cells are IgMhiIgDlowCD21+CD23+. The levels 
of CD21 expression helps to distinguish into FO type I that are CD21mid, while FO type II are CD21hi. 
MZ B cells are instead IgMhiIgDlowCD21hiCD1dhi and CD23-150. Therefore, the use of the markers CD21 
and CD23 helps to discriminate the two B populations. Moreover MZ B cells, similarly to B-1 cells, 
largely express CD9 and also this surface molecule is suggested as a new marker to distinguish MZ 
from FO B cells151. It is also worth noting the expression of CD1d, a non-classical MHC class I 
molecule that allows them to present lipid Ags to the invariant natural killer T cells (iNKT). CD1d 
expression identifies uniquely MZ B cells, a marker that is also suggested to be a marker of 
regulatory B cells152. 
 
3.2.2. B cell activation 
For their activation B cells need to meet an Ag and to recognize it through the BCR at the level of 
peripheral lymphoid organs. In this process, the Ag induces Ig receptor aggregation leading to a 
signal cascade and, “second” signals, notably cytokines, chemokines or growth factors lead to B cell 
activation. Activated B cells differentiate either into PCs, Ab-secreting cells, or memory cells that are 
responsible for long-term protection against secondary infections153. Depending on the nature of 
the Ag and the type of the second signal two types of B cell activation can be distinguished: T cell-
dependent (TD) and T cell-independent (TI). 
  
3.2.2.1. T cell-dependent activation 
 
TD activation involves Ags with non-repeated motifs that are not able to trigger an Ab response 
alone, for instance, B cells need the activity of helper cells. Indeed, the second signal required to 
induce the Ab response to these Ags is delivered by Th cells that recognize Ag fragments bound to 
MHC-II molecules presented by the B cells. This recognition induces from one side cytokine secretion 
by Th cells and a stronger physical co-stimulation through the axis CD28-B71/2, CD154(CD40L)-CD40 
or CD134(OX40)-OX40L respectively in the T-B cell interaction; in turns, this produces B cell 
proliferation and a process called class switch recombination (CSR)154. The CD40-CD40L co-
stimulatory system plays a central role in B cell activation, inducing processes such as proliferation, 
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clonal expansion, Ab production, GC formation, isotype switching, affinity maturation and induction 
of memory cells155. 
Ag-activated B cells can differentiate into short-lived PCs or enter B cell follicles in secondary 
lymphoid organs forming GCs. The GCs maturation involves mainly FO B cells but also MZ and B-1 B 
cells can respond to a TD activation with the formation of extrafollicular PCs156. GCs are structures 
in which somatic hypermutation (SHM) takes place: this important process allows the establishment 
of mutations on the variable regions of Ig genes producing high variability in the Ag recognition. 
Mutated GC B cells migrate in the light zone of the follicles. Here, favourable mutations are 
positively selected through the interaction with Th cells and follicular DCs. Negatively selected B 
cells undergo apoptosis.  
Positively selected GC B cells can undergo CSR. Mature B lymphocytes express on their membrane 
IgM Igs, with the μ heavy chain, and IgD, endowed of δ heavy chains, both with the same variable 
Ag binding regions. This process consists in changes in the Ig heavy chain constant region (CH) gene 
from Cµ to one of the other CH genes and this results in a switch of the Ig isotype from IgM or IgD to 
either IgG, IgE or IgA. The isotype is determined by the manner in which Ags are eliminated and the 
localization of delivering and accumulation the Igs157. 
A very important enzyme that is expressed in GCs by activated B cells is the so-called activation-
induced cytidine deaminase (AID) enzyme. It belongs to a group of mutagenic proteins of 
apolipoprotein B mRNA-editing catalytical component (APOBEC) family and is essential for initiating 
both SHM and CSR. It has been shown that AID deficiency causes the complete absence of class 
switching in mice before or after immunization with TD Ags157. 
Memory B cells and PCs, that are positively selected in the GCs, are long living cells that localize in 
specific microenvironments. Memory cells preferentially homes in secondary lymphoid organs, 
while PCs the bone marrow that provide survival and proliferating factors most of them belonging 
to the TNF family of ligands. Among them it is important to remember BAFF, that maintains B cell 
homeostasis by acting as a survival factor for transitional B cells, and the strictly related 
proliferation-inducing ligand (APRIL) cytokine. APRIL acts at a later stage, modulating the functions 
of Ag experienced B cells. These critical factors in the maintenance of the B cell pool and humoral 
immunity are also involved in several autoimmune diseases with autoreactive B cells such as 
systemic lupus erythematosus (SLE) and tumors (e.g. multiple myeloma) and are target of many 
therapeutic drugs158. 
 




Figure 11: GC reactions. In a TD GC reaction B cells present Ag to T helper cells and receive co-
stimulatory signals. These B cells enter the dark zone of the follicle and undergo SHM by 
upregulating the AID enzyme. After proliferation B cells migrate to the light zone. Here the 
mutated BCRs are exposed to Ags that are exposed to immune complexes on the follicular 
dendritic cells (FDCs). If the affinity of the BCR is extremely low, the B cell will face apoptosis. T 
helper cells favour the survival of higher affinity B cells and induce the others to undergo apoptosis. 
Surviving B cells can then have three possible fates: they can re-enter the dark zone and go through 
further proliferation and SHM, they can exit the GC as plasma cells or they can exit as memory 
B cells159. 
 
Excursus: Ab isotypes  
 
The generation of Ig diversity happens during B cell development and GC reactions and is a 
hierarchical process. In mammals, five main classes of Abs can be identified: IgM, IgD, IgG, IgA and 
IgE. The differences among the isotypes concern the sequence and number of constant domains, 
hinge structure and the valency of the Ab. The role of the Abs is to neutralize their targets preventing 
their entrance in the host cells, to activate immune cells by binding to Fc receptors (FcRs) and 
activating the classical pathway of the complement system by binding to C1q. The effector 
mechanism is regulated by the heavy-chain isotype and binding affinities of activating and inhibitory 
FcR on immune cells. For example, IgM and IgG3 are excellent complement activators, while IgG1 
and IgE bind FcR to activate macrophages and MCs respectively160. 
 




Figure 12: Ab structure. Igs are made of two 
heavy chains (VH and CH) and two light chains 
(VL and CL). The Ag-binding fragment, Fab, is 
composed of one variable domain from each 
heavy and light chain (VH and VL). The variable 
domains contain the complementarity 
determining regions (CDRs) with the most 
sequence variations and determine Ab 
specificity. The constant domains CH2 and CH3 
of the heavy chain make up the crystallizable 
fragment, Fc, which mediates effector functions 
through binding to Fc receptors (FcRs) on cells 
and to complement (C1q) 160. 
 
 
IgM is the first type of Ab to be produced during an humoral immune response  since it can be 
expressed without isotype switching and before SHR. IgM are therefore low affinity Abs, but they 
form pentamers whose ten Ag-binding sites can simultaneously bind to multivalent Ags such as 
bacterial capsular LPS, compensating the relatively low affinity with high overall avidity. Because of 
their size IgM are mainly found in the blood; they are very effective in activating the complement 
system and innate like-B cells such as B1. MZ B cells are mainly producers of this isotype.  
IgG isotype is mainly found in the blood and extracellular fluid, while IgA is the principal isotype in 
secretions, especially in the mucus epithelium of the intestinal and respiratory tracts. IgG efficiently 
opsonizes pathogens for engulfment by phagocytes and activates the complement system, IgA is a 
less potent opsonin and a weak activator of complement. The importance of IgA in mucosal 
immunity will be further discussed in section 3.3.2 “Mucosal immunology of the intestine”.  
IgE Abs are present at very low levels in blood or extracellular fluid, but are bound avidly by FcεRI 
on MCs that reside in the skin, in the mucosa and along blood vessels in connective tissues161.  
 
3.2.2.2. T cell-independent activation 
 
TI activation is mainly triggered by microbial products that do not have a protein nature and can 
directly activate B cells without the need of Th cells, allowing rapid responses to many bacterial and 
viral pathogens. In this case, the second signal can be provided by a direct recognition of a common 
microbial constituent or by an accessory cell belonging to the innate system. These Ags possess 
repetitive and conserved structures and are divided into two categories.  
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TI-1 Ag, also named mitogens of B lymphocytes, at low concentrations drive a specific Ab response 
while at high levels they cause a polyclonal B cells activation. One classical TI-1 Ag is the LPS that 
drive B cell activation via TLR4. LPS induces B cell proliferation and differentiation into Ab secreting 
cells and stimulates IL-6 secretion in mature B cells through PI3-K signaling pathways162. In men B 
cells lack TLR4, but alike in mice, express TLR9 that promotes proliferation, IgM and IL-6 production 
in response to the CpG DNA163.  
TI-2 Ags are characterized by repetitive structures and present high molecular weights. They are 
able to activate mature B cells thanks to the their capability to aggregate the BCR on the cell 
membrane. In particular, these Ags affect mostly B-1 and MZ B cell populations and induce their 
production of polyreactive and low affinity IgM Abs in the absence of a strong second signal or the 
establishment of GC reactions164. 
 
3.2.3. B cells: more than Ab-producing cells 
 
B lymphocytes are the only immune population capable of differentiating into Ab-secreting cells, 
however their importance goes far beyond this humoral function, for instance they can efficiently 
present Ags to T cells and produce a large plethora of cytokines.  
There are evidences supporting the contribution of B cells in the organization and remodelling of 
secondary lymphoid tissues in naive mice and after immune activation. It has been shown that B 
cells provide important factors that favour lymphoid organogenesis, such as the lymphotoxin α1β2 
(LTα1β2) and the TNF-α in the spleen, LNs and Peyer’s patches. A bidirectional interaction is 
established between B cells and stroma cells favouring the development of FDCs (that in turns 
produce CXCL13 that recall B cell in the follicles and induce their production of LTα1β2) and 
macrophages.  
Different cytokines produced by B cells such as TNF, IFN-γ and CCL3 have been show to affect in 
many stages the polarization of CD4+ T cells in lymphoid compartments. The differentiation of Th1 
and Th17 cells was shown to be promoted by B cell-derived IL-6 in experimental autoimmune 
encephalomyelitis (EAE). In mouse models of atherosclerosis, pulmonary infection and sepsis, some 
CD138hi PCs were observed producing GM-CSF that was responsible for increased IL-12 production 
by DCs and therefore being essential for polyclonal IgM secretion by B-1 cells after microbial 
stimulation. All these examples are reviewed in165.  
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Beyond active roles in the clearance of infections and T cell polarization, B cells are also known to 
cover important roles in the dampening of immune responses. First evidences that B cells could 
suppress inflammation by the provision of IL-10 emerged in models of colitis, EAE, and arthritis were 
published166,167,168. Unlike the expression of a common identified marker for Treg, the Foxp3 
transcription factor, there is no agreement on a specific phenotype for Breg, indeed multiple subsets 
of IL-10-producing Breg cells have been described. At the present moment, the most reliable 
hypothesis is that in response to certain stimuli, B cells take on a regulatory phenotype to suppress 
local inflammation169. The CD40 activation, stimulation through TLRs, the activation with IL-6, IL-21, 
IL-1β, IL-35 and BAFF cytokines are reported to induce a regulatory phenotype in immature B cell170. 
Many works conducted both in mice and humans have attributed their suppressive role to the 
capacity to produce IL-10 but there are also evidences that TGF-β and IL-35–producing murine B 
cells also exert regulatory functions169. Breg cells play a protective role in autoimmune diseases such 
as allergy, RA, SLE, multiple scerosis, and EAE, in which instead the proinflammatory Th1 or Th17 
profiles show detrimental effects in affected individuals. On the other side, therapeutic inhibition 
of Breg cells can have helpful effects in the progression of some cancers and infections171. 
 
3.2.4. Features of B cell chemotaxis in health and pathology 
 
Chemokines direct all the phases of B cell biology, starting from the maturation in the  bone marrow 
(or from the liver in the fetal life), driving their physiological egress and the localization in secondary 
lymphoid organs where they undergo activation. They play a fundamental role in the homeostatic 
trafficking of B lymphocytes and are also important modulators of B cell chemotaxis during 
infections and pathological conditions such as tumors. For this reason, physiological and 
pathological B cell-related chemokines can be distinguished. A list of mouse B cell-related 
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Table 2: Examples of B cell-related chemokines and receptor in homeostasis and inflammatory conditions 
*the CCL20/CCR6 axis covers importance in both physiological and pathological processes 
It is important to highlight that these receptor-ligand couples are not B-cell-specific since they are differently 
shared with other lymphocytic population such as T cells and innate immune cells (monocytes, DCs, 
macrophages, MCs, iNK cells…).  
 
Homeostatic B cell chemokines Pro-inflammatory B cell chemokines 
ligand receptor ligand receptor 
CXCL12 CXCR4 CCL2 CCR2 
CXCL13 CXCR5 CCL5 CCR1,3,5 




CCL17, CCL22 CCR4 
 
 
The chemotactic properties of B-2 and B-1 cells from their development are described here below. 
Changes occurring during pathological processes are also mentioned with a particular attention to 
the CCR6/CCL20 pair that is an important bridge between homeostatic and inflammatory conditions 
and is of great relevance for the results obtained in this work.  
Retracing the early B cell development, CXCR4 expression on B cells, the receptor for CXCL12, covers 
an essential role. Indeed, the lack of this receptor or of its ligand drastically blocks B lymphopoiesis. 
In the bone marrow the retention of B cell precursors is favoured by the CXCR4-CXCL12 axis172. 
Moreover, CXCL12 has been shown to be required also for the development of the B cell precursors 
in fetal liver173. 
At the stage of pre–pro B the cells  are responsive mostly to CCL25, the ligand to CCR9. Subsequently, 
at the level of pre- and immature B cells, these lymphocytes become first more receptive to CCL19, 
CCL21 (ligands of CCR7) and after they acquire responsiveness CXCL13 through the increased 
expression of CXCR5. This last receptor favours the migration of immature B cells into CXCL13-
expressing B cell follicles174. One interesting observation is that even though  in the MZ of the spleen 
(adjacent to the B cell follicles) CXCL13 is not expressed, MZ B cells possess a similar migration 
capacity to CXCL13 compared to FO B cells in vitro. Indeed, after a pro-inflammatory stimulation, 
MZ B cells are able to promptly migrate to B cell follicle in a CXCR5-CXCL13 dependent manner. In 
this regard, it has been shown that under physiological conditions, MZ B cells receive a retention 
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signal triggered by sphingosine 1-phosphate (S1P) suggesting an inhibition of motility and 
accumulation of MZ B in B cell follicles while during inflammation there is a reduction of the S1P 
signalling in MZ B cells175.  
B-1 cells, that are closely related to MZ B cells, also have the ability to migrate to mucosal sites, 
especially in the gut mucosa, where they are reported to secrete polyvalent IgA Abs, always in a TI-
fashion. To date, up to the 40% of plasma and intestinal IgA is considered to have a B-1 origin and 
to be IL-5 dependent176,177. The CXCR5-CXCL13 axis is fundamental for B-1 cell homing, regarding 
their retention in the peritoneum, high levels of integrins and tetraspanin CD9 are essential. When 
B-1 cells egress from the peritoneal cavity CD9 down-regulation occurs, a process that is favoured 
by stimulation of TLRs among which the LPS is one of the most relevant178. Peritoneal cavity B-1 B 
cell migration in the intestine is also influenced by S1P since its deficiency alters the composition of 
peritoneal cavity B cell populations and reduces secretory IgA levels. S1P is suggested as a target to 
affect the migration and activation of peritoneal cavity B-1 B cells in pathological conditions such as 
IBD and sepsis where they are reported to play a role179. 
Upon activation, a conventional B cell can become a long-living memory or PCs. IgG PCs express high 
levels of CXCR3 and the integrin α4β1, allowing their  retention in non-mucosal sites; moreover they 
express high levels of CXCR4 that is responsible for their homing in the bone marrow180.  
PPs are the main site of B-cell activation in response to intestinal Ags, leading to the generation of 
gut-homing plasmablasts that produce secretory IgA and attract great numbers of circulating B cells. 
IgA-secreting PCs are activated in mucosal tissues and aero-digestive tract. Their mucosal homing is 
favoured by the expression of α4β7, CCR9 and CCR10. There are however some specificities: CCR9 
allows the selective localization in the colon, mammary gland and respiratory tract; the small 
intestine, instead, is colonized by both CCR9+ and CCR10+  IgA+ PCs, so CCR9 and CCR10 have 
overlapping roles in localization of these cells to the small intestine. Interestingly, higher levels of 
circulating α4β7+CCR10+ plasmablasts have been detected in patients with acute colitis compared 
with healthy subjects181.  
Naïve and memory B cells express CCR6 and are selectively responsive to its ligand CCL20. The 
expression of this receptor is not fundamental to  induce their proliferation but is essential in their 
ability to respond to a recall response to their cognate Ag182. Its expression on B cells is increased 
after a BCR-, CD40+IL-4- or LPS-dependent activations but is drastically decreased in PCs. B cells 
from CCR6 K.O. mice produce Abs with lower affinity, suggesting that CCR6 influences GC dynamics 
and is important in the entry of B cells into the GC reactions183. In the PPs, where the expression of 
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CCR6 and CCL20 is high, CCR6 deficiencies have been shown to impair TD-IgA production that lead 
to a dysregulate antimicrobial peptide production and an imbalanced intestinal microbiota184. 
CCR6 is involved also in pathological processes, for example, men suffering from IBD and in murine 
models of colitis present higher levels of CCL20 compared to uninflamed colon tissues. Ab 
treatments against CCL20, or the desensitization to CCR6, are described to inhibit adhesion of T and 
B cells to inflamed microvessels in mice with dextran sodium sulphate (DSS)-induced colitis185. This 
axis has also been lately investigated in autoimmune conditions, where autoreactive B cells play a 
dominant pathogenic role. In SLE CCR6 has been shown to be up-regulated in patients; moreover in 
the pathogenesis of RA, the accumulation of autoreactive B cells within inflamed synovia, was seen 
to be synergistically favoured by CXCL13 and CCL20186. CCL20 augmented expression is also studied 
in several cancer types such as hepatocellular carcinoma, colon cancer, breast and ovarian cancer, 
thyroid cancer, pancreatic cancer, melanoma and many others187,188. As an example, in the 
hepatocellular carcinoma, tumor derived-CCL20 interacts with CCR6 highly positive CD5+ B cells. In 
this work, conducted both in humans and mice, the recruitment of the B cells favoured cancer 
progression by enhancing angiogenesis189. 
The most widespread barrier to the external environment is the skin, which is indeed rich in both 
innate ad adaptive immune cells. During dermis infections, autoimmunity or cancer, an 
accumulation of B cells in the skin is observed while in homeostatic conditions B cells are almost 
absent. However, in the last years B cell trafficking in the skin during homeostasis has been 
reconsidered and the most known skin-homing chemokine receptors for lymphocytes are CCR4 and 
CCR10 and CCL17 and CCL28 their respective ligands. As an example, Geherin et colleagues showed 
the presence of B cells  in both uninflamed skin-draining afferent lymph and the uninflamed flank 
skin; in addition, in a model of granulomatous skin inflammation they observed that the greatest 
relative increase of lymphocyte subsets was the one B cells. In their work, they identified B-1-like 
cells recirculating through the skin and they showed that skin draining B cells are spontaneously 
responsive to CCL20, thus proposing the CCR6-CCL20 axis as a candidate for inducing B cell 
localization to skin190. The existence of innate-like IL-10-producing B cells in the skin of both mice 
and humans was later confirmed. A peritoneum–skin migratory axis for  α4β1+  B-1 cells has also been 
suggested, in this work B-1 cells in a context of chronic skin inflammation, were playing a regulatory 
role191. 
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3.3. MAST CELLS AND B CELLS IN HEALTH AND DISEASE 
 
As we already said above, one of the most interesting features of MC biology is its “sociality”. MCs 
are indeed predisposed to the cross-talk with other cell types thanks to the expression of several 
membrane co-stimulatory molecules and receptors and their capability to release a plethora of 
soluble mediators that can shape the behaviour of almost all other immune and non-immune cell 
types. The advantage of colonizing nearly all the vascularized body tissues allow them to interact 
with phenotypical and functional different cells such as B lymphocytes. 
 
3.3.1. MC-B cell cross-talk: what is known and what is missing 
 
In 1993, the first evidence of an interaction between these two cell types was reported. Specifically, 
Gauchat showed the expression of CD40L on both MCs and basophils and demonstrated that in the 
MC-B crosstalk, the axis CD40-CD40L, in conjunction with the presence of IL-4, was sufficient to 
promote IgE synthesis in B cells. The importance of this discovery lies on the fact that isotype 
switching could take place not only in LNs GCs but also in peripheral organs192. In 1996, BMMCs 
were shown to be able to induce resting B cells activation: the effect was shown after culture of the 
two cells and resulted in B cell proliferation and IgM production193. Another study appeared in 2002 
when Skokos and collaborators showed that MC-derived exosomes are enriched in co-stimulatory 
molecules such as MHC-II, CD86, CD40L, LFA-1 and ICAM-1 that are able to drive B cell activation111. 
Afterwards, the following reports on a relationship between MCs and B cells were observed in 
inflammatory processes involving secondary lymphoid organs (e.g. LNs, tonsils) where the numbers 
of MCs increased compared to their physiological levels, suggesting an active role of MCs in driving 
adaptive immune responses. Moreover, increased numbers of MCs have been reported also in B-
cell neoplasms including Hodgkin lymphoma, diffuse large B-cell lymphoma, lymphoplasmacytic 
lymphoma, and chronic lymphocytic leukemia194,195. In 2010 in Pucillo’s group, the mechanisms 
responsible for the MC-dependent B cell survival and proliferation were deeply investigated. They 
showed the contribution of both resting and activated BMMCs in B cell survival and proliferation. 
Cell-to-cell contact through the CD40-CD40L axis and the release of soluble mediators by activated 
MCs resulted to be synergistic. In addition, the CD40 expression on B cells was favoured in the 
setting of this interplay. Finally, both membrane contact and MCs’ soluble mediators, such as IL-6, 
were involved in the expansion of CD138+ and IgA-producing PCs. In the same work, evidences 
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concerning the close contact of IgA+ PCs and infiltrating MCs were shown in human samples of 
intestinal mucosa of patients suffering from IBD195. 
Later, in the same group, a novel mechanism involving the CD40-CD40L axis was reported in the 
expansion of IL-10-competent B cells, evocative of a B cell-dependent regulatory potential. 
Interestingly, by using a Kit-deficient animal model they showed that, in tissue-specific 
microenvironments such as in the gut, the absence of MCs was paralleled by a reduced proportion 
of IL-10 competent B cells196. 
In the figure below the main roles of MCs in the regulation of B cells’ biology are illustrated.  
 
 
Figure 13: MC’s derived soluble 
mediators and the physical contact 
through the CD40L-CD40 axis 
favours B cell activation and 
functionality. Signals derived from 
the CD40 signalling and the 
stimulation through IL-6, IL-4 and 
IL-13, or exosome-carrying co-
stimulatory molecules, induce, in 
different combinations and diverse 
microenvironments, either survival 
and activating signals that lead to 
Ab switching or sustain the 
amplification of a regulatory IL-10-
competent B cell population . 
 
 
In literature, we can also find  more recent reports concerning MC-B cell interaction analysed in 
different pathological process. In 2015, Kim and collaborators proposed a negative role played by 
IL-10-producing CD5+ splenic murine B cells in dampening MC’s allergic activation. They observed 
both in vitro and in vivo a reduced FcεRI signalling in the presence of splenic CD5+ B cells-derived IL-
10 197. In 2016 another  group showed that MCs are able to induce the L-selectin up-regulation on B 
cells, suggesting a role in their homing properties, and of CD19, MHC-II and CD86 molecules, 
decreasing the threshold of activation of  B cells and enhancing their Ag-presenting capacity. In their 
study, they also extended the role of MCs in B cells’ isotype switching in the sustain of IgG 
production. Moreover, they investigated the impact of MCs on FO and MZ B: they observed that 
the effect on L-selectin modulation is higher on MZ, and that there is a larger effect on the Ab 
production while the impact on MHC-II and CD86 expression was more relevant on FO B cells198. 
                                                                                                                                                           Introduction 
44 
 
The MC-B cell axis was also identified in a model of pulmonary hypertension. In a gene array 
analyses, the authors revealed that several components of Igs were among the most regulated MC-
dependent genes. In agreement with this analysis, they detected increased circulating IgG after the 
infiltration of MCs into the hypertensive lungs. They propose that during the initial phases of the 
onset of pulmonary hypertension, MCs  accumulate in the lung perivascular space and release their 
stored mediators pro-inflammatory factors, suggesting a role for IL-6. B cells in turn promote 
endothelial dysfunction resulting in vascular remodelling and pulmonary hypertension through an 
auto-Ab- mediated response199. A recent report was aimed at analysing IgE responses during 
helminth infections in RAG1-/- mice, appropriately reconstituted with specific populations of 
lymphocytes. They showed that, during helminth infections, B-1 cells make large amounts of IgE in 
a T-cell-dependent manner. This IgE production was enhanced by IL-25, that is increased following 
parasite infection. Moreover, this mechanism inhibits the IgE production by B-2 cells and, 
interestingly, were unable to induce MCs’ degranulation and parasitic clearance proposing a 
regulatory mechanism that inhibits MC’s functions. They demonstrated that helminth clearance by 
B-2- IgE cells was instead MC-dependent200. 
All the cited works highlight the importance of MCs in promoting the activation of conventional B 
cells  in different physiological and pathological contexts. However, many aspects of this interplay 
still remain to be determined. A little attention has been put in characterizing the cross-talk 
comparing different B cell subtypes, such as the B-2 and B-1 lineages. Moreover the effect of B cells 
on MCs subtypes in allergic, autoimmune or cancer conditions still are unexplored fields. 
 
3.3.2. Mucosal immunology of the intestine 
 
Many of the works regarding MC-B cell interplay  that are done in in vivo contexts involve the 
mucosal sites of the body. MCs indeed, as sentinels of the microenvironment are strategically 
located in close proximity not only with the blood vessels and nerves, but  also close to the barriers 
that separate the organism with the external environment. Among the barriers of our body, the 
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How homeostasis is maintained in the intestinal mucosa 
 
The gastrointestinal tract of mammals can be defined as the non-self environment of the body par 
excellence because of the continuous presence of food Ags and a tremendous number of 
microorganisms. For this reason, evolution has developed a complex system of barriers that, 
together with immune tolerance, are aimed at preventing activation and continuous inflammation. 
The system of resident bacteria, fungi and viruses that evolved in symbiosis with mammals form the 
gut microbiota. The microbiota offers several benefits to the host: it synthesizes the B and K 
vitamins, produces metabolites such as the short-chain fatty acids (SCFA), which is a source of 
energy and  enhances the mucus production. SCFA, in particular, promotes the development of 
Tregs, essential for the immune tolerance201. The integrity of the mucosal barrier is fundamental to 
keep separated the host immune cells and the gut microbiota. In fact, intestinal barrier dysfunctions 
have been associated with the development of IBD202. Antimicrobial peptides such as α-, β-, θ-
defensis and cathelicidins in the small intestine are produced mostly by Paneth cells that cover a 
fundamental role in segregating gut Gram-positive and Gram–negative bacteria and small intestinal 
epithelia. At the level of the large intestine, Paneth cells are absent and the mucin glicoproteins 
secreted by goblet cells act as a physical barrier203. Here two layers of mucus, composed of globlet 
cell-secreted Mucin-2 (MUC2) protein, are formed. The inner mucus is anchored to the Intestinal 
epithelial cells (IECs), located at the surface of the mucosal barrier, and is free of gut bacteria since 
IECs produce defensins and transport antimicrobial IgA, preventing the penetration of 
microorganisms204. The production of these molecules by IECs is controlled by TLR4/MyD88 and 
NOD2 signalling that are in turns driven by gut microorganisms themselves205,206. 
 




Figure 14: Segregation of microorganisms in 
the lumen side of the intestinal mucosa. 
Intestinal bacteria and IECs are 
compartmentalized in the intestine in order to 
maintain the homeostasis of the gut. The 
segregation of gut microbiota is favoured by the 
high sensitivity of enterocytes to the 
microorganisms at producing antimicrobial 
molecules, by the presence of a network of 
mucin glycoproteins and by the transport of 




The importance of the IgA in the intestine is clear, as it was demonstrated to be the most abundant 
Ig at the mucosal site where its production is strictly tuned by the presence of commensals208,209. 
Indeed, studies performed in germ-free animals showed very low levels of IgA in these animals210. 
In the mucosal lymphoid organs PCs secrete IgA, these are bounded to the polymeric Ig receptor 
(pIgR) and through IECs they are transported in vesicles in the lumen after a proteolytic cleavage of 
the pIgR. After transport, the secretory component is left attached to the IgA: the heavy chain of 
two molecules of IgA are linked together by a J chain making a dimer. These Abs, under specific 
physiological or pathological conditions, are then spread in other mucosal compartments such as 
the mammary gland211. IgA responses are compartmentalized within the gut mucosa and, as 
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mentioned before, B cells that recirculate in blood and lymphoid organs preferentially home the 
intestine when they over-express specific receptors.  
In the intestine, DCs  constitutively produce retinoic acid, that induces mucosal IgA CSR in B cells 
and Treg differentiation (figure 15). Moreover intestinal B and T cells are programmed to express 
CCR9, which in turn directs their homing into the mucosa.  
 
 
Figure 15: Intestinal DCs promote IgA 
PC formation. Lamina propria (LP) DCs 
actively sample the pathogens located 
at the apical surfaces of epithelial cells 
by extending their dendrites between 
the epithelial cells. Bacteria-activated 
DCs migrate to Peyer’s patches and 
mesenteric LNs (MLN) where they 
induce B cells to differentiate into IgA+ 
PCs. IgA+ PCs in  the LP produce and 
release dimeric IgA+ that are 
transported across the epithelial layer 
to prevent bacteria colonization of the 
LP207. 
 
Cytokines produced by immune cells contribute in the maintenance of mucosal barrier homeostasis. 
Th17 lymphocytes that produce and release protective IL-17 and IL-23 in the LP are induced to 
develop thanks to IECs-derived serum amyloid A (SAA). The segmented filamentous commensal 
bacteria (SFB) instead promote the release of IL-17 and IL-22 by type3 ILCs212. These cytokines 
promote the release of anti-inflammatory peptides. When there is an impairment of the barrier, IL-
4 and IL-13 Th2 cytokines promote colonic wound healing by inducing the alternative activation of 
macrophages and the proliferation of IECs213.  
 
3.3.3. Roles of MCs and B cells in diseases: focus on the intestinal environment 
 
The protective role of differentiated B cells-derived IgA in maintaining the homeostasis of the 
intestine has been described above. It has also been demonstrated that IL-10 produced by B cells 
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has an important role in the formation of mucosal Treg cells in allergic and tumoral animal 
models214,215. MCs’ contribution in tissue healing as well as in the resolution of an inflammation 
through the production of anti-inflammatory mediators (such as IL-4, IL-10 and TNF-β) are well 
known216. MCs, indeed, are known to be equally central in the maintenance of mucosal homeostasis 
in the gut since they are reported to regulate intestinal epithelial permeability during inflammatory 
responses217. In the gut MCs interact and modulate the activity of several cell types, as illustrated in 
figure 16. It has been reported, for instance, that KitW-sh or Mcpt4 K.O. mice show a decreased 
epithelial permeability and turnover, aside from diminished intestinal epithelial cell migration along 
the villus-crypt axis and altered intestinal morphology. Notably, the reconstitution of these mice 
with Wt MCs restored the barrier functions218. Moreover MC’s tryptase was shown to degrade 
cytokines and matrix metalloproteinases (MMPs) and participates in bacterial defense102.  
 
 
Figure 16: MC’s roles in the intestinal barrier. MCs in the intestinal mucosa potentially interact 
with a broad spectrum of cell types. They participate in the regulation of epithelial and vascular 
permeability, in the recruitment and activation of other immune cells, they also modulate 
peristalsis and pain signalling by communicating with the nervous system219. 
AJ, adherens junction; CRFR1/2, CRF receptors 1 and 2; CNS, central nervous system; CRF, corticotropin-
releasing factor; D, desmosome; ENS, enteric nervous system; GM-CSF, granulocyte and monocyte colony 
stimulating factor; IgLC, immunoglobulin free-light chains; ILs, interleukins; LT, leukotrienes; PAR2, 
proteinase-activated receptor-2; TJ, tight junction). 
 
Since the intestine is a privileged site in which MCs and B cell reside and are shown  to interact195, 
we describe below how these two cell types not only are affected by, but also how they actively 
regulate the gut imbalanced homeostasis. 
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3.3.3.1. MCs and B cells in IBD 
 
IBD encloses a group of disorders characterized by inflammation of the intestine, in human, the two 
major forms are Chron’s disease, that can involve a wide tract of the gastrointestinal apparatus, and 
the ulcerative colitis (UC) that affects instead the large intestine220. IDB is still an incurable disease, 
characterized by a mutual interaction of genetic factors, intestinal epithelial barrier dysfunction, 
alterations in the intestinal microbiota and immune dysregulation221. A role of MCs in the 
pathophysiology of IBD has long been known from the discovery of their increased number: 
degranulated MCs and an increase of  their mediators are reported in patients with both Crohn's 
disease and UC222,223,224,225,226. In addition, MCs have been suggested to be major drivers of acute 
colitis227. Despite an accepted role for MCs in IBD, conflicting roles of MCs are reported in different 
animal models. In some studies of chemical models of induced colitis, MCs are reported to be 
detrimental. As an example, in a rat model of intracolonic administration of trinitrobenzene sulfonic 
acid (TNB) and ethanol, that cause haemorrhagic and ulcerative damage to the proximal colon, the 
use of ketotifen, a MC’s stabilizer, ameliorated the mucosal damage228. Moreover in dextran sodium 
sulfate (DSS)-induced colitis many reports showed that genetic MCs’ depletion ameliorated colitis. 
Beyond the already mentioned importance of MC-derived MCP-4, other MC’s derived mediators 
have been elucidated to drive the development of colitis such as the chymase, that was shown to 
strengthen the activity of MMP-9 in the degradation of the matrix229,230. However, many authors 
proposed that MC deficiency is associated with the exacerbation of the inflammation in 
spontaneous colitis models, thus proposing beneficial roles of MCs in IBD231. Recently, Rigoni and 
collaborators showed that increased MCs in the LP played a role in colonic epithelial regeneration 
after DSS withdrawal. They propose a model by which, MCs infiltrating the colon upon DSS 
withdrawal upregulate ST2, the receptor for IL-33. IL-33 is a cytokine that has been associated to 
intestinal inflammation and proposed as one driver of colorectal cancer (CRC): this protein and its 
receptors are increased in patients with IDB232. MCs, activated by the IL-33 release proteases such 
as the MCP-4, which degraded IL-33 favouring the reduction of the inflammation. Indeed, both in 
vitro and in vivo, MCP-4 K.O. BMMCs were unable to promote mucosal healing after DSS 
withdrawal, unlike Wt BMMCs reconstituted- MC-deficient mice233. In IL-10-deficient mice an earlier 
onset of spontaneous colitis and the increased intestinal permeability were observed after deletion 
of MCs234. In support of this evidence, in a double IL-10 and MCs K.O. mice model, the lack of MCs 
increased the pathological score and impaired the mucosal barrier, the pro-inflammatory cytokines 
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were increased as well as the oxidative stress and goblet cell loss235. It was recently confirmed the 
improvement of the colitis with systemic MC engraftment in these mice even if the exact 
mechanisms are not yet well understood236. 
Also adaptive immunity covers important roles in the pathogenesis of IBD. Considering B cells’ role 
in IDB there are controversial reports. The association of B cells with colitis was suggested by the 
fact that IL-10 K.O. mice develop spontaneous colitis. Beyond the greater contribution of T cells, B 
cells are as well known to produce this anti-inflammatory cytokine as mentioned before. In patients 
suffering from UC the analysis of  CD24highCD38high and CD5+ cells, used by the authors to identify 
two major Breg phenotypes, showed that the numbers were significantly decreased while an 
increase in the CD95+ -exhausted Breg population was observed. Moreover, an increased serum IgG 
concentration was paralleled in these patients237. To mention, the anti-CD20 B cell depletion with 
the anti-CD20 rituximab, so far studied in UC, failed238. The inflamed intestine of IBD patients is 
hugely infiltrated with B cells and IgA+ and IgG+ PCs, with a skewing towards IgG production, 
depending on the severity of inflammation239. 
By studying the model of DSS, L. Wang and co-workers demonstrated a crucial role played by B cells 
in the suppression of colitis. They showed that DSS-induced colitis was more severe in B cell-lacking 
mice (µMT) and, contrary to previous suggestions, that IL-10 produced by B cells was not necessary 
for the amelioration of the inflammation. They showed instead a loop by which B cells promoted 
the proliferation of Treg cells in the GALT. In turns, these Treg enhanced protective IgA production. 
It is interesting to note that the total splenic B cell population, adoptively transferred in K.O. 
recipients, was responsible for the attenuation of colitis in μMT mice. This population, which 
accumulated in the GALT, was not IL-10 producing but was driven by Treg-derived TGF-β to switch 
into IgA producing PCs240. The importance of IgA production during colitis is also highlighted in other 
studies, for example IgA deficiencies predisposes to an increased rate of IBD241,242. In another study, 
IL-33 K.O. mice showed a greater body weight loss and an increased production of pro-inflammatory 
IL-1α; these animals had significantly decreased levels of IgA in colon explants, while the levels of 
other Igs were similar to Wt mice243. Even if the authors did not prove a direct or indirect mechanism 
by which IL-33 favours the production of beneficial IgA, once again they proved the importance of 
this mucosal Ab in the progress of the pathology. 
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3.3.3.2.  When inflammation turns into cancer: the activation of MCs and B cells in 
CRC 
 
Patients with chronic IBD, and in particular those suffering from UC,  have an increased risk of 
developing CRC, which is the third most common tumor worldwide244. The association with 
inflammatory diseases suggests a direct interaction between immune cells in the LP and epithelial 
cells that undergo the adenoma to carcinoma phase 245. Two main types of CRC can be distinguished: 
the hereditary colon cancer, where patients have generally loss of functions in the adenomatous 
polyposis coli (APC) gene, that leads to the destabilization of the β-catenin, and the sporadic CRC 
neoplasia, associated mostly to IBD. 
The presence of tumor associated inflammation is an important sign of cancer progression246 . For 
example MCs infiltrate the mucosa of inflamed intestine and accumulate during tumor formation 
(figure 17),suggesting a role for them in the regulation of different phases of intestinal 
tumorigenesis, even there are conflicting results.  
 
 
Figure 17: MCs accumulate during the 
progression to adenocarcinoma. A Leder 
stain  identifies rare MCs (purple dots) in a 
normal mouse intestinal mucosa. MCs 
accumulate during cancer formation in the 
Apc+/- genetic tumor mouse model245. 
 
In the tumour tissue of human CRC, tryptase positive MCs have been observed to be located mainly 
in the stroma at the interface between rising cancer and healthy tissue and, frequently, in 
association with blood vessels within the tumour microenvironment (TME). The presence of MCs at 
the invasive margin of tumors has been associated to a poor prognosis and related to the expression 
of the protease-activated receptor 2 (PAR-2)43. One of the factors responsible for the accumulation 
of MCs in the tumor is the SCF produced by the tumor itself. The SCF, not only attracts MCs, but also 
sustains their activation to release factors (e.g. TNF-α, IL-6, VEGF, CCL2, iNOS, adenosine , MMP-9 
among others) responsible to increase the vascularity, inflammation and chemotaxis of other 
immune populations247 (illustrated in figure 18). 
 




Figure 18: MCs in the TME: MCs are attracted in the TME where they release a wide range of 
bioactive mediators influencing the angiogenesis and the tumor growth. MCs mediators attract 
tumor related- immune cell subsets (such as Treg cells or myeloid derived suppressor cells (MDSC)) 
and cross-talk with them modulating their immune responses248. 
 
In CRC polyps the prognosis is often associated to a high MCs (and MC precursors) density, these 
cells seem indeed to promote progression cancer and sustain inflammation. MCs have been 
identified as an essential hematopoietic component during polyp development both in humans and 
in genetic APC mutated mouse models. Moreover TNF-α was identified to be an indispensable factor 
for MCs proliferation and expansion in APCΔ468 mice produced as an autocrine factor by MCs 
activated in the tumor growing249.  
Direct interactions between MCs and cancer cells have been shown. For instance, MCs have been 
described to manifest a sort of “piecemeal degranulation” releasing factors that can promote colon  
cancer proliferation and invasion in vitro and in vivo. In a study, conducted in a murine setting in a 
Balb/c background, MCs were able to increase the expression of factors such as RhoA, VEGF, and 
TGF-β as well as to activate MAPK and STAT pathways in the CT26 cancer cell line250. In a metastatic 
model of CRC, MCs sustained the tumor, on the contrary a protective role of MCs has been 
suggested in the ApcMin/+ mouse model in the early intestinal tumorigenesis251. Mehdawi and 
collaborators investigated in the specific the protective role of MCs in human CRC. Interestingly in 
their study they did not observe phenotypical differences between MCs in normal and tumor tissues 
but the higher MC density was associated with a longer overall survival of a cohort of patients 
analysed. In support to their observations, in cysteinyl leukotriene receptor 1 (CysLTR1) K.O. 
animals, that were previously shown to display fewer polyps, higher polyps MCs density was 
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observed252. In the previously mentioned work by Rigoni A., the authors studied also  the role of 
MCs in CRC by using the AOM/DSS model: they showed a higher MC infiltration in most aggressive 
tumors233.  
In addition to TNF-α produced by MCs upon activation in the cancer context, another very important 
factor of the CRC TME is the IL-33. In CRC it has been shown, both in human and mice, that the 
epithelial cancer cells release high levels of this cytokine. In addition to the IL-33-dependent 
enhancement of metastatic capacity on tumor cells, it activates the stroma to create a permissive 
environment for tumor expansion. In 2015 the group of Heaney J.D. reported that IL-33 signalling 
promote polyp-associated mastocytosis by comparing normal ApcMin/+ mice to il33-deficient ApcMin/+ 
mice. The authors suggested that MCs establish a TME favourable to polyposis since, IL-33 activates 
MCs to release pro-inflammatory factors59. Even if there is a larger consensus concerning the pro-
tumorigenic roles of the IL-33/ST2 pathway253,254,255,256, there are some authors that showed an 
antitumorigenic role for ST2 in colon carcinogenesis. They detected in tumor tissue a decreased 
expression of the transmembrane receptor ST2L and that that IL-33 did not increase cancer cell 
proliferation and invasion, while the deletion of ST2 resulted in higher tumor growth in vivo257. 
 
In the analysis of lymphoid cells in the TME, tumor-infiltrating B cells (TIBs) have been considered 
as ignored players in tumor immunology258. The determination of the exact role of B cells in cancer 
is complicated by the fact that heterogeneous B cell subsets exist with functionally opposite roles 
(figure 19). IL-35,TGF-β and IL-10 together with PD-L1 and indoleamine 2,3-dioxygenase (IDO) 
expressing-B cells are important factors in immune suppression of T cells.  PCs secreting IgG and IgA 
Abs have been instead reported to have contradictory roles. In some cases these Abs sustain the 
progression of cancer, but other studies show that Abs may amplify adaptive immune responses. 
Positive roles of B cells include the immunosurveillance facilitating the expansion and the formation 
of memory tumor-infiltrating T cells by acting as local APCs. Direct killing activity of B cells against 
the tumor can also be established. For instance, the expression of membrane death-inducing 
molecule Fas ligand (FasL) and the production of granzyme by B cells can directly kill tumor cells259. 
 




Figure 19: Different B cell subsets in the TME. Pro-tumorigenic B cell responses are played by 
immunosuppressive regulatory B cells that secrete IL-10, IL-35 and TGF-β as well as by IgA-
expressing PCs that express IL-10, Fas-L and PD-L1. Bregs interactions with T cells induce their 
expression of Foxp3 and CTLA-4 (markers of Tregs). Anti-tumorigenic roles of B cells include IgG 
producing PCs that activate immunity against the tumor, APCs B cells for the stimulation of effector 
T cells, B cells expressing death-inducing molecules such as FasL (not shown in the picture) and B 
cells secreting granzyme B that directly induce apoptosis on cancer cells260. 
 
In CRC, infiltrating B cells were described at the invasive margin in lymphoid aggregates in close 
contact with DCs, this structure is known as “Crohn's like reaction”. The B cell populations identified 
were composed of mature B cells and of differentiated PCs. Moreover, high levels of MHC-I and -II 
and CD80 were detected on these TIBs. Ag-experienced PCs secrete Ig of the three types IgG, IgA, 
IgM with predominant polarization towards IgG261. Later, in a work conducted on human patients 
aimed at characterizing B cells in CRC, a higher percentage of memory B cells (IgD-CD27+) was 
identified in peripheral blood compared to healthy controls. Moreover, there was a reduced number 
of B cells in liver metastasis acquiring a regulatory phenotype. On the contrary, early-stage cancers 
were enriched in terminally differentiated PCs both in the blood and the tumor suggesting an 
antitumor response262.  
In our laboratory, we recently published a work in which we performed a fine characterization of B 
cell phenotypes and functions of B cells in lymphoid organs of murine models of CRC with a 
                                                                                                                                                           Introduction 
55 
 
particular focus in the genetic model of the ApcMin/- mouse. We observed that IL-10 competent B 
cells were increased in the LNs draining the tumor (dLNs) and that in the spleen and peritoneum 
there was an increased proportion of IgA+ lymphocytes. The increase of IgA PCs was also confirmed 
in the analysis of serum IgA Abs and in the identification of IgA+ cells in the transformed gut mucosa. 
Interestingly, we observed that the percentages of B cells in both MLNs of the ApcMin/- mouse model 
and AOM/DSS tumor model and in the dLNs of the subcutaneous model of ectopic CRC in CT26-
bearing mice were increased. Preliminary evidences suggest that this B cell accumulation was due 
to a higher expression of physiologic and inflammatory of lymphocytes-related chemokine: CXCL12, 
CXCL13, CCL19, CCL21 and CCL20263. This microenvironment favourable to a B cell recruitment at 
the level of tumor growth is extended in the context of this thesis work where a new interesting 
MC-tumor cell-B cell axis is proposed.  
Increased chemokines are indeed observed in several cancer types and are responsible for the 
infiltration of tumor leukocytes and for the process of metastatization of solid cancer such as the 
CRC. For instance, CCL2 and CCL5 have been correlated with high levels of tumor associated 
macrophages (TAMs) that promote angiogenesis and inhibit T cell responses in breast cancer264,265. 
CCR7 expression was reported to be crucial in melanoma, CXCL12 was seen to be involved in 
metastatization in the lungs and has been proposed as a therapeutic target266,267.  
In CRC many chemokine-receptor couples have been identified in cancer progression and 
metastasis, these axis are listed in the table3  and picture 20.  
In this thesis, the CXCR6-CCL20 axis will acquire a novel perspective with regards to the attraction 
of B lymphocytes in CRC tumor sites. From the literature it is known that increased levels of CCL20 
and CCR6 have been first described in human samples of primary and metastatic CRC compared to 
normal mucosa268,269. CCL20 is weakly expressed in normal colonic mucosa but in response to an 
inflammatory stimulus CCL20 is strongly up-regulated. The higher expression of CCR6 on CRC liver 
metastases suggested the hypothesis of a role played by CCR6 in the metastatization process270. 
CRC cells express in fact both CCL20 and CCR6 in a non-polarized manner. In this way efficient 
autocrine and paracrine loops are established271. These evidences have also been confirmed in 
animal models. Interestingly, in the generated CCR6 K.O.-ApcMin/+ mice, fewer intestinal tumors and 
smaller spleens (spleens size correlates with burden of intestinal adenoma) were developed 
compared to the ApcMin/+ mice272. In the same work the authors demonstrated a role for this axis 
for both macrophage infiltration and CCL20-induced proliferation of murine and human CRC cell 
lines through an auto-feedback loop. In another work it has been shown that TAMs are an 
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importance source of CCL20 in the tumor progression273. To date, the main cell types clearly 
reported to be recruited through this axis in CRC beyond monocytes are Th17 and Tregs 274,275. 




Figure 20: CRC cells-leukocytes interactions mediated by chemokines. In the TME chemokine-
receptor signallings are established between tumor cells and leukocytes. Tumor-promotive (red 
arrows) and tumor-suppressive (blue arrows) effects are produced following the recruitment of 
myeloid and lymphoid cell populations (BMDC: bone marrow derived cells)275. 
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4. AIMS OF THE THESIS 
 
MCs have increasingly gained notoriety for their multiple roles, not only in allergies, but also in 
pathological contexts such as acute inflammation and cancer. Their multiple phenotypes and 
functions and the continuous cross-talking with other immune cell types are among the most 
fascinating aspects in MCs’ biology. In previous works our laboratory uncovered an interesting cross-
talk, at the level of normal and inflamed intestine, established between MCs and B lymphocytes: 
MCs were shown to be capable of regulating and supporting several aspects of conventional B cells’ 
functions. The purpose of this thesis work was to investigate some unaddressed aspects of MC/B 
cell cross-talk in physiological and pathological contexts. Since sub-populations of both MCs and B 
cells can interact in specific and separate body compartments, the first  line of research aimed to 
study the interaction between different phenotypical and functional MCs subtypes with the B-2 and 
B-1 lineages of B lymphocytes. Since in many B cell-related pathologies increased numbers of MCs 
are reported, beyond the evaluation of the effects that MCs induce on B cell subtypes, we were 
interested in clarifying whether B cells could reciprocally favour or enhance the activation of MCs. 
After an in vitro study, some of the main observations were investigated also in mouse models. The  
distribution of MCs was analysed in the B-1 lacking bumble mice because of the interesting data 
emerged in the MCs/B-1 cells interaction. A systematic analysis of the distribution and activation of 
B cells was performed in two MCs-deficient models where both the homeostatic and the DSS-
induced colitis contexts were examined because of the great importance of the MC/B cell cross-talk 
in the intestine. 
As a second aim, the MC/B cell interplay was investigated in the CRC since this pathology can be a 
detrimental consequence of a persistent inflammatory state of the gut. Our recent data showed 
that the onset of CRC dramatically affects the distribution and phenotype of B lymphocytes and it is  
known that MCs are important immune drivers of this cancer type. The MC/B cell interaction was 
explored taking advantage of an in vivo subcutaneous model of CRC in Wt and MC-deficient animals. 
The analysis of the direct cross-talk between MCs and cancer cells helped us to determine how MC’s 
activation in this cancer context was responsible for some alterations of the B cell behaviour in this 
pathology.  
 





5.1. MC-B CELL BIDIRECTIONAL CROSS-TALK UNDER PHYSIOLOGICAL CONDITIONS: THE MC 
SIDE 
 
The latest advancements in MC’s biology show the great heterogeneity in phenotypes and functions 
acquired by MCs under the pressure of different physiological and pathological 
microenvironments5. The different body compartments are determined by the specificity of  
resident cell subsets and of their mediators and B lymphocytes and are one relevant cell type that 
populates many MCs’ sites of differentiation. With the aim of extending the knowledge about MCs 
and B cells interplay, we decided to investigate some of the unanswered traits of the MC-B cell cross-
talk in the murine setting. MC’s support in conventional B-2 cells-related functions is widely 
accepted: activation and isotype switching are favoured in the presence of soluble mediators 
released by MCs and by effect of a membrane-dependent cross-talk195,198; moreover, MCs induce 
the expansion and differentiation of IL-10-competent B cells196. On the contrary very little is known 
on the effects that B cells can have on MCs’ activation even if the concomitant increase and 
activation of MCs in many B cell-related inflammatory and tumoral pathologies suggest that, in vivo, 
B cells may affect MCs behaviour194,276. Moreover, some of the in vivo sites in which MCs are located 
and in which their activation is of great relevance in pathological conditions such as the peritoneal 
cavity and the intestine277,94 are populated to a great extent by innate-like B-1 cells. As a first 
objective we explored the effects that B cells can induce on the biology of the two main subtypes of 
murine MCs exploring in particular the modulation of activator membrane-bound receptors and the 
ability to release regulatory and inflammatory mediators, both in resting conditions and during an 
IgE/Ag dependent-stimulation. The second objective of the in vitro characterization of the mutual 
MC-B cell interplay was focused on defining common and different effects induced by MCs in the 
biology of B cell subsets. To address these aims we established an experimental set up (described in 
the methods section, paragraph 7.2.8) in which in vitro bone marrow-derived MCs (BMMCs) that 
are immature mucosal-like MCs and mature serosal-type peritoneal-derived MCs (PDMCs) were co-
cultured with freshly purified murine splenic or peritoneal cavity B cells. These two different 
anatomical B cell populations are representative of B-2 conventional lymphocytes or enriched in B-
1 innate-like lymphocytes respectively.  
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5.1.1. B cells do not affect MCs degranulation 
The degranulation of the MC in an allergic context is the best known sign of its activation and it is 
the result of the antigenic stimulation through the cross-linking of IgE bound at its high affinity 
receptor FcεRI278. In literature it has been shown that conventional T cells are able to potentiate 
MC’s degranulation and the synthesis of mediators through the physical contact and the release of 
soluble vesicles279. Treg cells induce the suppression of MC’s allergic activation through the OX40-
OX40L axis280. However, through a TGF-β dependent mechanism, Treg are also reported to enhance 
IL-6 production in MCs281. Concerning B cells’ effect on MCs degranulation, in 2016 Palm and 
collaborators reported that resting and BCR-activated splenic B cells did not modulate MCs’ 
degranulation198. Similarly to what observed with Treg cells, IL-10-producing CD5+ splenic B cells 
have been shown to reduce FcεRI signalling in MCs by decreasing Syk activation which results in a 
diminution of degranulation197. 
From these evidences, it is clear that there is no consensus on B cell’s role on MC’s degranulation 
and moreover this seems to be different depending on the specific B cell subset analysed. We 
decided therefore to deeper investigate the effect of B cells on MC’s degranulation by comparing 
the effect given by conventional splenic B-2 and peritoneal B-1 cells. IgE pre-sensitized BMMCs were 
challenged in Tyrode’s buffer with DNP for 30 min in the presence or absence of an equal amount 
of splenic or peritoneal cavity B cells. To detect basal levels of degranulation also unstimulated 
BMMCs were put in the same buffer solution for 30 min in the presence of B cells. Degranulation 
extent was measured in terms of the amounts of β-hexosaminidase, an enzyme enriched in MC’s 
cytoplasmic granules, released after 30 min of DNP challenge as described in the experimental 
procedures paragraph 7.2.3. Our data show that both the basal release of β-hexosaminidase and 
the degranulation of MCs induced by a high Ag concentration (50 ng/ml) was only minimally 
increased over the control by both the B cell subsets analysed (figure 21A). Statistically significant 
increases are indicated, however from a biological point of view these differences can be considered 
marginally relevant. We also tried to boost B cells’ effect by pre-stimulating the cells with LPS for 
48h before culturing them with BMMCs. However, even when activated, no biologically relevant 
effects were observed (right graph panel A). We then hypothesized that B cells support could have 
a role in the presence of lower doses of Ag. Therefore, the same experiments were repeated 
activating BMMCs with intermediate (10 ng/ml DNP) and low Ag concentrations (1 ng/ml DNP). 
However our results showed that, even in the presence of lower Ag concentrations, B cells are not 
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able to promote a biologically relevant increase of MC’s degranulation. Moreover, the 
representative experiment conducted in the analysis of Leukotrienes C4, D4 and E4 support this 
observation since the levels of leukotrienes were unchanged in the presence of B cells (figure 21C). 
Altogether, these data indicate that, at least in vitro, MC’s anaphylactic degranulation is not 
potentiated neither by the B-1 nor the B-2 B cell subsets and this distinguishes the MC-B cell 
interaction from the cross-talk with T cells. 
 
 
Figure 21: The degranulation of MCs is slightly affected by the presence of both B-2 and B-1 
enriched B cell populations. (A) β-hexosaminidase release by not stimulated (nst) or anti-DNP IgE 
pre-sensitized BMMCs challenged with 50 ng/ml of DNP after 30 min from the addition of 
unstimulated splenic (Spl) or peritoneal cavity (PerC) B cells (left panel) or 48h 1µg/ml LPS-
stimulated B cells (right panel). (B) 10 ng/ml or 1 ng/ml (respectively left and right panel) of DNP 
are used to induce BMMCs’ degranulation under intermediate and low Ag concentrations 
respectively. (C) Detection of the release of leukotrienes from activated BMMCs cultured with 
freshly purified B cells under high Ag concentration (50ng/ml DNP). A representative experiment is 
shown. (A, B) Means (+SEM) from at least three independent experiments are shown. *p<0.05, ** 
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5.1.2. Peritoneal cavity B cells modulate the expression of MCs’ membrane-bound 
molecules 
MCs express a considerable amount of activating and inhibitory receptors that can fine tune the 
level of MCs’ activation282. In this light, we decided to explore the possibility that B cells could 
modulate the expression of some membrane-bound molecules on MCs. We decided to compare the 
effect of splenic and peritoneal cavity B cells on BMMCs and PDMCs in terms of ICAM-1, CD28, MHC-
II, ST2, LAMP-1 and c-Kit expression. 
 
 Table 4: Membrane-bound molecules of MCs analysed in the co-culture system 




Constitutive Up-regulated in response to 
inflammatory stimuli. IL-33 induces 




CD28 Low levels Co-stimulatory molecule. Modulated by 
bacteria products. When engaged 
together with the FcεRI, it increases the 
release of TNF-α by MCs  
 
284 
MHC-II Very low levels/ 
inducible 
Present to a limited level at the cell 
surface and mainly in intracellular 
granules. Expression increased following 
stimulations with stimuli such as LPS, 




ST2 Highly expressed Receptor of the IL-33 cytokine. Among 
the markers for the phenotyping.  
288 
LAMP-1 
(late phase marker 
lysosomal-associated 




Marker used to follow MC degranulation 
by flow cytometry. 
 
289 
c-kit High levels Main marker that through the binding of 
the SCF is able to influence virtually all 




In accordance with what reported in literature we first observed that, under resting conditions, only 
c-kit and ST2 were more expressed in PDMCs compared to BMMCs  (respectively a fold induction of 
1.3 and 1.5), while all the other molecules were expressed at comparable levels (figure 22) 291. In 
the presence of B cells, no modulations of ICAM-1, CD28 and LAMP-1 expression were observed on 
resting and activated MCs. Of note, the result that B cells did not affect the expression of LAMP-1 
after 1h of IgE/Ag activation of MCs confirms the evidences of the β-exosaminidase dosage 
experiments and, therefore, the conclusion that B cells do not provide any support in MCs’ 
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degranulation. On the other hand, the expression levels of MHC-II, ST2 and c-Kit underwent 
modulation in the presence of B cells. More in detail, in the presence of both B cells’ subsets, MHC-
II expression increased on both resting and activated PDMCs and BMMCs, suggesting that B cells 
can promote the reported MCs’ inducible activity to process and present antigens to CD4+ T cells286. 
Regarding ST2, its expression was further upregulated both on BMMCs and PDMCs in the presence 
of peritoneal cavity, but not splenic, B cells. Therefore, the MC/peritoneal cavity B cell interplay is 
able to promote the increase of an “inflammatory” receptor, which can lower the threshold of MCs 
activation in the presence of tissue injury, which results in IL-33 release. It is particularly relevant 
that IL-33 binding to ST2 is actually able to induce the release of pro-inflammatory mediators from 
MCs and to potentiate the IgE-dependent activation, therefore sustaining inflammation55. Finally, 
we observed a downregulation of c-Kit in IgE/Ag activated PDMCs, also in this case given by 
peritoneal cavity B cells.  
 




Figure 22: MCs’ expression of 
MHC-II, ST2 and c-Kit are 
differently modulated in the 
presence of splenic and 
peritoneal cavity B cell subsets. 
Resting (nst) or 100 ng/ml DNP 
challenged IgE stimulated MCs 
(IgE/Ag) were co-cultured with 
splenic (Spl) or peritoneal cavity 
(PerC) B cells. Following co-
culture, c-Kit+ MCs were 
analysed by flow cytometry for 
the expression of specific 
membrane molecules. Both 
BMMCs (left column) and 
PDMCs (right column) were 
analysed. ICAM-1, ST2 and c-Kit 
were analysed after 24h of co-
culture, MHC-II and CD28 at 
48h, while LAMP-1, a MC’s 
marker of degranulation, was 
evaluated after 1h of co-culture. 
Expression levels of c-Kit is 
indicated as mean fluorescence 
intensity (MFI), ICAM-1, CD28 
and ST2 are indicated as MFI 
over the control isotype (MFI 
ratio). MHC-II and LAMP-1 
molecules, that are not 
uniformly expressed by the MCs 
populations, are expressed as 
percentage of positive cells in 
the total population analysed (% 
positive cells). Means (+SEM) 
from at least three independent 
experiments are shown. 
*p<0.05, ** p<0.01, *** 
p<0.001 by one-way ANOVA 
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5.1.3. Activated MCs-related soluble mediators are increased in the co-culture system 
Beyond the expression of a large number of membrane-bound receptors and co-stimulatory 
molecules, MCs can release a wide range of de novo synthesized mediators that are important in 
the modulation of immune responses to pathogens, and to orchestrate the behaviour of other 
immune and non-immune cells292. 
We observed that B cells, and in particular B-1 enriched peritoneal B lymphocytes, were able to 
modulate MC’s expression of membrane-bound molecules (MHC-II, ST1 and c-Kit), but had no effect 
on MCs’ degranulation. Therefore, as a next step we decided to assess whether B cells could affect 
the ability of MCs to produce and release soluble mediators. In particular, we chose to focus on 
soluble mediators which are important in the contexts of initiation and resolution of an 
inflammatory process. We established co-cultures between BMMCs and splenic or peritoneal cavity 
B cells and, at different time points, supernatants were collected and tested for the soluble 
mediators listed in table 5.  As reported in table 5, the cytokines IL-1β, IL-4, IL-5 and IL-33 were not 
detectable in our system while there was no modulation of the release of the anti-inflammatory 
cytokine IL-10 (figure 23).  
 
Table 5: Soluble mediators analysed in the MC-B cell co-
culture system. The presence of different soluble 
mediators was assessed in the supernatants collected at 
different time points in the MC-B cell co-culture system. 
In our conditions, measurable levels of IL-6, IL-10, IL-13, 















Interestingly, the amount of IL-13, an important mediator for allergic inflammation in several 
tissues293 released by MCs after IgE/Ag activation was two-fold higher in the presence of peritoneal 
B cells. A very similar result was obtained for the pro-inflammatory cytokines TNF-α, IL-6 and CCL2. 
Also in these cases, the release was enhanced only by peritoneal cavity and not splenic B cells. As 
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observed for the modulation of MC’s surface molecules, these results suggest that a specific cross-
talk is established between MCs and peritoneal cavity B cells.  
 
 
Figure 23: Analysis of the release of mediators in the co-culture between BMMCs and splenic 
versus peritoneal cavity B cells. Secreted IL-6, IL-10, IL-13, TNF-α and CCL2 from resting (nst) and 
activated BMMCs (IgE/Ag) alone (//) or cultured for 48h (IL-6, IL-10 and IL-13), 24h (TNF-α) or 6h 
(CCL2) with splenic or peritoneal cavity B cells were detected by ELISA. The B cells alone condition 
was also evaluated. The results showed are average (+SEM) of values from at least three 




5.1.4. B-1 B cells support the neo-synthesis of the pro-inflammatory mediators TNF-α and 
CCL2 in activated MCs 
Except for IL-13, all the other mediators tested were produced by both MCs and B-1 cells (figure 23). 
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responsible of the increased amount of soluble mediators detected in the co-culture supernatant. 
Given the importance of TNF-α and CCL2 in MC’s biology, we decided to focus on these two soluble 
mediators.  
MCs are an important cellular source of TNF-α which can be released as a consequence of two 
different processes. Indeed, MCs can store granules of TNF-α that are immediately released during 
degranulation but they are also able to synthesize new TNF-α proteins after an IgE/Ag-dependent 
stimulation and therefore release TNF-α within longer time points (e.g. 24h)69. To better 
characterize the modulation of TNF-α release, we first repeated the co-culture experiment using 
PDMCs in place of BMMCs, to determine if the observed data were the result of a specific cross-talk 
established between peritoneal B cells and mucosal-type MCs or a general mechanism observed 
with different MC subtypes. As shown in figure 24, a higher release of TNF-α was observed also from 
IgE/Ag stimulated PDMCs. In vivo the high importance of TNF-α derived from MCs in the peritoneal 
cavity during infections has long been known294 and in our experiments, a stronger increase of TNF-
α release has been observed by co-culturing the two peritoneal cavity cell types (figure 24).  
 
 
Figure 24: Comparison of TNF-α release in co-cultures between B cells and BMMCs or PDMCs. 
Secreted TNF-α from resting (nst) and activated (IgE/Ag) BMMCs (on the left) or PDMCs (on the 
right) alone or cultured for 24h with splenic or peritoneal cavity B cells is detected by ELISA. 
Reported results are mean (+SEM) of values from at least three independent experiments. *p<0.05, 
** p<0.01 by one-way ANOVA. ns=not significant; nd=not detected. 
 
We then performed a time course analysis after 30min, 1, 6, and 24h of co-culture between BMMCs 
and peritoneal cavity B cells to determine the kinetic of the TNF-α release. Although at 30 min we 
did not observe any relevant TNF-α release (probably due to the sensitivity of the ELISA kit), at 1h 
we were able to detect a statistically significant increase of the amount of TNF-α which reached its 
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of the B PerC/MC crosstalk in the production of TNF-α, we finally performed the co-culture 
experiment at 1 and 6h using Wt and TNF-α K.O. BMMCs (kindly provided by the group of Prof. 
Kollias G, Vari) in order to determine the cellular source of this mediator. As shown in figure 25B, 
our results show that MCs were the major contributor of TNF-α production. In fact, in the case of 
TNF-α K.O. BMMCs, the concentration of TNF-α in the co-culture was even lower than that detected 
for peritoneal B cells cultured alone (figure 25).  
 




Figure 25: The analysis of TNF-α 
release in the BMMCs-peritoneal 
cavity B cells co-culture revealed an 
early effect induced by peritoneal 
cavity B cells on activated BMMCs. (A) 
Time course analysis of released TNF-α 
from resting (nst) and activated 
BMMCs (IgE/Ag) alone or cultured for 
30 min, 1, 6 and 24h with peritoneal 
cavity (PerC) B cells. (B) The same co-
culture with PerC B cells has been 
established with Wt and TNF-α K.O. 
BMMCs and supernatants were 
analysed by ELISA for soluble TNF-α. 
Means (+SEM) from at least three 
independent experiments are shown. 
*p<0.05 by one-way ANOVA. nd=not 
detectable. ns=not significant 
 
In order to understand whether peritoneal cavity B cells are acting on the pre-formed or on the 
newly synthesized TNF-α, we pre-treated BMMCs with Brefeldin A (BFA) and performed an 
intracellular cytokine staining (ICS) for TNF-α after 1h of co-culture. Indeed, after IgE/Ag stimulation,  
the TNF-α pre-stored in the granules is released in the culture media while the newly synthesized 
TNF-α is trapped in the cytoplasm and can be detected through ICS (the gating strategy in reported 
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an IgE/Ag stimulation, a neo synthesis of the pro-inflammatory mediator is induced since the 
percentage of TNF-α+ BMMCs increases from 25% to 45%. We concluded that a potentiation of the 
protein synthesis was reflected in a stronger release of the mediator. 
 
 
Figure 26: Peritoneal cavity B cells induce an increase  of TNF-α production by MCs. ICS for TNF-α 
performed after 1h of co-culture between BMMCs and splenic or peritoneal B cells. (A) Gating 
strategy used for the flow cytometry analysis. BMMCs, selected on the basis of their morphology and 
of c-Kit expression, were then analysed for the positivity of TNF-α. (B) A representative experiment 
shows all the conditions analysed. Columns indicate whether BMMCs were cultured alone (//) or in 
the presence of splenic (Spl) or peritoneal cavity (PerC) B cells, rows show unstimulated (nst) or 
activated (IgE/Ag) MCs. The stimulation with PMA and ionomycin (PMA/Iono) is shown as a positive 
control since it is known to have a strong effect on TNF-α neo-synthesis. (C) In the graph, the mean 
percentages (+SEM) of TNF-α producing cells from three independent experiments are indicated. 
**p<0.01 by one-way ANOVA. 
 
Moving to CCL2, in order to assess whether the increase of CCL2 shown in figure 23 originates from 
MCs, we took advantage of CCL2-eGFP (green fluorescent protein) K.I. mice (generated in the 
laboratory of Prof. Blank U. in Paris) in which the production of the CCL2 protein is coupled with the 
one of the GFP protein. More specifically, CCL2 e-GFP BMMCs were first treated with BFA to allow 
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the accumulation of the fusion protein and its detection by flow cytometry. Then, we set up the co-
cultures with peritoneal cavity B cells and performed a two points time course analysis (1 and 5h). 
As shown in panel A of figure 27, we were able to observe a positive shift in the fluorescence on 
activated BMMCs after 5h of co-culture with B-1 enriched B cells. This result was confirmed 
analysing the co-culture through fluorescence microscopy. Indeed, the representative images 
reported in figure 27C show an increase of the granularity of MCs and of the green fluorescence in 
the intracellular compartment of MCs that were cultured for 5h in the presence of peritoneal B cells 
compared to the resting condition. Therefore, the results obtained from the analysis of CCL2 
production, lead us to speculate that peritoneal cavity B cells promote the production of pro-

















Figure 27: Peritoneal 
cavity B cells promote the 
increase of the green 
fluorescence in CCL2-
eGFP BMMCs. CCL2-eGFP 
resting (nst) or IgE/Ag 
stimulated BMMCs, 
cultured for 1 or 5h with 
splenic (Spl) or peritoneal 
cavity (PerC) B cells in the 
presence of 2µM BFA, 
were analysed by flow 
cytometry and by 
fluorescent microscopy. 
(A) BMMCs, first selected 
on their morphology and 
for c-Kit positivity (not 
shown), were analysed for 
the expression of the GFP, 
indicative of the CCL2 
protein accumulation in 
the cytoplasm. 
Representative histogram 
plots show all the 
conditions analysed. (B) 
Bar charts, mean of at 
least 3 independent 
experiments, show the 
mean fluorescence 
intensity (MFI) of the GFP 
in BMMCs in the different 
condition of culture. 
**p<0.01 by one-way 
ANOVA. (C) 
Representative 
microscopy images of the 
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5.1.5. Soluble mediators arising from B-1 B cells are important for the potentiation of 
MCs’ activation 
Collectively, the obtained results indicate that peritoneal B cells play an important role in favouring 
and sustaining the allergic activation of MCs, potentiating their pro-inflammatory protein synthesis 
and release. We next decided to investigate whether this effect depends on a contact-mediated or 
soluble mediator-dependent mechanism. We chose to perform the following experiments by 
analysing the regulation of TNF-α production as representative since this MC-derived mediator is 
extremely important in both the early phases of inflammation and in tumor conditions, the two 
pathological process that are studied in the MC-B cell cross-talk in vivo.  
We first hypothesized the existence of a membrane axis, established peculiarly with peritoneal and 
not with splenic B cells. The most known co-costimulatory pathway in the MC-B cell crosstalk is the 
CD40/CD40L axis195,196. However, the CD40 molecule is expressed at comparable levels between B-
2 conventional lymphocytes and innate-like B-1 cells295. In literature, it is reported that a concurrent 
stimulation of MCs through CD28 and FcεRI induces an increase of TNF-α secretion in a dose-
dependent manner296. Importantly, peritoneal B cells have a higher expression of CD80 and CD86 
co-stimulatory molecules compared to splenic B cells297. Therefore, we hypothesized the 
instauration of a stronger CD28 - CD80/CD86 crosstalk between the MCs and peritoneal cavity B 
cells. To test this hypothesis, B/MCs co-cultures were set up and the signalling through CD28 was 
blocked using the non-stimulatory E18 Fab anti-CD28 Ab. However, as shown in figure 28, the 
secretion of TNF-α was not affected when this axis was blocked. 
 
Figure 28: Analysis of TNF-α release by blocking the CD28 signalling in MCs in the MC-B cell co-
culture. Secreted TNF-α from resting (nst) and activated (IgE/Ag) BMMCs alone or cultured for 6h 
with splenic (Spl) or peritoneal cavity (PerC) B cells is detected by ELISA. On the left normal medium 
was used in the co-cultures (//), on the right, the experiments were conducted by adding the E18 
Fab anti-CD28 Ab. Reported results are mean (+SEM) of values from three independent 
experiments.  
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 We next tested the hypothesis that soluble mediators released from freshly purified peritoneal B 
cells in their resting conditions could be responsible for the sustained neo-synthesis of TNF-α. 
We explored this possibility by activating BMMCs in the presence of normal medium or of 
conditioned media derived from an 1h culture of either splenic or peritoneal B cells. Interestingly, 
the sole presence of the 1h conditioned medium derived from peritoneal cavity B cells given for 6h 
to IgE/Ag activated BMMCs was sufficient to sustain the previously described increase of TNF-α 
release (figure 29A). Differently from conventional B-2 B cells, B-1 B cells are able to produce a broad 
range of mediators without the need of stimulation. Indeed, our previously reported ELISA analysis 
showed that purified peritoneal B cells release IL-6, IL-10, low levels of TNF-α and CCL2 in steady-
state (figure 23). Cell supernatants are rich in mediators of different nature and since MCs are 
sensitive not only to protein molecules but also to lipid mediators, the B cells-derived conditioned 
media derived from a 1h culture were boiled at 80°C in order to denaturate protein molecules.  
IgE/Ag activated BMMCs were cultured in the boiled media and the result of this assay was that the 
effect on TNF-α production was abrogated (figure 29B). Therefore, this experiment suggest that 
mediators responsible for the effect of the B cells-derived conditioned media have a thermolabile 
nature, such as cytokines. 
 
 
Figure 29: Soluble 
thermolabile mediators 
derived from peritoneal 
cavity B cells are able to 
promote TNF-α production 
in activated MCs. (A) 
Measurement of TNF-α 
release after 6h of culture of 
resting or IgE/Ag activated 
BMMCs cultured alone or in 
the presence of 1h 
conditioned supernatant 
(SN) from B cells. (B) IgE/Ag 
stimulated BMMCs were 
activated for 6h in the 
presence of 1h B cells’ 
derived normal or of a SN 
boiled for 10 min at 80°C. 
Reported results are mean 
(+SEM) of values from three 
independent experiments. 
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In the context of the analyses conducted to identify the molecular partners of the PerC B cell/MC 
interplay responsible for the switch towards an inflammatory phenotype of the MC, we 
hypothesized the involvement of the IL-33/ST2 axis. Specifically, we addressed the  possibility that 
the mediators released from peritoneal cavity B cells induce IL-33 production in MCs which in turn 
is responsible for the increased membrane ST2 expression on MCs and synthesis of inflammatory 
cytokines. The choice to investigate the IL-33/ST2 axis was a consequence of our previous discovery 
that peritoneal cavity B cells induce an up-regulation of ST2 on MCs, and of literature data reporting 
that the IL-33 stimulation of MCs potentiates the production of pro-inflammatory mediators from 
IgE activated MCs55,71. According to our hypothesis, BMMCs cultured for 5h in peritoneal B cell-
derived conditioned media present a slight increase of IL-33 gene transcription (figure 30A). 
However, this signalling pathway does not influence ST2 up-regulation nor TNF-α release, since IL-
33 K.O. BMMCs in co-culture with peritoneal B cells act in the same way in terms of membrane ST2 
induced up-regulation and TNF-α production and release (figure 30B-C).  
 
 
Figure 30: IL-33-dependent activation of MCs is not responsible for the increase of membrane 
ST2 and TNF-α neo-synthesis. (A) Wt BMMCs were cultured for 5h in normal medium or in the 1h 
supernatant (SN) derived from either splenic (Spl) or peritoneal cavity (PerC) B cells. The graph 
reports il33 mRNA gene expression expressed as fold induction over not stimulated (//) MCs. MCs 
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activated BMMCs from IL-33 K.O. mice were analysed by flow cytometry for the expression of 
membrane ST2 after 24h of co-culture with splenic (+B Spl) or peritoneal cavity (+B PerC) B cells.  
(C) TNF-α was detected by ELISA after 24h of IL-33 K.O. MCs culture in the absence or presence of 
B cell subpopulations (splenic=Spl; peritoneal cavity=PerC). One sample Student’s t-test (A) and 
one-way ANOVA (B,C) have been used. na= not amplified, nd=not detected. 
  
Altogether, this first part of our data demonstrates an intriguing and specific cross-talk established 
between MCs and peritoneal cavity B cells. We can argue that peritoneal cavity B cells are essential 
during an acute or chronic allergic activation of MCs since they exacerbate the release of pro-
inflammatory mediators by MCs. A wider screen is needed to determine the specific factor (or the 
combination of more mediators) responsible for the observed effect. For example, IL-10, that is 
highly released by peritoneal B cells, has been shown to sustain and potentiate the allergic activation 
of MCs298.  
We can conclude that, in vivo, the peritoneal cavity and the intestine, which are known to be 
colonized by both MCs and innate-like B lymphocytes299, should be considered as important 
anatomical sites where an exacerbation of MCs detrimental activation may be controlled by acting 
on B-1 lymphocytes. 
 
5.1.6. MCs’ distribution in bumble B1-lacking mice 
Our in vitro study concerning the interplay between MCs and B-1 versus B-2 B cells highlighted an 
important role for peritoneal B cells in sustaining MC’s activation. For this reason, we were 
interested in determining if the presence or the absence of B-1 cells could affect MCs distribution 
and phenotype in vivo. To our knowledge, two types of B-1 cell-deficient animal models are 
available: μ−/− mice reconstituted with the conventional B-2 cell population200 or the bumble 
model, a mutated mouse in which the impaired expression of the atypical IκB protein IκBNS 
drastically reduces the frequencies of B-1 cells in these animals130. Thanks to the collaboration with 
the group of Prof. Karlsson Hedestam GB., we analysed the role of B-1 B cells on the distribution 
and phenotype of MCs in bumble mice. As a first step we decided to assess the percentages and 
absolute numbers of peritoneal MCs and, as a control, of the B cell subsets. The combination of anti-
CD19, anti-CD23 and anti-CD5 mAbs was used to follow the peritoneal B cell subsets (see methods  
paragraph 7.3.3) while anti-c-Kit plus anti-FcεRI mAbs to identify peritoneal MCs. Through this 
phenotypical analysis, we confirmed that the mice were B-1-lacking (figure 31A), and we found that 
the relative numbers of peritoneal MCs are not affected in the mutated bumble mouse (figure 31B). 
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Moreover, the expression of FcERI and c-Kit phenotypical markers on MCs are not significantly 
altered in the absence of B-1 cells (figure 31C). We next examined other MCs-populated tissues: the 
intestine (duodenum, jejunum and ileum) and the lungs. In collaboration with the Tumor 
Immunology Unit led by Prof. Tripodo C., we performed two types of histological stains on the 
paraffin sections of the tissues of interests: Hematoxylin and Eosin (H&E), to obtain information 
about the architecture of the tissues, and Toluidine Blue, to detect MCs which are red-purple cells 
in a blue background. Compared to the normal tissue situation of the Wt samples, all the bumble 
mouse tissues analysed had signs of inflammation, hyperplasia and increased immune infiltrates, as 
illustrated in figure 32. Concerning MCs distribution, a significant increase of MCs was observed in 
the lungs and an increase in the jejunum portion of the intestine (figure 33). The pleural cavity and 
the intestine are known to be a B-1 B cells colonized sites and the increase of MCs in these 
anatomical compartments suggests that the absence of B-1 cells somehow affects the normal 
distribution of MCs. Together, all these analyses indicate that these mice had some abnormalities 
of the immune cells with an increase of local spots of inflammations directly or indirectly due to the 
severe reduction of the B-1 cell subsets and that B-1 cells may have a role in regulating MCs 
distribution in the tissue analysed. To determine any role of B-1 cells on MCs phenotype and 
activation further analyses are needed.   
 




Figure 31: B cells and MCs counts in peritoneal lavages from bumble mice. (A) Peritoneal lavages 
from Wt and bumble mice were stained with anti-CD19, -CD23 anti -CD5 mAbs and analysed by flow 
cytometry. B cells subsets were identified as: total B cells (CD19+ cells), B-1a (CD19+CD5+CD23-), B-
1b (CD19+CD5-CD23-) and B-2 (CD19+CD5-CD23+). Percentages among total peritoneal cells are 
indicated in the upper panels, absolute numbers are shown in the lower panels. (B) FcεRI+c-Kit+ 
peritoneal MCs are shown as % and absolute numbers among total cells. (C) The MFI for FcεRI and 
c-Kit receptors on MCs are shown for both the two groups of animals. Each symbol depicts individual 














































































































































































































Figure 32: Representative pictures of H/E-
stained tissues of Wt and bumble mice. Tissue 
samples were recollected from 3 bumble and 3 
control mice (Wt). Small intestine (composed 
of duodenum, jejunum and ileum) and lung 
sections were stained with Hematoxylin/Eosin 
(H&E). Images were taken with 20x (pictures 
on the left) and 40x magnificence (pictures on 
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Figure  33: MCs organ distribution in Wt and B-1 cell-lacking bumble mice. Tissue samples were 
recollected from 3 bumble and 3 control mice (Wt) and Toluidin Blue staining for MCs was performed. 
Representative histological images are shown. The graphs indicate the number of MCs per field analysed 
in all mice samples. *p<0.05 by two-tailed Student’s t-test. 
 
 
5.2. MC-B CELLS BIDIRECTIONAL CROSS-TALK UNDER PHYSIOLOGICAL CONDITIONS: THE B 
CELL SIDE 
 
5.2.1. B-2 B cells activation and antibody production are sustained by MCs 
T helper lymphocytes are the most important B cells’ partners since they are able to give 
proliferative priming and to induce specific antibody responses300. However, in a T-independent B 
cell activation, infective soluble mediators or pro-inflammatory cytokines released by other immune 
cell types are able to promote B cell survival and activate them into effector cells. Previous works 
by our group showed that BMMCs induce both survival and proliferation of naive splenic B cells and 
that they can lead to the switch of B cells into effector IgA-producing cells. Both cell-to-cell contacts 
(where the CD40/CD40L axis covers a relevant contribute) and soluble mediators released by 
stimulated BMMCs (among which IL-6 was shown to be highly important) have been discovered to 
co-operate for the sustaining of the survival and proliferation of B cells and to their switch into IgA-
producing cells195. 
Because of the importance of considering the different local microenvironments in the study of the 
cross-talk between two different immune cell types, we decided to extend our previous study and 
compare the effect of MCs on the survival and proliferation not only of B-2 B cells but also of B-1 B 
cells. Therefore, freshly purified splenic or peritoneal cavity B cells were cultured alone or with 
either unstimulated or IgE-Ag-activated MCs, in a 1:1 ratio. Panel A of figure 34 shows the results of 
our analysis of B cell viability. The amount of viable splenic B cells is lower if compared with 
peritoneal B cells (respectively about 20 and 50%). In accordance with the previously published 
data195, the culture in the presence of both resting and activated MCs supports B-2 B cells survival. 
Conversely, the viability of peritoneal B cells is not affected by the presence of MCs. Similarly, the 
proliferation of splenic B cells is favoured by the presence of MCs while peritoneal cavity B cells are 
not induced to proliferate by effect of MCs (figure 34B). The explanation for our evidences that 
peritoneal B cells do not require the support of MCs for their survival and proliferation could be 
inherent in the fact that B-1 cells are evolutionary self-sustaining and self-renewing. 
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Next, we decided to explore the possibility that MCs could modulate the expression of B cell 
receptors important for their status of activation. Among the different pathways, we decided to 
focus on CD80 and CD86 co-stimulatory receptor molecules that are expressed on APCs and are up-
regulated by inflammatory and antigen-specific signals (Greenwald, Freeman, & Sharpe, 2005). 
Moreover, the CD80/86-CD28 is a membrane co-stimulatory axis that can be established between 
the two cell types. Ag-derived peptides are bound and presented through the MHC-II complex 
expressed constitutively in APCs such as B cells. Programmed cell death 1 (PD-1), as well as its ligand 
PD-L1, are shown to be expressed on B cells. This axis affects cell proliferation, growth and apoptosis 
and is studied for its modulation of cell tolerance in terms of inhibition of immune responses in 
cancer. Moreover it has been shown that the transient expression of PD-1 on Ag-experienced B-1b 
cells suppresses their in vitro proliferation and IgG polarization, in the absence of other co-
stimulations301.  
Under resting conditions, CD80, and to a lesser extent CD86, are more expressed by peritoneal 
cavity B cells compared to splenic B cells. PD-1 is also expressed with more intensity by peritoneal 
cavity B cells while MHC-II has comparable levels of expression on the two B cell subtypes. While 
CD80 expression on both B cell types is not affected after co-culture with MCs, CD86 and MHC-II, as 
previously shown by Palm and co-workers198, are modulated on the B-2 population by the presence 
of MCs. Conversely, peritoneal cavity B cells do not change their basal expression of the markers 
after co-culture with MCs.  Interestingly PD-1 is downregulated on splenic B cells in the presence of 
MCs (figure 34C). Regarding this last result, we can speculate that, similarly to what happens with 
B-1b cells301, the decreased expression of PD-1 following the interaction with the MC could promote 
cell proliferation. On the contrary, higher levels of PD-1 on peritoneal B cells may explain their 
“unavailability” to proliferate in the presence of MCs’ mediators and cell contact. 
Igs, which are exclusively produced by B cells, are essential to protect vertebrates from infections 
and are the preponderant component of the immunological memory. The formation of long-lived 
memory B cells and PCs that produce high-affinity, isotype-switched Abs crucial for host defence is 
the emblem of humoral immunity160. In light of the evidences that MCs  promote B cells’ humoral 
responses in the context of the B-2 B cell population195,198, we decided to carry on our study by 
comparing the amount of IgM, IgG, IgA, IgE released in the media after 48h in both the B Spl/MC 
and B PerC/MC co-culture systems. Panel D of figure 34 shows the result of our analysis for the sole 
IgM, IgG and IgA isotypes since no IgE release was detectable in our system. The presence of IgE/Ag 
triggered MCs favours an augmented release of all the three Ab isotypes analysed compared to 
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basal levels on splenic B cells. On the contrary, once again, no MC’s contribution has been 
appreciated for peritoneal cavity B cells’ Ab production. 
 
 
Figure 34: MCs sustain the activation of the B2-eriched B cell population and have no impact on 
peritoneal B cells’ functions. (A) Naive splenic (Spl) or peritoneal cavity (PerC) B cells, respectively enriched 
in B-2 and B-1 cells, were cultured for 48h in the presence of resting (+ BMMCs) or activated (+ BMMCs 
IgE/Ag) MCs. Percentages of viable B cells were determined by flow cytometry following Annexin 
V/Propidium Iodide staining. (B) CFSE-labeled splenic or peritoneal B cells were cultured for 72h either 
alone or in the presence of non-sensitized or activated BMMCs. The percentages of B cells with diminished 
CFSE intensity were detected among total CD19+ cells by flow cytometry. (C) Naive splenic and peritoneal 
B cells, cultured for 48h in the presence of non-sensitized or activated BMMCs, were stained for PD-1, 
CD80, CD86 and MHC-II complex and analysed by flow cytometry. Percentages of CD19+ cells expressing 
the markers are reported in the analysis for CD80 and CD86, MFI ratio is indicated in the MHC-II and PD-1 
analysis. (D) Splenic and peritoneal cavity B cells were cultured for 48h in the presence of resting or 
stimulated (IgE/Ag) MCs. Soluble Igs were quantified by ELISA. Means (+SEM) from at least three 
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5.2.2. B cell-related chemokine receptors are modulated by MCs 
In pathological conditions activated B cells can leave the lymphoid organs and accumulate in 
inflammatory sites302. The work of Palm, suggested that MCs may enhance the capacity of B cells to 
home lymphoid tissues and inflammatory sites by modulating their L-selectin membrane 
expression198. In this light, we decided to determine if MCs are able to modulate B-cell related 
chemokine receptors involved in chemotaxis. After 48h of MC-B cell co-culture CCR4, CCR6, CCR9 
and CCR10 chemokine receptors were analysed on CD19+ cells by flow cytometry. We focused on 
CCR6, CCR9 and CCR10 since it is known that these receptors drive the migration of B cells and of 
activated PCs in intestinal lymphoid structures both in physiology and in inflammation. The CCR4 
skin-related receptor was analysed as a control (figure 35). Among the receptors analysed, the basal 
expression between cultured B-2 and B-1 cells is comparable. Our results indicate that, when 
activated, MCs may influence the chemotactic properties of B cells by modulating their chemokine 
receptors. Specifically, while CCR10 is not affected by MCs in both B cell subsets, CCR9 and CCR4 
expression are decreased on splenic B cells. This result can be either a decreased expression because 
of the binding of the receptor to its chemokine ligand (CCL25 for CCR9 and CCL17 for CCR4) 
hypothesizing that MCs has released these chemokines, or the polarization of B-2 cells’ migration in 
different anatomical sites. Conversely, activated MCs induce the up-regulation of CCR6 (the 
receptor of CCL20) on both B cells subtypes. As mentioned in the introduction of this thesis, CCL20, 
drives the migration of B cells in both homeostatic and inflammatory conditions, mostly in intestinal 
lymphoid structures. MCs can therefore play a role in facilitating B cells migration towards a CCL20 
gradient.  
 




Figure 35: Activated MCs are able to induce the up-regulation of CCR6 chemokine receptor on 
both splenic and peritoneal cavity B cells. Naive splenic (Spl) and peritoneal cavity (PerC) B cells 
were cultured alone (//) or in the presence of resting (+ BMMCs) or activated (+ BMMCs IgE/Ag) 
MCs for 48h. CD19+ cells were analysed for the expression of CCR4, CCR6, CCR9 and CCR10 
chemokine receptors by flow cytometry. MFI ratio is indicated in the analysis. Means (+SEM) from 
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5.3. THE B CELL/MC CROSS-TALK UNDER PHYSIOLOGICAL CONDITIONS: B CELLS 
DISTRIBUTION, PHENOTYPICAL CHARACTERIZATION AND ACTIVATION IN MC-DEFICIENT 
MICE MODELS 
 
Although the role played by MCs in supporting B cell related functions is widely accepted, to our 
knowledge  the impact of the absence of MCs on B cell subsets distribution, phenotype and effector 
properties under physiological conditions has not been investigated in detail. To explore this 
condition, we decided to characterize B cells in different lymphoid organs by comparing two MC-
deficient mice models: the KitW-sh mouse, that, as extensively described in the introduction, lacks 
mature MCs in all body tissues because of the mutation a the level of the Kit gene, and the RMB 
(Red Mast Cell and Basophil) mouse in which the tracking of both MCs and basophils is possible by 
the red fluorescence of the td-Tomato (tdT) protein. In our experiments we compared on the one 
hand Wt C57BL/6 mice, KitW-sh mice and KitW-sh mice i.p. reconstituted with BMMCs, and, on the 
other, RMB mice with DT-treated-RMB mice (DT-RMB). From all mice we sampled the blood, spleen, 
peritoneal cavity lavage, lymph nodes (LNs) and colon and performed B cell-related analysis. In order 
to ascertain that MCs’ depletion or reconstitution occurred, the presence of FcεRI+c-Kit+ cells was 
checked by flow cytometry. 
 
5.3.1. MCs do not affect the phenotypical distribution of B cells in different lymphoid organs 
We first determined the distribution of B cell subsets in the spleen, peritoneum and in a pool of 
mesenteric, inguinal and axillary LNs. On the basis of the differential expression of the CD21 and 
CD23 surface markers, splenic B lymphocytes can be divided into three main populations: newly 
formed (NF) CD21-CD23-, marginal zone (MZ) CD21highCD23- and follicular (FO) CD21+CD23+ B cells. 
Moreover, the staining with anti-CD19, -CD21 and -CD23 mAbs allows also the identification of 
CD21low transitional 2-marginal zone precursors (T2-MZP) B cells. The CD1dhi, CD1d+CD5-, 
CD1d+CD5low and CD1d+CD5+ subsets were determined through the staining with anti-CD19, -CD1d 
and -CD5 Abs (methods section 7.3.2). Anti-CD19, -CD23, -CD5 Abs were instead used to follow the 
B-1a, B-1b and B-2 peritoneal cavity B cell subsets (as described before). For all these stainings, a 
representative gating strategy is reported in the methods section 7.3.2 and 7.3.3. Interestingly, both 
the MC-deficient mouse models analysed showed that total B cell percentages were not altered in 
the absence of MCs in none of the anatomical sites investigated in our experiments. Of note,  total 
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peritoneal cavity B cells were slightly increased upon reconstitution of KitW-sh mice (figure 36A). 
Similarly, the B cell distribution in the different splenic phenotypical subsets was not affected by the 
absence of MCs (figure 36B). A discrepancy between the two MC-deficient mouse models emerged 
instead from the analysis of the B cell distribution in the peritoneum. While in the RMB system no 
differences were observed in the peritoneal B cell subsets between RMB and DT-RMB mice, an 
inverted proportion of B-1 and B-2 B cells was uncovered in KitW-sh mice which presented a 
considerable increase (from 40% to 80%) of conventional B-2 B lymphocytes (figure 36C). However, 
upon MCs reconstitution of KitW-sh mice the B-1 and B-2 distribution is unchanged, indicating that 
the presence of MCs within the peritoneal cavity is not sufficient to restore the Wt condition. 
 




Figure 36: B cell subsets distribution in lymphoid organs in MC-deficient mice models. Upper 
graphs of each figure section A, B and C compare Wt, Wsh and BMMCs-reconstituted rec-Wsh mice. 
Lower panels compare instead RMB with MCs-depleted RMB (DT-RMB) mice. Cells were isolated 
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frequencies of B cells in the spleen, lymph nodes (LNs) and peritoneum are shown as CD19+ cells. 
(B) Splenocytes were isolated and stained with anti-CD21, -CD23 and -CD19 (histograms on the left) 
or with anti-CD1d, -CD5, and -CD19 (histograms on the right) mAbs and analysed by flow cytometry. 
CD19+ cells with the phenotype of newly formed (NF), CD21low transitional 2-marginal zone 
precursors (T2-MZP), marginal zone (MZ) and follicular (FO) cells or of CD1dhi, CD1d+CD5-, 
CD1d+CD5low and CD1d+CD5+ are shown in the graph as percentages among the total B cell 
population. Each symbol indicates individual mice among the groups analysed. (C) Peritoneal 
lavages from the Wt and MCs-deficient mice were stained with anti-CD19, -CD23 and -CD5 mAbs 
and B cell subsets were identified as B-2, B-1a and B-1b cells.  
Each symbol depicts individual mice among the different groups *p<0.05, **p<0.01, *** p<0.001 by 
two-tailed Student’s t-test (for RMB mice) or one-way ANOVA (Wsh mice). 
 
5.3.2. Splenic B cells’ antibody production is affected in the absence of MCs 
Since we observed that B cell frequencies in MC-lacking mice are not altered by the absence of MCs, 
we next investigated if markers related to B cells’ activation were affected. In the light of the fact 
that our in vitro data showed that MCs provide a support for only the B-2 enriched splenic B cell 
population, we decided to analyse the expression of membrane CD80, CD86, MHC-II and CD138 only 
on B cells obtained from the spleen. As shown in figure 37A, no differences were observed in the 
expression of the activation markers analysed in both the MC-deficient mouse models under 
investigation, suggesting that in physiological conditions MCs are not responsible for the modulation 
of these molecules on B cells.  
Considering these results, we decided to investigate whether the absence of MCs in vivo “primed” 
B cells to respond differently to a T cell-dependent stimulation (mimicked by an anti-CD40 mAb) or 
to a bacterial bioproduct (LPS) or to a viral stimulation (CpG). To this aim, purified B cells were kept 
in culture in normal medium or with the aforementioned stimuli and cell proliferation and viability 
were analysed as readouts. As shown in figure 37B, ex vivo, B cells from normal and MC-deficient 
mice responded in the same way to the stimulations in terms of cell survival and proliferation.   
Since one of the major effects of MCs on B cell biology is related to Ab production, we next assessed 
whether the absence of MCs in vivo “primed” B cells to respond differently to anti-CD40 mAb, LPS 
or CpG in terms of IgM, IgG and IgA production. Cell supernatants were collected after 48h of culture 
and Ab concentrations  were detected by ELISA. Interestingly, in the KitW-sh system, the absence of 
MCs seems to slightly affect the B cell capacity to secrete the IgM and IgG isotypes, especially in 
resting conditions and in response to the a-CD40 mAb for IgM and in response to LPS stimulation in 
the case of IgG. This effect was due to the absence of MCs and not the Kit mutation per se since B 
cells purified from the spleens of reconstituted KitW-sh mice recovered the ability to produce IgM 
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and IgG at their normal extent. A similar tendency was observed for the analysis of the IgA released 
by stimulated B cells. Indeed, in vivo, the presence of MCs is required for the full capability of B cells 
to respond to stimulation and produce IgA. Moving to the RMB mouse model, a different scenario 
was uncovered. No differences between normal and MC-deficient mice were observed for the IgM 
and IgG isotypes. On the contrary, B cells purified from MC-depleted DT-RMB mice released higher 
levels of IgA in both the presence and absence of stimulation.  
These results altogether suggest that MCs have a role in the regulation of Ab production in 
homeostatic conditions. The differences observed between the two models can lie in the fact that 
MCs are absent from the birth of the animal in the KitW-sh model while in the RMB model MCs are 
depleted in the adult life. 
 
 




Figure 37: Analysis of splenic B cells’ phenotype, survival, proliferation and Ab production from MC-
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graphs of each panel) and from RMB and DT-RMB mice (lower graphs) were analysed by flow cytometry. 
Among the CD19+ population, the % of CD80 and CD86 positive cells was identified based on control 
isotypes. MHC-II expression on CD19+ cells is indicated as MFI. Splenic B cells were purified through a 
beads-based negative selection and CD138+ cells were identified as % based on control isotypes in the 
CD45R+ and CD45int stained population. (B) B cells were cultured either alone (nst) or in the presence of a-
CD40 mAb, LPS or CpG for 48h. Percentages of viable B cells were determined by flow cytometry following 
Annexin V/Propidium Iodide staining (graphs on the left). CellTrace Violet Cell Proliferation Dye-labeled 
splenic B cells were cultured for 72h either alone or in the presence of a-CD40 mAb, LPS or CpG. The 
percentages of B cells with diminished dye intensity, indicative of proliferation, were detected among total 
CD19+ cells by flow cytometry. (A, B) Each symbol depicts individual mice among the different groups. (C) 
Naive splenic B cells were cultured for 48h in the presence or absence of a-CD40 mAb, LPS or CpG and 
afterwards supernatants were collected for the following IgM, IgG and IgA sandwich-based ELISA 
measurements.  Means (+SEM) from at least three independent experiments are shown. *p<0.05 by two-
tailed Student’s t-test (for RMB mice) or one-way ANOVA (W-sh mice). 
 
In order to explore the results we obtained in the analysis of Abs produced by splenic B cells ex vivo, 
we detected IgM, IgG and IgA Ab isotypes also at the systemic level, in the blood. 
The analysis of seric Abs was in line with the results relative to ex vivo splenic B cells’ antibody 
production. No significant difference was observed in IgG concentration in the blood of KitW-sh and 
DT-RMB mice in respect to the normal counterpart. IgM was tendentially decreased in the KitW-sh 
model and recovered in rec-KitW-sh mice compared to the Wt condition. Instead, in the RMB system, 
we detected an opposite tendency, with an increase of IgM titres in the absence of MCs. Finally, IgA 
concentrations were higher in both KitW-sh and DT-RMB mice with respect to the MC-suffcient 
conditions, although the reconstitution of  KitW-sh mice did not restore Wt condition (figure 38A and 
B). Concerning the RMB model, to ascertain that IgA and IgM modifications were MC-dependent, 
and not a consequence of the injection of the DT itself in mice, we injected i.p. either PBS or DT into 
C57BL/6 recipient mice (B6) and serum was analysed through ELISA. No increase of IgA or IgM was 
observed in DT-treated B6 mice supporting the evidence of a role for MCs in the regulation of Ab 
responses in healthy mice (figure 38C). 
Altogether these results indicate that, although MCs do not affect B cells distribution in different 
lymphoid organs nor their expression of activatory molecules, they cover a significant role in the 
modulation of Abs production by B cells. 
 




Figure 38: Seric antibodies in Wt and MC-deficient mice in homeostatic conditions. IgM, IgG and IgA 
concentrations were measured in blood samples of Wt, Wsh and rec-Wsh (A), RMB and DT-RMB (B) mice 
and in Wt C57BL/6 animals injected either with PBS (BS) or DT (DT-B6) (C). *p<0.05 by two-tailed Student’s 
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5.4. THE B CELL/MC CROSS-TALK UNDER PATHOLOGICAL CONDITIONS: B CELLS DISTRIBUTION, 
PHENOTYPICAL CHARACTERIZATION AND ACTIVATION IN THE DSS-RMB MOUSE MODEL 
 
After getting an overview of B cells distribution and functional properties in MCs-depleted mice 
under homeostatic conditions, we further explored the effect of this immune cell type on B cell 
behaviour in a pathological condition. Specifically, we analysed the B/MC cross-talk in the context 
of intestinal inflammation since the intestinal compartment is an important anatomical site in which 
MCs and B cells were shown to co-localize in physiology and in IBD patients195,196. In this view, we 
set up the model of the dextran sodium sulfate (DSS): 2% DSS was added to the normal drinking 
water and this induced acute colitis in our mice. Among the two available MC-deficient mouse 
models we decided to explore the RMB model since the analyses conducted in physiological 
conditions in the KitW-sh model highlighted additional anomalies in the B cell compartment (such as 
in the peritoneal cavity) that are independent from the presence of MCs since upon reconstitution 
the Wt condition is not restored. In addition, the DSS-induced inflammation has never been studied 
in the RMB mouse context. Since our aim was to investigate if during inflammatory conditions B cell 
subpopulations and functionality were affected, we decided to reproduce the most relevant 
analyses conducted in healthy conditions.  
 
5.4.1. DSS-induced intestinal inflammation in the RMB mouse model: overview  
Before analysing B cell behaviour we decided to evaluate the disease progression in the RMB model 
since, compared to Wt mice, a worse prognosis of intestinal inflammation was reported for KitW-sh 
animals following DSS administration233. In light of literature data reporting a reduction of colon 
length following the establishment of colitis303, the analysis of this parameter was chosen as an 
indicator for evaluating the status of inflammation. Figure 39A shows that, as expected, DSS 
administration induced a reduction in colon length in both RMB and DT-RMB mice compared to 
their control counterparts. However, colon length was inferior in DSS-treated DT-RMB with respect 
to RMB mice, confirming the data emerging from the KitW-sh model. In support to the colon length 
result, the analysis of weight loss in DSS-treated RMB and DT-RMB mice showed that MC-depleted 
mice had a worse progress of inflammation since, at the day of the sacrifice, they had lost more 
weight compared to the RMB counterpart (figure 39B). In addition, a more intense rectal bleeding 
in the DT-RMB mice was noticed (not shown). Finally, we also observed that mesenteric LNs (MLNs) 
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size was increased in both RMB and DT-RMB DSS-treated mice compared to healthy controls 
because of the direct effect of inflammation (not shown). 
To sum up, in accordance with previously reported data233, in the DSS-RMB mouse model the 
absence of MCs has a negative impact on the disease. Therefore, this  aspect must be kept in mind 




Figure 39: DSS-induced colitis has a worse progression in DT-RMB mice. (A) Colon lengths were measured 
and are indicated in cm. (B) Weight analysis of RMB and DT-RMB 2% DSS-treated mice is expressed as % 
of the starting weight of individual mice. Each symbol indicates individual mice. *p<0.05 by one-way 
ANOVA. 
 
5.4.2. B cell distribution and phenotype during intestinal inflammation is not altered in 
the absence of MCs  
Concerning B cell distribution in spleen, MLNs and peritoneum, no differences in B cells percentages 
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splenic B cell subsets was not altered with the progression of colitis, peritoneal B-1 cells were slightly 
increased in the B-1b component in the absence of MCs condition (figure 40B-C). We next analysed 
CD80, CD86, MHC-II and CD138 membrane markers on splenic B cells to determine whether, 
differently from the homeostatic condition, the absence of MCs in inflammation could influence the 
activation status of B cells. However, in the two mice analysed, no differences were observed (figure 
40D). Finally, splenic purified B cells were further investigated in their ex vivo survival rate but also  
this feature was not altered in DT-RMB mice (figure 40E).  




Figure 40: Panoramic of B cells’ distribution, phenotype and survival in DSS-induced colitis in the RMB 
model. (A) The frequencies of B cells are shown for the spleen, mesenteric lymph nodes (MLNs) and 
peritoneum as CD19+ cells. (B) Splenocytes were stained with anti-CD21, -CD23 and -CD19 (left panel) 
or with anti-CD1d, -CD5, and -CD19 (right panel) mAbs and analysed by flow cytometry. CD19+ cells with 
the phenotype of newly formed (NF), CD21low, transitional 2-marginal zone precursors (T2-MZP), 
marginal zone (MZ) and follicular (FO) cells (graphs on the left) or of CD1dhi, CD1d+CD5-, CD1d+CD5low 
and CD1d+CD5+ (graph on the right) are shown in the graph as percentages among the total B cell 
population. (C) Peritoneal lavages from DSS RMB and DT-RMB mice were stained with anti-CD19, -CD23 
and -CD5 mAbs and B cell subsets were identified as: B-2, B-1a and B-1b cells. (D) Isolated splenocytes 
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% of CD80 and CD86 positive cells was identified based on control isotypes. MHC-II expression on CD19+ 
cells is indicated as MFI. CD138+ cells are identified as % based on control isotypes in the CD45R+ and 
CD45int B cell population. (E) Purified splenic B cells were cultured either alone (nst) or in the presence 
of a-CD40 mAb, LPS or CpG for 48 h. Percentages of viable B cells were determined by flow cytometry 
following Annexin V/Propidium Iodide staining. Each symbol depicts individual mice among the different 
groups (panels A, B, C, D and E), *p<0.05 by two-tailed Student’s t-test. Means (+SEM) from at least three 




5.4.3. IgA increase in DSS mice is positively regulated by the presence of MCs 
We next examined ex vivo Ab production from splenic purified B cells. Among the Ab isotypes, IgA 
analysis is particularly interesting in the context of the intestinal inflammation since it has been 
reported that higher level of protective IgA are produced to face intestinal inflammation and to 
protect mucosal surfaces242,243. Our analysis of Ab production, in the presence or absence of 
stimulation, showed that IgM and IgG are not affected DT-RMB mice compared to the RMB controls. 
Concerning the IgA isotype, what we observed upon DSS treatment was that while splenic B cells 
from RMB mice increased their IgA production both in resting condition and upon stimulation, B 
cells from DT-RMB mice did not increase upon DSS treatment (figure 41A).  
Clearer and robust data concerning the contribution given by MCs in sustaining B cells IgA 
production during colitis are also shown in figure 41. Indeed, following DSS administration, IgA levels 
were significantly increased in RMB mice but not in DT-RMB mice if compared to their respective 
healthy controls. This effect seems to be peculiar of the IgA isotype since serum levels of IgG were 
unchanged in DSS RMB and DT-RMB mice compared to their respective physiological controls, while 
on the contrary serum IgM levels are significantly diminished (figure 41B). In order to further 
investigate this result, we assessed the accumulation of IgA+ PCs at the site of colonic inflammation 
by performing immunohistochemistry analyses. Interestingly, in homeostatic conditions no 
differences in the numbers of IgA+ elements between RMB and DT-RMB colons were observed. 
However, following DSS treatment, RMB mice presented an increase in the number of PCs, which 
we did not observe in DT-RMB mice (figure 41C), suggesting again that the lack of MCs might affect 
the correct increase of IgA+ PCs that are important actors in the resolution of the inflammation. 
Altogether these results led us to hypothesize that, during the establishment of the colitis, B cells of 
MC-depleted mice lack the factor given by MCs that support their IgA class switching. It is interesting 
to note that our data indicate that MCs play a role in the sustaining of the IgA switching only in 
inflammatory conditions, since in homeostasis, on the contrary, an increase in the IgA production 
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has been observed in the absence of MCs. We can speculate that resting MCs in homeostatic 
conditions provide factors that control the production of IgA by B cells while, when they are 
activated in the context of an acute inflammation, such as colitis, the contact of the two cells and 
the released mediators favour the expansion of IgA+ PCs and their Ab release.  
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Figure 41: IgA production in DSS treated mice is supported by the presence of MCs. (A) Naive splenic 
purified B cells were cultured for 48h in the presence or absence of a-CD40 mAb, LPS or CpG and  
supernatants were collected for ELISA measurements. In the graphs, both the homeostatic and the DSS 
analyses are plotted together. (B) IgM, IgG and IgA concentrations were measured in serum samples of 
DSS RMB and DT-RMB by ELISA. Results are plotted in comparison with the analysis of healthy controls of 
respective mice. Each symbol indicates individual mice among the groups analysed. (C) Representative 
immunohistochemistry analysis of anti-IgA immunostaining of formalin-fixed paraffin-embedded colon 
sections from control and DSS RMB and DT-RMB mice. Counts of IgA+ elements are also provided. Each 
symbol of the scatter plot is the mean count of 5 fields (40x). *p<0.05 by two-tailed Student’s t-test or one-
way ANOVA. ns=not significant. 
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5.5. THE B CELL/MC CROSS-TALK UNDER PATHOLOGICAL CONDITIONS: B CELL BIOLOGY IN A 
SUBCUTANEOUS MODEL OF CRC 
 
Focusing our attention on another pathological context we tried to decipher the contribution of 
MCs for B cells’ activation in the context of CRC. The MC is a relevant cell type to consider when 
analysing tumor development and several therapeutic approaches targeting MCs have been 
attempted for different cancer types304. The choice of analysing this type of cancer is due to the fact 
that the accumulation and activation of MCs in CRC have been thoroughly investigated and it has 
emerged that MCs accumulation at the tumor edge have a prognostic significance248. 
Recently, the characterization of the modifications in the distribution, phenotype and effector 
functions of B lymphocytes during CRC progression has been object of interest of the research group 
in which this work of thesis has been carried on. Specifically, an extensive analysis has been 
conducted by comparing three models of CRC: the genetic ApcMin/+ mouse, the colitis-associated 
CRC induced by AOM/DSS, and BALB/c mice subcutaneously injected with the CT-26 cell line263 .  
In order to investigate the role of the MC in the changes observed in the B cell population during 
CRC onset and progression, we first injected the MC-38 colon adenocarcinoma cell line in the right 
flank of C57BL/6 mice (for further details about the procedure see methods 7.2.1) and performed a 
characterization of B cells’ distribution, phenotype and Ab production comparing tumor-bearing 
mice with the PBS-injected counterpart. The properties of B cells in Wt tumor-bearing mice were 
then compared with those observed in KitW-sh and in i.p. BMMCs-reconstituted KitW-sh -tumor 
bearing mice. The MC is defined as an antenna of the microenvironment and, in this light, the 
interactions established between MCs and colon cancer cells might induce changes in the 
phenotype and functionality of MCs that could be relevant for the different behaviour of the B cell 
population in the tumor context. For this reason, the last part of these results section concerns the 
in vitro characterization of the cross-talk between MCs and the MC-38 colon adenocarcinoma cell 
line.  
 
5.5.1. The frequencies of CD19+ cells are increased in tumor draining LNs 
First, we aimed at understanding if the growth of the MC-38 tumor could promote any variations in 
B cell numbers in different lymphoid organs and in the tumor site itself by effect off the micro- and 
macroenvironments generated upon cancer development. Interestingly, while no differences 
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(compared to controls) were observed in the B cell numbers in the spleen and peritoneum, a 
significant increase of CD19+ elements was found in tumor-draining LNs (dLNs). Moreover, B cells 
were detectable also within the tumor, although at lower numbers compared to CD4+ cells (figure 
42A). In order to investigate whether, at a peripheral level, B cells acquire a peculiar tumor-
dependent phenotype, we analysed the expression of surface markers related to B cell activation 
(CD80, CD86, MHC-II) and tumor-related molecules (PD-1, PD-L1, FasL) on splenic B cells. 
Interestingly, among the markers analysed, splenic B cells isolated from tumor-bearing mice 
differentially expressed MHC-II and PDL-1 (figure 42B). Next, we assessed whether splenic B cells 
have an impaired capacity to produce Igs, and therefore purified splenic B cells were cultured for 
48h in presence or absence of a-CD40 mAb, LPS or CpG. We observed a trend toward a higher basal 
release of all the three Ab isotypes (IgM, IgG and IgA) from tumor-bearing mice purified splenic B 
cells. Moreover, although not significant, an increased release of IgA was observed also upon CD40 
mAb, LPS and CpG stimulations (and of IgM in the presence of CD40 mAb) (figure 42C).  
Altogether, these data indicate that, B cells are shaped and activated in the context of 
tumorigenesis, not only at the tumor site but also in different lymphoid organs. Moreover, the 
higher percentages of CD19+ cells detected in dLNs suggest that B cells are induced either to 
proliferate or to be recruited in anatomical sites directly affected by the establishment of the tumor. 
 
 





Figure 42: B lymphocytes are expanded in tumor-draining LNs of MC-38 tumor mice and infiltrate the 
tumor. (A) Percentages of CD19+ cells were analyzed by flow cytometry in cell suspensions obtained 
from the spleen and peritoneum of control and tumor-bearing mice and in control or draining (d) and 
non-draining (nd) LN. B lymphocytes were also identified by flow cytometry after tumor digestion and 
compared with tumor-infiltrating CD4+ T cells (far right panel). (B) CD19+ splenocytes from control and 
tumor-bearing mice were analysed for membrane expression of CD80, CD86, MHC-II, PD-1, PD-L1 and 
FasL and results are indicated as MFI. (C) IgM, IgG and IgA were detected by ELISA in supernatants of 
48h cultured resting or stimulated (anti-CD40 mAb, LPS, CpG) purified splenic B cells from at least 3 
control and 3 tumor-bearing mice.  
Each symbol depicts individual mice among the control and tumor-bearing groups. Analyses were done 
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5.5.2. Higher chemotactic densities are observed in tumor dLNs 
We already proposed that the enlargement of the B cell population in tumor dLNs is a generalized 
mechanism related to tumor onset and we excluded an increased proliferative rate263. In the present 
thesis, we addressed two different hypothesis considering chemotactic-related mechanisms: 
increased levels of LNs-related-B cell-chemokine receptors and an alteration of B cell-related 
chemokines in tumor dLNs. 
To investigate the first hypothesis we analysed the expression levels of CXCR4, CXCR5, CCR7, CCR6 
on splenic B cells by flow cytometry and the results we obtained was that no relevant differences in 
chemokine receptors expression between healthy and tumor-bearing mice is present (figure 43A). 
We then moved to the second possibility and analyzed mRNAs expression of the cxcl12, cxcl13, 
ccl21, ccl19, and ccl20 chemokine in LNs of tumor-bearing and control mice. Very interestingly, a 
significant increase of CXCL13 and CCL20 expression was observed in dLNs with respect to the 
control mice LNs (figure 43B), suggesting that these two chemokines could be responsible for the 
accumulation of B cells observed in tumor dLNs. 
 




Figure 43: Increased expression of CXCL13 and CCL20 in dLNs of MC-38-tumor mice. (A) Surface 
expression of CXCR4, CXCR5, CCR7 and CCR6 chemokine receptors was analysed by flow cytometry on 
CD19+ splenocytes isolated from control and MC-38 tumor-bearing mice and the. MFI are indicated in the 
graphs. (B) The relative expression of cxcl12, cxcl13, ccl19, ccl21 and ccl20, normalized to the housekeeping 
gene g3pdh, was analysed by qPCR in the total cellular population of LNs isolated from control and tumor-
bearing mice. LNs from tumor mice were distinguished between non-draining (ndLNs) and draining (dLNs). 
For each chemokine, the control sample with the lowest expression was used as control and set to 1. Each 
symbol depicts individual mice among the control and tumor groups. Two-tailed Student’s t-test has been 
used in panel A. *p<0.05 by one-way ANOVA in panel B. 
 
5.5.3. A decreased frequency of B cells has been observed in MCs-deficient tumors 
Our data revealed a role of the MC in the regulation of B cells activation both in the physiological 
and in the pathological contexts of the intestinal inflammation. We were afterwards interested in 
determining whether MCs could affect B cells in the framework of the CRC. Therefore, we analysed 
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MC-38 tumor-bearing mice. The reconstitution of KitW-sh was done i.p. before the i.d. injection of 
MC-38 cells in the mice flanks as described in material and methods (paragraph 7.2.2). We analysed 
B cells’ accumulation as in paragraph 5.4.1, but no relevant differences were observed whether the 
MC was present or absent. All the three groups of tumor-bearing mice presented a higher frequency 
of CD19+ cells in dLNs compared to ndLNs, meaning that this result was not dependent on the MC 
(figure 44A). Since the MC is reported to be an important infiltrating cell type in the context of 
CRC245, we analysed the B cell population infiltrating the tumor mass by flow cytometry (figure 44A) 
and through histological analysis (figure 44B). Interestingly, the histological analysis of tumors 
showed a higher number of infiltrating B cells (CD45R+ elements) in  Wt tumors and in the ones 
grown in rec-KitW-sh mice compared to KitW-sh tumors (figure 44B). 
Although no significant difference was instead obtained through flow cytometry between the Wt 
and KitW-sh conditions, a higher percentage of B cells was observed in rec- KitW-sh tumor mice by flow 
cytometry (figure 44A), indicating that the reconstitution of the MC population before the tumor 
establishment implies a higher infiltration of B cells in the tumor. 
We also analysed the expression of membrane activator markers and molecules associated to a 
tumor phenotype on splenic CD19+ cells: FasL resulted to be differently expressed on rec-KitW-sh 
splenic B lymphocytes, and a similar trend was detected also for PD-L1 (figure 45A). This increased 
expression suggests that MC reconstitution has a role in the induction of a specific cancer phenotype 
of splenic B cells. Splenic purified B cells were then tested for their capability to produce Igs. Ex vivo, 
while no differences were observed in the presence or absence of MCs in the levels of released IgG, 
higher IgM amounts were detected in the absence of MCs from resting and a-CD40 mAb stimulated 
B cells that returned to normal levels upon MCs reconstitution. On the contrary, splenic B cells from 
KitW-sh-tumor-bearing mice released higher levels of IgA in the presence or absence of the 
stimulations. Interestingly, in the rec-KitW-sh -tumor mice increased quantities of this Ab isotype 
were detected compared to the MC-deficient tumor condition, suggesting again a role of MCs in 
promoting B cells activation in tumor mice (figure 45B).  
Considering altogether the  reported differences between the KitW-sh  and the rec-KitW-sh -tumor mice 
conditions, we can speculate that in the context of tumorigenesis the activation of MCs directly or 
indirectly contribute to enhance B cells’ activation in tumor-bearing mice. 
 




Figure 44: B cells’ distribution in Wt, Wsh and rec-Wsh tumor-bearing mice. (A) Percentages of CD19+ 
cells were analysed in cell suspensions obtained from the spleen, peritoneum and LNs of Wt, Wsh, and 
rec-Wsh tumor-bearing mice by flow cytometry. B lymphocytes were also identified by flow cytometry 
after tumor digestion (far right panel). (B) Representative immunohistochemistry analysis of anti-CD45R 
and anti-tryptase immunostaining of formalin-fixed paraffin-embedded sections of MC-38 tumors grown 
in Wt, Wsh and rec-Wsh mice. Counts of CD45R elements are also provided in the graph below where each 
symbol of the scatter plot is the mean count of 5 fields (40x). 
Each symbol depicts individual mice among the three tumor groups. Analysis were done by two-tailed 
Student’s t-test or by one-way ANOVA, *p<0.05, **p<0.01. 
 


























































































































Figure 45: Splenic B cells’ phenotype and antibody production comparing Wt, Wsh and rec-Wsh tumor-
bearing mice. (A) CD19+ splenocytes from tumor-bearing mice were analysed for membrane expression 
of CD80, CD86, MHC-II, PD-L1 and FasL and data are indicated as MFI. Each symbol depicts individual mice 
among the three tumor groups. (B) IgM, IgG and IgA were detected by ELISA in supernatants of 48h 
cultured resting or stimulated (anti-CD40 mAb, LPS, CpG) splenic B cells. Results are the means +SEM from 
3 mice in the Wt and Wsh groups and from 2 mice in the rec-Wsh condition. Analyses were done by two-
tailed Student’s t-test or by one-way ANOVA, *p<0.05 
 
5.5.4. CXCL13 and CCL20 overexpression in dLNs  depends on the presence of MCs  
Since tumor dLNs are extremely important predictors of cancer spread305,306, among the observed 
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do so, we evaluated the expression of chemokine receptors and of the related-chemokines in LNs 
comparing Wt, KitW-sh, rec- KitW-sh ndLNs and dLNs. Although no significant differences were 
detected in the expression of LNs-related B cell chemokine receptors between Wt, KitW-sh and rec-
KitW-sh tumor mice splenic B cells, a tendency toward an increase in the expression of CXCR5 and 
CCR6 in W-sh mice was observed (figure 46A). Importantly, this effect was reverted in rec- KitW-sh 
splenic B cells. Moving to the analysis of chemokine expression in ndLNs and dLNs, a trend toward 
an increased expression of CCL19 and CXCL13 in Wt dLNs compared to matching ndLNs, and a 
significant increase in the case of CCL20 were detected. Importantly, in KitW-sh tumor-bearing mice 
these differences were abrogated and, remarkably, in MCs-reconstituted tumor-bearing mice the 
increase in the expression of CXCL13, CCL19 and CCL20 in dLNs was restored (figure 46B). These 
results suggest a role imputable to MCs for the sustained expression of B cell-related chemokines. 
 
Figure 46: CXCL13 and CCL20 overexpression in dLNs is lost in Wsh tumor mice. (A) Surface expression of 
CXCR4, CXCR5, CCR7 and CCR6 chemokine receptors was analysed by flow cytometry on CD19+ splenocytes 
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Relative expression of cxcl12, cxcl13, ccl19, ccl21 and ccl20, normalized to the housekeeping gene g3pdh, 
was analysed in the total cellular population of LNs isolated from tumor mice by qPCR. LNs were 
distinguished between ndLNs and dLNs. For each chemokine, the ndLN sample with the lowest expression 
within each one of the three groups of mice was used as control and set to one. Each symbol depicts 
individual mice. One-way ANOVA has been used in panel A, two-tailed Student’s t-test has been used in 
panel B, *p<0.05. 
 
Among the chemokines that were differentially expressed in dLNs (compared to ndLNs) the analysis 
of the CCL20 chemokine reached statistical significance in the Wt tumor condition. We decided to 
proceed with a more detailed study of this axis since the involvement of the CCL20/CCR6 axis has 
been linked to both human and murine CRC by many authors as it is described in the introduction 
of this thesis and reviewed in271.  
Our aim was to determine whether B cells that accumulate in dLNs had a higher expression of the 
CCL20 receptor as a consequence of its ligand enhanced gradient. From our analysis, we observed 
that B cells that home dLNs have an increased expression of CCR6 receptor in all the three models 
of tumor-bearing mice. Although we proposed that at the peripheral level splenic B cells have the 
same ability to migrate towards CCL20 gradients, a real implication of CCL20 in promoting B cell 
accumulation in dLNs can be hypothesized. Moreover, interestingly, in MCs-reconstituted mice, the 




Figure 47: B cells that accumulated in tumor-
draining LNs had a higher expression of CCR6. 
CD19+ lymphocytes in cell suspension from Wt, Wsh 
and rec-Wsh tumor nd- and dLNs were analysed for 
the membrane expression of CCR6 by flow 
cytometry. 
Each symbol depicts individual mice among the 
tumor groups. Analyses are done by two-tailed 
Student’s t-test (ndLNs versus dLNs within each 
mice genotype) or by one-way ANOVA between 
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5.5.5. Serum concentrations of CCL20 are increased after tumor development in Wt but 
not in W-sh mice  
Our data suggest a role for CCL20 and CXCL13 in the accumulation of B cells in the tumor dLNs and 
interestingly, CCL20 has been proposed to be a prognostic factor in CRC since its serum levels 
increase during its development307. Moreover the axis CXCL13/CXCR5 has also been associated to 
CRC progression and metastasis308. 
With the purpose of determining if in our tumor model a systemic increase of these two chemokines 
was present, we measured their concentrations in sera samples comparing levels before the 
injection of the tumor and at the moment of the sacrifice. Our results showed a significant increase 
of CCL20 and a trend towards increased levels of CXCL13 upon tumor development in Wt mice. In 
KitW-sh MC38-tumor mice these increases were not maintained after the development of the tumors. 
To date, due to the lack of an appropriate number of mice in the analysis of the rec-KitW-sh tumor 
condition, we are not able to ascribe to the absence of MCs the systemic effect of chemokines up-
regulation (figure 48). 
 
 
Figure 48: CCL20 is increased in the serum of MC-38-tumor-bearing Wt mice. CCL20 and CXCL13 
concentrations were measured by ELISA from Wt, Wsh and re-Wsh mice blood samples collected before 
the injection of the M-C38 cell line (pre-injection) and at the moment of the sacrifice (tumor). Each symbol 
depicts individual mice. The lines follow the trend of the CCL20 serum concentration of a single mouse. 
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5.6. IS THE DIRECT MC-CANCER CELL INTERACTION ABLE TO CREATE FAVORABLE MICRO- AND 
MACRO-ENVIRONMENTS FOR B CELL ACTIVATION AND CHEMOTAXIS?  
 
With the last part of this thesis we tried to clarify whether some traits of MCs’ phenotype and 
behaviour in the CRC setting were responsible for promoting B cells’ accumulation in the anatomical 
sites affected by the tumor. For our analysis we assumed that MCs establish a cross-talk with cancer 
cells since they are known to be recruited and to proliferate in the tumor. Furthermore we 
considered that MC’s biology in malignancies is characterized by plasticity and heterogeneity in 
phenotypes and functions309,310. We first determined whether the MCs/CRC cells direct interaction 
induced a modulation in the expression of MCs’ membrane-bound receptors, next we analysed the 
release of soluble mediators. These two parameters were accounted for defining a specific cancer 
phenotype of MCs. Besides, we evaluated the modulation in the expression of chemokines that 
could be involved in the accumulation of B cells in both MCs and cancer cells. 
 
5.6.1. Surface markers expression on MCs are not modulated in co-culture with cancer 
cells  
To determine the variations in the membrane phenotype of MCs we established a co-culture 
between BMMCs and the MC-38 cell line or tumor cells isolated directly from the mass and cultured 
ex vivo (for further details about the procedure, see section 7.2.8). 
After 24h of co-culture, MCs were analysed by flow cytometry for the expression of inflammatory 
receptors (ST2, TLR2 and TLR4), the activatory molecule MHC-II, the adhesion molecules ICAM-1 
and co-stimulatory molecules (CD40L, OX40L, CD30L and CD28). We chose to explore this set of 
receptors because of their importance in MCs’ activation, while co-stimulatory molecules were 
analyzed for their importance in the interplay with other leukocytes infiltrating the tumor, such as 
B cells. In figure 49 it is possible to observe that no differences in the expression of these molecules 
were identified after MCs’ culture in the presence of MC-38 cells or ex vivo cultured tumor cells.  
 




Figure 49: Cancer cells do not affect the expression of MCs’ surface markers. Surface expression of ST2, 
TLR2, TLR4, MHC-II, ICAM-I, CD28, CD40L, OX40L and CD30L was analysed by flow cytometry on c-Kit+ 
BMMCs alone (//), after 24h of co-culture with the MC-38 cell line (+MC-38) or with MC-38 tumor-derived 
adherent cells (+ Tumor). MFI are indicated in the graphs. The results reported are mean (+ SEM) of 3 
independent experiments. There were no statistically significant differences between group means as 
determined by one-way ANOVA. 
 
5.6.2. MCs release soluble mediators during direct cross-talk with cancer cells  
Since the analysis of this set of membrane molecules did not result in cancer-driven phenotype for 
MCs, we wondered whether MCs-derived soluble mediators could be involved in the modulation of 
the tumor microenvironment (TME)248. In order to mimic the TME we set up our co-cultures in the 
absence or in the presence of the IL-33, alternatively. The importance of IL-33 during CRC 
progression, even if debated, has been documented and the dynamics of the axis ST2/IL-33 have 
been thoroughly studied. In fact its increased activation along the colorectal adenoma–carcinoma 
sequence is involved in the neoplastic transformation311. Moreover, MCs, which are a target of 
therapies in many solid tumors, are highly sensitive to the IL-33 cytokine96.  
Supernatants from co-culture between BMMCs and MC-38 cells or ex vivo adherent tumor cells 
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and can participate in creating a pro-inflammatory environment312. In addition we quantified also 
IL-10, which generally promotes tumor growth, and SCF, that is a factor released by tumor cells 
involved in the recruitment and the activation of MCs during tumor development247. 
No TNF-α release was observed from BMMCs and MC-38 cells cultured alone in resting conditions, 
while the mediator was detectable after 1h, increased at 5h and still detectable after 24h, in the co-
culture (figure 50A). The addition of IL-33 in the co-culture medium stimulated TNF-α  release by 
BMMCs cultured alone, while MC-38 cells do not produce this factor after IL-33 stimulation (lower 
graphs in figure 50A). Interestingly, also in this case, in the co-culture, higher amounts of TNF-α were 
measured compared to the BMMCs condition alone, suggesting that the contact with MC-38 cells 
promoted a spontaneous release of this pro-inflammatory factor from MCs. Moreover, by 
establishing the co-culture between MCs and ex vivo derived-tumor cells we were able to reproduce 
the same effect (figure 50B).  
To confirm that MCs were responsible for the TNF-α release in the co-culture, by taking advantage 
of TNF-α K.O. BMMCs, we set up the same co-culture system at 1 and 5h time points and no 
mediator release was detectable. Hence we confirmed that MCs were the source of the TNF-α early 
released just after the encounter with CRC cells without the presence of any other stimulation 
(figure 50C). 
 




Figure 50: The contact 
between MCs and CRC 
cells promoted the 
release of the pro-
inflammatory TNF-α 
factor by MCs. TNF- α was 
measured by ELISA in 1, 5 
and 24h supernatants 
derived from: 
(A) BMMCs (MC) and MC-
38 cell line cultured alone 
or in co-culture. In the 
lower graphs, 50 ng/ml of 
IL-33 was added to the 
culture medium. 
(B) BMMCs cultured alone 
or with adherent cells 
derived from MC-38 
tumor mass grown in 
C57BL/6 mice (Tumor). 
(C) BMMCs TNF-α K.O. 
cultured alone or in the 
presence of MC-38 cells.  
The results reported are 
mean (+ SEM) from at 
least 3 independent 
experiments, *p<0.05, 
***p<0.001 by one-way 
ANOVA. nd = not detected 
 
We then measured IL-6, IL-13 and IL-10 cytokines, adding the 48h time point since we cannot 
exclude late production of these de novo synthesized mediators by MCs. 
Similar results to TNF-α were obtained for IL-6: no IL-6 has been detected from BMMCs, MC-38 cells 
or tumor cells cultured alone, while in the co-culture IL-6 levels in the supernatants increased (figure 
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cells) release IL-6 after the addition of the cytokine, but, in the co-culture, the release is higher, 
indicating  that cancer cells are able to increase the production of these cytokine.  
  
 
To elucidate better this second evidence, we performed qPCR analyses for il-6 mRNA expression on 
BMMCs and MC-38 cells cultured for 5h alone or in co-culture. As shown in figure 52A, only MC-38 
cells start transcribing il-6 gene post-co-culture with BMMCs (and not vice versa). Moreover, an ICS 
analysis for the IL-6 protein was performed on MC-38 cells after culturing the cells o.n. with BMMCs 
 
Figure 51: The contact between MCs and CRC cells promoted the release of the pro-inflammatory IL-6. 
IL- 6 was measured by ELISA in 1, 5, 24 and 48h supernatants derived from: 
(A) BMMCs (MC) and MC-38 cell line cultured alone or in co-culture. In the lower charts, 50 ng/ml of IL-33 
was added to the culture medium. 
(B) BMMCs cultured alone or with adherent cells derived from MC-38 tumor mass grown in C57BL/6 mice 
(Tumor). 
The results reported are mean (+ SEM) from at least 3 independent experiments, *p<0.05, **p<0.01, 
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in the presence of monensin. As shown in a representative experiment depicted in figure 52B, the 
ICS result confirms the qPCR analysis, showing an increased production of IL-6 (from the 6% of the 
basal level to the 12% of the co-culture) after the co-culture with MCs. It is therefore probable that 
the encounter between MCs and cancer cells favoured the establishment of an IL-6 enriched 
microenvironment where MCs contributed with an early release of the mediator (similarly to what 
observed with TNF-α) and tumor cells participate with a late production sustained by the presence 
of MCs. 
Similar considerations can be made concerning IL-13 production in the co-culture system (figure 53), 
it is possible that MCs and cancer cells sustain each other in the production of the mediator. IL-13 
can therefore be included among the mediators that create a pro-inflammatory milieu during 
MC/CRC interaction.  
IL-10, an anti-inflammatory mediator that is known to favour tumor progression, was on the 
contrary not released in MC-cancer cell interaction (data not shown). This result corroborates the 
specificity of the establishment of a pro-inflammatory TME, consequence of the accumulation and 
activation of MCs at tumor sites.  
  
 




Figure 52: MC-38 cells increased their 
production of IL-6 post co-culture with MCs. 
(A) il-6 gene expression was analyzed by RT-
qPCR after 5h of co-culture between BMMCs 
and MC-38 cells in normal culture medium. 
The panel on the left shows il-6 expression in 
BMMCs that were cultured alone (//) or with 
MC-38 cells, the right panel shows il-6 
expression in MC-38 cells cultured alone (//) 
or with BMMCs (+ MC). Relative fold 
induction over BMMCs (on the left) and MC-
38 (on the right) are indicated. Means (+SEM) 
of three independent experiments analysed 
by two-tailed Student’s t-test are shown in 
the graphs. (B) Representative ICS for IL-6 
performed in MC-38 cells (//) and MC-38 + 
BMMCs (upper and lower density plots 
respectively). Cells, gated on their double 
negativity for the Live/Dead and c-Kit staining 
(left panels) are identified as % of IL-6+ cells 






























































































Figure 53: The contact between MCs and CRC cells promotes the release of IL-13. IL- 13 was measured 
by ELISA in 1, 5, 24 and 48h supernatants derived from: 
(A) BMMCs (MC) and MC-38 cell line cultured alone or in co-culture. In the lower graphs, 50ng/ml of IL-
33 was added to the culture medium. 
(B) BMMCs cultured alone or with adherent cells derived from MC-38 tumor mass grown in C57BL/6 
mice (Tumor). 
The results reported are mean (+ SEM) from at least 3 independent experiments, *p<0.05, **p<0.01, by 




5.6.3. Soluble factors derived from MC-38 cells are sufficient to induce the release of pro-
inflammatory mediators by MCs 
Taken together, our data indicate that MCs are induced by tumor cells and by the tumor context 
(mimed by adding IL-33 in the co-culture system) to release pro-inflammatory cytokines. In order to 
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by tumor cells, we stimulated MCs with an 8h conditioned medium derived from MC-38 cells and 
analyzed TNF-α and IL-6 release after 1 and 5h. Interestingly, as shown in figure 54, the MC-38-
derived conditioned medium is sufficient to promote the release of both the soluble factors 
analyzed by MCs, the effect was even stronger than the one observed in the co-culture of the two 
cell types.  
SCF is an important factor released from tumor cells that can strongly activate MCs’ tumor 
infiltration and production of mediators247. In this regard, we decided to test in our system the 
possibility that MCs are induced to release the factors observed because of MC-38 cells’ production 
of SCF. As shown in figure 55, MC-38 cells release SCF without stimulation, while in the presence of 
MCs it is probably consumed. In the presence of IL-33, SCF production is marginally impacted. 
 
 
Figure 54: The MC-38 cells’ derived supernatant 
is sufficient to induce MC’s release of TNF-α and 
IL-6. TNF-α (A) and IL-6 (B) were measured by 
ELISA in 1 and 5h supernatants from BMMCs (MC) 
and MC-38 cell line cultured alone or in co-culture 
and from BMMCs cultured in the 8h conditioned 
medium derived from MC-38 cells (MC + SUP MC-
38). 
The results reported are means (+ SEM) from 3 
independent experiments. *p<0.05 by one-way 















































































































Figure 55: SCF is detected in the MC/MC-38 
co-culture system. SCF was measured by 
ELISA in 1 and 5h supernatants derived from 
BMMCs (MC) and MC-38 cell line cultured 
alone or in co-culture. In lower graphs, 50 
ng/ml of IL-33 was added in the culture 
medium. 
Reported results are mean (+ SEM) from 2 






5.6.4. The release of soluble mediators by MCs is specifically induced by CRC cell lines  
We were then interested in determining whether or not the effects observed in the release of pro-
inflammatory mediators by MCs were specific of the cross-talk with CRC cell lines. To address this 
question we established control co-cultures between BMMCs with CT26 (a fibroblast colon 
carcinoma cell line), B16-FO melanoma and 4T1 breast cancer cell lines, matching the BALB/c or 
C57BL/6 background. Similarly to what observed with MC-38, by using CT26 colon carcinoma cell 
line, IL-6 was released. Moreover we observed not detectable levels of TNF-α and no release of IL-
10. By culturing MCs with B16 melanoma cells we found no release of TNF-α and IL-6, and detectable 
levels of SCF, even though with a reduced concentration compared to MC-38 cells (figures 56 and 
55). Finally, by using 4T1 breast cancer cell line, we observed no release of TNF-α in the co-culture 
system and low levels of IL-6 (less than 10 pg/ml) compared to the 200 pg/ml measured in the co-
culture with MC-38 and the 50 pg/ml of the CT26. To sum up, the effects we observed in the CRC 



















































































Figure 56: The release of pro-inflammatory mediators is specific for CRC/MC interaction. TNF-α , IL-
6 , IL-10 and SCF were measured by ELISA in 5h supernatants derived from BMMCs (MC) and CT26 
(A), B16 (B) and 4T1 (C) cell lines culture alone or in co-culture. The results reported are means (+ 
SEM) from at least 2 independent experiments. nd = not detected. 
  
 
5.6.5. MCs-cancer cells reciprocal influence in the expression of B-cell related 
chemokines: the importance of CCL20  
The results presented above suggest that infiltrating MCs may alter the TME by influencing cancer 
cells behaviour and regulating inflammatory and immune reactions. The main purpose of the 
following experiments is to assess whether the MC-cancer cell interaction can affect B cells’ 
chemotaxis in tumor-bearing mice, as suggested from our in vivo data. Therefore, we performed RT-
qPCR analyses aimed at investigating the modulation of B cell-related chemokines in the co-culture 
system between MCs and MC-38 cells. We analysed the transcriptional expression of chemokines 
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cell type in the co-culture system, where a pro-inflammatory environment is established at early 
time points (1 and 5h) and maintained at longer time points (24 and 48h). 
The CCL2 and CCL5 pro-inflammatory chemokines promote the chemotaxis of immune cell types in 
CRC environment275 and both are expressed by MCs and MC-38 cells. Increased CCL2 expression in 
MC-38 was observed post co-culture with MCs, this effect is enhanced in the presence of IL-33 
(figure 57). CCL5 expression was increased in both MCs and MC-38 cells after the conditioning of 
the corresponding cell type. Again, in the presence of IL-33, the up-regulation was further increased 
in the system. It is interesting to highlight that in MCs pre-conditioned by MC-38 cells, a strong 
upregulation of CCL5 was observed (40 times fold with respect to resting MCs). 
Since MC-38 cells are intestinal epithelial cancer cells, we decided to investigate in our system also 
the modulation of CCL25, CCL28 and CCL20 that contribute to the homing of PCs in the gut180. MCs 
express only CCL25 but its expression is not modulated by the presence of MC-38 cells. Our in vitro 
cultured MC-38 cells instead expressed CCL25 and CCL20 (and not CCL28, data not shown). While 
we observed no modulation of CCL25, the expression of CCL20, which was also increased in tumor 
dLNs (figure 43 and 46), is up-regulated in MC-38 cells that were cultured with MCs. Interestingly, 
the increase in CCL20 transcription is observed again in this context. 
We then investigated the expression of CXCL12, CXCL13, CCL19 chemokines in the MC-CRC cross-
talk, the other chemokines were analysed in LNs of control and tumor-bearing mice. MCs do not 
express any of these chemokines (data not shown) while MC-38 cells express detectable levels of 
CXCL13. However no modulation was observed in the presence of MCs.  
It is important to remember that the pattern of chemokines we analysed are B cell-related but not 
specific, since many immune cell types such as T lymphocytes, monocytes and tumor cells 
themselves are responsive to their chemotactic action275. 
 




Figure 57: Chemokine expression was modulated in both MCs and MC-38 cells when they cross-talk. 
Ccl2, ccl5, ccl25 ccl20 and cxcl13 gene expression was analyzed by RT-qPCR after 5h of co-culture between 
BMMCs and MC-38 cells in normal culture medium of in the presence of 50 ng/ml IL-33 (where indicated). 
Means (+SEM) of at least three independent experiments are shown in the graphs. *p<0.05 by two-tailed 
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5.6.6. TNF-α released by MCs is an essential factor that induces CCL20 expression in MC-
38 cells 
Our data from MC-38 tumor-bearing mice suggested that CCL20 and CXCL13 play a role in promoting 
B cells accumulation in dLNs of tumor-bearing mice (figure 43). Since in dLNs of KitW-sh tumor-bearing 
mice CCL20 and CXCL13 up-regulation was not observed, and neither their seric levels (figure 48), 
we hypothesized that MCs have a role in the induction of these factors. Moreover, analyses 
conducted in KitW-sh tumor mice showed reduced levels of TIBs (figure 44).  It is now evident that 
MCs promote CCL20 transcriptional expression in MC-38 cancer cells (figure 57), this led us to 
believe that MCs participate in the creation of a CCL20 enriched TME. Accordingly, we decided to 
study in deep the CCL20 transcriptional and protein modulation in MC-38 cells.  
To confirm the specificity of the observed effect in the CRC setting, we analysed the modulation of 
CCL20 in the presence of BMMCs in CT26, B16 and 4T1 cell lines by qPCR. Interestingly, in CT26 cells 
CCL20 upregulation after co-culture with MCs has been reproduced. While B16 melanoma cells do 
not express CCL20, 4T1 cell line expressed CCL20313 but, interestingly, its level were not modulated 
in the presence of MCs (figure 58A).  
We then considered the factors that from the literature are known to be involved in CCL20 
transcriptional overexpression: TNF-α, IL-1 and IL-17314. We focused our attention on TNF-α since 
we uncovered that MCs are induced to release this mediator upon stimulation by CRC cells. We set 
up co-cultures between MC-38 cells and Wt of TNF-α K.O. BMMCs and analysed CCL20 modulation. 
When culturing the MC-38 cell line with TNF-α K.O. BMMCs, no up-regulation of CCL20 was 
observed. As a control we also performed an experiment by using IL-6 KO BMMCs. In this case CCL20 
was still up-regulated, suggesting that IL-6 is not indispensable for CCL20 transcription, while TNF-α 
on the contrary is necessary (figure 58B). We then wanted to demonstrate the veracity of the TNF-
α/CCL20  axis in the MCs/CRC cells at the protein level.  
We first performed ELISA measurements for CCL20 in the co-cultures supernatants between MCs 
with MC-38 cells (in the presence or absence of IL-33), or ex vivo MC-38 tumor cells, CT26 and 4T1 
cells after 24 and 48h. At 24h time point, the levels of CCL20 released by MC-38 and CT26 alone 
cultured cells are similar with the ones of their co-cultures with MCs. Differently, at the same 24h 
time point, a lower extent of CCL20 is shown in the MCs/4T1 co-culture medium compared to 4T1 
cells alone. This last result suggests that no support is given by MCs in CCL20 expression (figure 59). 
At 48h, lower levels are detected in all co-culture settings. We can speculate that MCs, upon contact 
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with cancer cells release pro-inflammatory cytokines but also proteases that could be responsible 
for chemokine degradation and consumption in the medium. We then analysed soluble CCL20 by 
comparing co-cultures between Wt or TNF-α K.O. BMMCs and MC-38 cell line (figure 60). In these 
analyses, after 24h of culture, CCL20 concentration is of the same extent between MC-38 alone and 
in co-culture with Wt BMMCs, while it is inferior in co-culture with TNF-α K.O. MCs, probably 
because of the lack of the mediator that is fundamental for its increased production. 
Further analyses are needed to determine the relevance of MCs’ derived TNF-α upon tumor 
establishment in inducing CCL20 chemokine production by CRC cells and LNs, and the potential role 
of this axis in the chemotaxis of B lymphocytes in dLNs and tumor. In the conclusive part of this 




Figure 58: TNF-α derived from MCs is necessary for 
CCL20 overexpression in CRC tumor cells. (A) Ccl20 
gene expression was analyzed in CT26, B16 or 4T1 
cell lines by qPCR after 5h of culture alone (//) or in 
co-culture with BMMCs (+ MC). (B) Ccl20 gene 
expression analyzed in MC-38 cells that were 
cultured alone or with BMMCs Wt or TNF-α K.O. 
(left panel) and with Wt or IL-6 K.O. BMMCs (right 
panel). 
Relative fold induction over each cell line cultured 
alone are indicated. Mean (+SEM) from two 
independent experiments is shown for 4T1 cells and 
a representative experiment in shown in the 
comparison between co-culture with Wt or IL-6 K.O. 
cells; other graphs are mean (+SEM) of at least three 
independent experiments. *p<0.05 by two-tailed 
Student’s t-test. 












































































































































































































Figure 59: CCL20 chemokine released by cancer 
cells is consumed in the co-culture system. CCL20 
was measured by ELISA in 24 and 48h 
supernatants derived from co-cultures between 
BMMCs (MC) and MC-38 cells in the presence or 
absence of 50 ng/ml IL-33 (A) or adherent cells 
derived from MC-38 tumor mass (Tumor) (B), 
CT26 (C) or 4T1 (D) cell lines cultured alone or in 
co-culture. Reported results are mean (+ SEM) 
from 2 (in CT26 and 4T1 analyses) or at least 3 (in 
MC-38 and tumor cells analyses) independent 
experiments. *p<0.05, *p<0.01 by one way 







































































































































































































































Figure 60: Higher levels of CCL20 are detected in 
the culture medium of MC-38 in the presence of 
Wt MCs compared to TNF-α K.O. MCs. CCL20 was 
measured by ELISA in 24h supernatants derived 
from MC-38 cell line cultured alone or with Wt or 
TNF-α K.O. BMMCs. Reported results are mean (+ 
















































































































MCs are innate immune cells that are highly shaped by different local tissue environments. This 
aspect is arguably the most modern paradigm of MC’s biology, as is stated multiple times in this 
thesis. Indeed, these cells acquire their mature phenotype in the periphery after the migration of 
immature MCs precursors and virtually populate all vascularized tissues of mouse and human 
bodies. As a consequence, MCs manifest great plasticity in phenotype and functions and high 
“sociality” with other cell types5. 
The main contribution of this work is providing concrete demonstrations that there is a reciprocal 
functional influence between MCs and microenvironmental cells, in particular, MCs and B cells are 
strict partners contributing to homeostatic and pathological responses, such as colitis and CRC that 
are studied in this thesis. 
Most of the literature about MC-B cell interplay conducted in vitro made use of immature BMMCs 
and conventional B-2 lymphocytes, however it is important to consider that also B cell types, like 
MCs, vary according to the anatomical site. Mouse peritoneal cavity and intestine are good 
examples because these compartments are B-1 enriched sites and are populated  by two different 
MCs sub-types, serosal- and mucosal-MCs respectively. This is the reason why we decided to extend 
the conventional BMMCs/B-2 cells cross-talk analysis with PDMCs and peritoneal cavity B cells in 
our co-culture system. 
Analysing the most known MCs’ anaphylactic response, the degranulation upon an IgE/Ag 
stimulation, we observed that it was slightly altered in the presence of both resting or activated B 
cell subsets (figure 21). A major effect instead was observed both on BMMCs and PDMCs’ surface 
molecules that were modulated by B cells (figure 22). MHC-II, that is almost absent on resting MCs 
and upon an IgE/Ag-dependent activation, was upregulated after culturing MCs with both sub-
populations of B cells. We can speculate that, in vivo, MCs acquire APCs ability after interacting with 
B cells. In turn, antigen sensitized T cells could efficiently stimulate B cells in GC reactions: this would 
finally favour B cells’ effector functions and terminal differentiation. Another possible explanation 
is that this increase is not due to an endogenous MHC-II overexpression on MCs, but results from 
the transfer of MHC-II proteins in vesicles from B cells during the formation of a synapse-like 
structure, as it has recently been shown to happen in vivo between MCs and DCs in inflamed skin315. 
Another surface marker that was up-regulated on the surface of MCs was ST2, the membrane 
receptor for IL-33. This modulation was obtained by the sole effect of the co-culture with B-1 
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enriched cells. This suggests that an ST2high phenotype of MCs might be favoured in body 
environments in which they are in contact with innate B lymphocytes such as the peritoneal cavity 
and the intestine. During the early phases of tissue injury, MCs are early targets of IL-33 since they 
are the first tissue-resident “sentinel” cell that constitutively express ST2316. The importance of an 
IL-33 dependent activation of MCs is further highlighted in the analysis of the cross-talk between 
MCs and MC-38 cancer cells. When we analysed the release of pro-inflammatory mediators by MCs 
upon stimulation by cancer cells and the mutual-induced regulation of cancer-related chemokines, 
we added this factor to mimic the CRC milieu (figures 50-57). MCs and MC-38 cells respective 
activations were potentiated concurrently with the addition of IL-33, however the contribution 
given by the interplay with the other corresponding cell type was still noticeable. It is important to 
remember that IL-33 is not only an important component of tumor growth (whose effect is still 
debated317,318), as a matter of fact, it is also released upon intestinal acute inflammation. In this 
regard, an ST2high  phenotype, a possible consequence of the cross-talk with innate-like B cells, would 
be essential for an adequate activation of MCs during colitis and at the early stages of tumorigenesis.  
By analysing MCs’ related soluble mediators we uncovered novel specificities in the MCs/peritoneal 
cavity B cells interplay: IgE/Ag triggered MCs are sustained by B-1 lymphocytes in the neo-synthesis 
and release of the TNF-α, CCL2, IL-13, and IL-6 pro-inflammatory mediators (figure 23-27). We 
excluded the involvement of the membrane CD28 - CD80/CD86 axis in the increased production of 
these factors (figure 28). On the contrary, we showed that soluble thermolabile mediators derived 
from peritoneal cavity B cells were sufficient to generate the TNF-α enhanced production in IgE/Ag 
stimulated MCs (figure 29). Innate-like B cells are known to spontaneously release a wide range of 
mediators, most of them necessary for their self-sustaining and long-living (e.g. IL-10, IL-6...)134. 
Since we also obtained the ST2 up-regulation by the effect of peritoneal cavity B cells, we 
hypothesized that B-1 cells’ mediators might promote an autocrine loop for IL-33 production in MCs. 
However, IL-33 K.O. BMMCs showed the same ST2 increase and augmented production of TNF-α 
(figure 30). In literature, no reports indicate that B cells are able to produce IL-33, but we cannot 
completely exclude that peritoneal cavity B cells could produce this cytokine. It is well known instead 
that peritoneal cavity B cells spontaneously release high levels of IL-10: a compelling candidate for 
this effect. Indeed, a link has already been shown between B cell-derived IL-10 and MCs 
functionality: in 2015 Kim and collaborators showed that CD5+ and IL-10 producing splenic B cells 
suppress IgE-mediated MCs’ anaphylaxis and mediators release197 but it was also shown that IL-10 
can enhance MC’s activation through a Stat3-dependent process319.  
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To sum up, these in vitro data proved that peritoneal cavity B cells are important modulators of 
MCs’ inflammatory activation. This led us to study MCs distribution in a B-1 lacking mouse model, 
the so-called bumble mice130. Among the organs analysed so far, in a scenario characterized by tissue 
hyperplasia and increased immune infiltrates (figure 32), MCs were observed to be unaffected in 
their distribution in the peritoneal cavity while they were increased in the lungs and in the jejunum 
of this newsworthy mouse model (figure 31 and 33). We also set up a culture of PDMCs from bumble 
mice but we did not observe any differences in the expression of the ST2 receptor compared to the 
Wt cultures (data not shown). These preliminary observations from the bumble mice require further 
studies with an extended panel of MCs characterization and functionality: it is possible that any 
variations in MCs’ phenotype in the mouse model were lost after culturing the cells. It may also be 
worth performing a functional test such as the passive systemic anaphylaxis (PSA). Briefly, mice are 
first sensitized by a systemic injection of IgE and then anaphylaxis is induced by the Ag trigger. For 
our purposes, TNF-α released within the peritoneum after 1h of the Ag injection would be compared 
between control and bumble mice.  
Studying MCs’ contribution in B cells’ survival, proliferation, antibody production and up-regulation 
of activating membrane molecules (CD86 and MHC-II), we observed a relevant role for the sole 
splenic population. Indeed, we observed that peritoneal cavity B cells, which are self-sustaining, did 




Figure 61: A novel paradigm of MC/B cell cross-talk: immature mucosal-type MCs (BMMCs) support 
survival, proliferation, up-regulation of the membrane molecules CD86 and MHC-II and promote the 
antibody production of the splenic B-2 population. On the contrary, none of these effects were reported 
on the peritoneal cavity B-1 enriched subset. The MHC-II expression on both mucosal and serosal-type 
MCs (PDMCs) is induced after their co-culture with both B-1 and B-2 lymphocytes. ST2, in addition, is 
overexpressed on MCs by the sole effect of B-1 cells. Moreover, soluble mediators spontaneously secreted 
↑MHC-II
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by innate B-1 lymphocytes are able to sustain the neo-synthesis and the release of pro-inflammatory 
factors such as TNF-α, CCL2, IL-13 and IL-6 from IgE/Ag activated MCs. 
 
To analyse whether MCs have a role in the development and differentiation of B cells in vivo, in 
homeostatic conditions, we performed a systematic analysis of B cell distribution in two MCs-
deficient mice models: the well-known KitW-sh mouse which lacks mature MCs from the birth of the 
animal, and the more recently developed MCs- and basophils-depletable RMB mouse. Our 
observations did not point out alterations in the distribution of B cell populations in spleen and LNs 
of the MC-deficient mice. No differences were observed in the absence of MCs in splenic B cells’ 
membrane markers expression nor in their ex vivo ability to survive and proliferate in both models. 
Interestingly, differently from the RMB model, the peritoneal cavity of KitW-sh mice presented an 
inverted proportion of B-1 and B-2 cells (figure 36). This inversion was not restored upon MCs 
reconstitution and can be the case of an additional, but neglected, defect of this mouse model due 
to the germline kit gene mutation. However, more intriguingly, the pre-natal development of the B-
1 cells could be affected by the lack of MCs. The yolk sac and the fetal liver are anatomical sites in 
which the B-1 lineage develops130 and recently it was shown that the yolk sac and the liver are 
important sources of MCs precursors17. Another detected alteration in the absence of MCs was 
reported in Abs production. In the DT-RMB model, increased levels of IgA produced by ex vivo 
splenic B cells upon stimulation and in the serum were measured (figure 37-38). Moreover, IgA PCs 
detected by histology in the DT-RMB mice, even if comparable in numbers, were increased in 
dimension, probably because of an increased Abs synthesis (figure 41).  In KitW-sh mice higher basal 
levels of IgA were detected in the serum and these levels were maintained upon MCs reconstitution. 
Altogether, these results suggest a direct or indirect role of MCs in maintaining homeostatic levels 
of IgA.  
Next step was to set up an inflammatory model, not MCs or B cells dependent, in which both cell 
types are known to be activated and affected by the progression of the disease: the model of the 
DSS-induced intestinal acute inflammation was chosen and performed in the RMB mouse model. 
The intestine, as we said before, is an important environment in which MCs and B cells can cross-
talk. In fact, in the past we showed in histological sections the evidence of co-localization of these 
two cells 196 but, to our knowledge, no in vivo demonstrations indicating their functional interaction 
in the gut are available so far. Interestingly, MCs-depleted DT-RMB mice had a worse progression of 
the colitis (figure 39). This aspect indicates a beneficial impact provided by MCs in the recovery of 
the acute intestinal inflammation, in agreement with what proposed in 2015 by the group of Prof. 
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Colombo that studied the DSS-induced colitis in KitW-sh mice. According to Prof. Colombo’s model, 
MCs infiltrating the colon upon DSS withdrawal upregulated ST2, in this context IL-33 activity on 
MCs was essential in the resolution of inflammation and MCs-derived MCPT-4 was fundamental to 
promote mucosal healing233. In our model, we focused on understanding whether MCs deficiency 
impacted B cells’ activation in DSS-treated mice. While the central reservoir of splenic B cells’ 
distribution and phenotype seemed not to reflect signs of activation, the levels of IgA released after 
the ex vivo culture of these cells were tendentially increased in DSS-RMB mice. A clearer evidence 
of IgA increase upon DSS treatments was observed systemically in the serum, and in the increased 
accumulation of IgA+ PCs provided by the histological sections of the inflamed colons (figure 41). In 
addition, this increase in IgA was accompanied by decreased levels of IgM in the serum, suggesting 
a phenomenon of isotype switching. Higher IgA production in colitis and in the DSS mouse model is, 
as a matter of fact, a known mechanism of anti-inflammatory response242240. Interestingly, this 
skewing towards IgA+ PCs in the inflamed colon was not observed in DSS treated DT-RMB mice and 
neither increased in the serum, compared with their respective controls (figure 41). These results 
indicate that, in the absence of MCs, B cells were deprived of important sustaining factors for their 
activation. Further investigations are needed to determine the in vivo mechanism on which this 
effect is based. However, from in vitro data published by our group, it is known that both the co-
stimulatory axis CD40/CD40L and MC-derived-IL-6 are responsible for controlling the expansion of 
IgA PCs195. It is therefore likely that the lack of MCs is accompanied by the reduction of those factors 
that are fundamental to sustain B cells’ IgA isotype switching in a context in which these Igs would 








Figure 62: MCs control IgA+ PCs’ function in the intestine: In homeostasis, after the depletion of MCs (DT-
treated RMB mice condition) the number of IgA+ PCs in the colon is unaffected, however, these cells are 
increased in dimension. In the serum higher levels of total IgA are reported and also splenic purified B cells 
release spontaneously higher levels of this Ab (not shown in the figure). During inflammation, in MCs-
competent mice, the number of IgA+ PCs in the colon is increased and in the blood a higher level of IgA is 
detected compared to the homeostatic condition. When the intestinal inflammation is established in MCs-
depleted mice both, the number of IgA+ PCs in the colon and the amount of seric IgA are not augmented, 
compared to the control condition. These evidences suggest the importance of MCs in the regulation of 
PCs in the intestine both in healthy conditions and upon colitis. The combination of contact-mediated 
mechanisms and the release of soluble mediators from activated MCs could support the effector functions 
played by B cells in response to the damage at the intestinal barrier. 
 
   
It is well known that patients suffering from IBD are exposed to increased risks to develop CRC. This 
cancer type, that is a major health problem and the fourth cause of cancer deaths worldwide, is 
accompanied by disorders of the immune system320. A better characterization of specific immune 
reactions in carcinogenesis is indeed a primary goal. MCs and B cells are important components of 
tumor infiltrates but whether they have tumor-promoting or anti-tumoral roles is still undefined 
because of conflicting results43,252,258,262. We aimed at determining whether MCs’ phenotype and 
activation induced by the direct effect of cancer formation could influence B cells’ behaviour.  
To investigate this aspect we established a subcutaneous model of CRC in which we first 
characterized B cells’ distribution, phenotype and activation comparing B cells from MC-38 tumor-
bearing and control mice. We observed an accumulation of B lymphocytes in tumor dLNs and 
infiltrates of B cell in the tumor mass (figure 42). The accumulation of B cells in dLNs was not 
unexpected305 and our group recently proposed this as a generalized mechanism related to CRC 
onset that joined three different set-ups of CRC. Moreover, we showed that CRC profoundly affects 
B cells’ ongoing in tumor mice not only locally but also at the system level263. In this thesis, we 
carried out a splenic B cells’ characterization analysing a set of activating and tumor-related 
membrane molecules. An increased expression of PDL-1 and MHC-II on tumor splenic B lymphocytes 
compared to control splenic B cells was observed, expression of a tumor-dependent phenotype 
(figure 42). Consistently, it has been recently shown that B cells with a high expression of PDL-1 are 
associated to an immunosuppressive phenotype in the CRC context321. We also investigated the B 
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cells’ ability to release Abs: the basal release of IgM, IgG and IgA isotypes from tumor-bearing mice 
purified splenic B cells was tendentially increased.  
By exploring B cells accumulation in dLNs, we hypothesized an increased chemotaxis since in our 
previous work we demonstrated that the enhanced proliferation rate was not the explanation of 
the accumulation of B cells in dLNs263. Therefore, we evaluated the expression of chemokine 
receptors on splenic B cells of tumor-bearing mice and healthy controls, but no differences were 
observed, suggesting that B cells have the same ability to home peripheral lymphoid structures 
(figure 43). We then assessed the expression of B cells-related chemokines in LNs and, interestingly, 
increased expressions of and CCL20 and CXCL13 were detected in tumor-dLNs compared to control 
mice LNs (figure 43). This suggested a role of these two factors in the accumulation of B lymphocytes 
in dLNs.  
In the light of these results, we focused on our main goal: determining if MCs could affect the 
behaviour of B cells upon tumorigenesis. To this end, we repeated the same experiments by 
comparing the analyses of B cells from Wt, KitW-sh and rec-KitW-sh tumor mice. Again, B cell 
accumulation in dLNs compared to ndLNs was observed in all three tumor-bearing mice models. 
Interestingly, we noticed a tendentially reduced percentage of B cells in the spleen and dLNs of rec-
KitW-sh compared to the KitW-sh tumor-bearing mice. This aspect may indicate a preferential B cells 
accumulation in other compartments, for instance in the tumor. Indeed, by flow cytometry, we 
observed increased B cell infiltrates in the tumor of rec-KitW-sh mice compared to KitW-sh and Wt mice. 
In addition, according to histological analyses, tumor infiltrating CD45R+ elements are strongly 
reduced in the KitW-sh tumors compared to the Wt condition, while in in rec-KitW-sh mice tumors a 
tendency to restore the Wt condition was obtained (figure 44). These observations indicate the 
presence of MCs as a needful element for the correct integration of B cells in the TME. In 2016, in 
line with our hypothesis, Palm and collaborators suggested that MCs have a role in enhancing the 
capacity of B cells homing to inflammatory sites by inducing their up-regulation of surface L-
selectin198. Concerning our model, we are able to advance both an indirect and a direct role of MCs 
in promoting B cells’ homing in TME. 
Specifically, the increased expression of and CCL20 and CXCL13 in dLNs observed in Wt tumor mice, 
was not detected in KitW-sh tumor-bearing mice; on the contrary, it was restored upon MCs 
reconstitution of KitW-sh mice (figure 46). In support to our observations in mouse studies, by 
analysing a human database of CRC-derived cell lines, we found higher CCL20 expression in LNs 
metastasis compared to the primary tumor (see Appendix section). CCL20 is indeed known to 
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promote cancer spreading and metastasis, as it has recently been confirmed322. Moreover, CCR6 
(CCL20 receptor) expression on B cells that accumulate in dLNs is higher if compared to ndLNs in all 
the three mice groups. This corroborates the thesis that CCL20 may attract B cells in the tumor dLNs 
and, since the expression of its receptor is even higher in rec-KitW-sh mice, the presence of MCs is 
somewhat relevant (figure 47). It is useful to correlate this data with the analyses done on 
chemokine receptors modulation on B cells in the framework of the interplay with MCs: CCR6 
resulted up-regulated by the effect of activated BMMCs (figure 35). All these results strongly suggest 
that increased chemokine levels promote B cells accumulation in dLNs and that MCs are involved in 
the generation of a B cells attracting microenvironment at the levels of tumor and dLNs. Moreover, 
CCL20 involvement in our model was also confirmed by analysing serum levels of the chemokine 
that in Wt tumor mice rise upon tumor development, while its increase is not equally reproduced 
in KitW-sh tumor-bearing mice (figure 48).  
CCL20 has been reported to attract tumor-promoting immunosuppressive cells (e.g. Treg) to the 
tumor microenvironment273. As a future perspective of this study, it would be interesting to 
determine whether CCL20 attracts preferentially B cells with an immunosuppressive phenotype.  
To address the mechanism by which MCs could be involved in creating a favourable environment 
for B cell infiltration, an in vitro co-culture system between cancer cells and MCs was used to 
investigate the MCs-CRC cells cross-talk. First, we uncovered that an enriched pro-inflammatory 
milieu was established as a consequence of the direct interplay between cancer cells and MCs. 
Specifically, the inflammatory TNF-α, IL-6, and IL-13 were detected in the co-culture medium as well 
as the potent MCs’ chemotactic and activator SCF (figure 50-55). More importantly, we 
demonstrated that resting MCs release TNF-α spontaneously after interaction with cancer cells or 
their conditioned medium. This was an essential step in the investigation of the chemotactic 
mechanism. When we analysed the MCs/MC-38 cancer cells mutual interaction in the expression of 
chemotactic molecules, we uncovered that tumor cells that were conditioned by the presence of 
MCs, increased their basal expression of CCL2, CCL5 and notable CCL20. It is also worth noting that, 
even though murine MCs are not able to express the CCL20 chemokine (differently from human 
MCs323), their CCL5 transcriptional activity was increased after the contact with MC-38 tumor cells. 
This indicates that also MCs are induced to synthesize inflammatory chemokines that can co-
operate in the recruitment of immune populations at the tumor sites (figure 57). The data obtained 
with CCL20 was very interesting and made us believe in a connection between MCs’ activation and 
the generation of a CCL20 enriched tumoral environment. Very interestingly, transcriptional 
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analyses and ELISAs conducted in the co-culture between MC-38 cells and TNF-α K.O. BMMCs 
highlighted that TNF-α release by MCs is an essential factor for the CCL20 sustained expression in 
cancer cells (figures 58, 60). Our hypothesis is that MCs, attracted in the TME, participate in the 
generation of a pro-inflammatory environment which can recall and activate other immune cell 
populations. Among these factors released upon activation, TNF-α plays a role by inducing higher 
expression of CCL20, that in turns attracts B lymphocytes. This factor may act not only locally in the 
tumor but also at the level of the dLNs favouring increased expressions of CCL20 in LNs resident 
cells. Moreover, at the levels of the LNs also other factors, such as the CXCL13, can participate in 
the creation of enriched sites of B cells. With the purpose of demonstrating the actual role of MCs 
and of its derived-TNFα in the CCL20 induction, MC38 tumor-bearing mice established in Wt- or 
TNFα K.O.- BMMCs reconstituted-KitW-sh mice would be suitable. Any differences in B cells 
accumulation and CCL20 levels in the two types of MCs-reconstituted tumor-bearing mice will 
reasonably be attributed to MCs.  
In conclusion,  the second part of this thesis, enlightened a novel and intriguing mechanism by which 
MCs, shaped by the tumor, could indirectly enhance B cell activation and accumulation in tumor 
sites (the model is proposed in figure 63).  
 
 




Figure 63: MCs promote the chemotaxis of B cells in CRC: On the left, CRC is established in MCs-competent 
mice. MCs are the first innate immune cells that as «sentinels» react to the imbalanced homeostasis. 
Thanks to their ability to promptly respond to tumor-derived SCF and IL-33, MCs release inflammatory 
factors including the TNF-α. In an hypothetical orthotopic scenario, B-1 cells that are known to home the 
gut, can favour a faster and stronger activation of MCs (e.g. by inducing ST2 up-regulation on the 
membrane of MCs). The TNF-α released in the TME sustains the production of the CCL20 chemokine that 
attracts B cells and other leukocytes. TNF-α released at the tumor level, may induce further production of 
CCL20 in dLNs. CCL20, together with CXCL13 and other chemotactic factors, recall B lymphocytes. On the 
right, in MCs-deficient tumor mice, because of the lack of the MC’s contribution in enhancing CCL20 
production in the tumor, reduced TIBs are reported. Moreover, a reduced increase of CCL20 and CXCL13 
are also reported in the dLNs. B lymphocytes equally accumulate in the dLNs thanks to the contribution of 
other factors that are produced upon tumor formation. 
 
An aspect to take into account when analysing immune cells in tumor setting is the phenotype that 
they acquire which, as said before, can reflect tumor -promoting or tumor-suppression hallmarks. B 
cells, depending on the phenotype and the priming by other cell types (e.g. by myeloid derived 
suppressor cells (MDSCs) in the context of breast cancer324), are known to play pro-tumoral or anti-
tumoral effects. By exploring phenotypical surface markers of splenic B cells in rec-KitW-sh  tumor-
bearing mice (beyond the already mentioned PD-L1) higher FasL levels were detected (figure 45). 
This molecule is included among the markers associated with a “killing” phenotype of B cells in 
cancer259. Nevertheless, the phenotype of B cells that accumulate in the tumor and dLNs is our 
system is still an open question and an important perspective of the study.  
 
The take-home message from this work is on the one hand that a complex cross-talk is established 
between MCs and different B cell subtypes: MCs during an allergic IgE/Ag dependent activation may 
find a support in anatomical sites populated by innate B lymphocytes which provide exacerbating 
factors for the activation of MCs. On the other hand, concerning MC’s activation, the presence of 
this “sentinel” cell is important in conditions of acute insults, such as intestinal colitis and also in 
CRC formation. MCs-derived factors, upon appropriate and prompt activation, are known to be 
essential in the tissue repair during acute intestinal insults (e.g. through the action of MCPT-4233) 
and, as we propose in addition, they are essential partners for intestinal B cells sustenance in the 
production of mucosal protective IgAs. Moreover, during cancer development MC’s pro-
B cell
Key:
Activated MC CRCB-1 cell Tumor dLN ST2/IL-33 c-Kit/SCF CCR6/CCL20 CXCR5/CXCL13
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inflammatory mediators, by enhancing the expression of chemotactic  factors both in the tumor and 
in dLNs, are also indirectly responsible for B cells accumulation in tumoral sites. 
In conclusion, we hope that our study will provide new strategies to target the generally ignored 
“rheostatic” ability of MCs to range over activation to suppression of inflammation, which, if 
appropriately manipulated, could lead to new therapeutic approaches for human diseases such as 
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7. MATERIALS AND METHODS 
7.1. SOLUTIONS AND CULTURE MEDIA  
Wash medium  RPMI 1640 (Euroclone); 10% FBS (Sigma Aldrich); 20 mM Hepes (Euroclone); 
2 mM L-glutamine (Euroclone); antibiotics (100 U/ml penicillin and 100 
μg/ml streptomycin) (Euroclone) 
Complete culture medium 
for B cells and co-culture 
experiments 
RPMI 1640 (Euroclone); 10% FBS (Sigma Aldrich); 20 mM Hepes (Euroclone); 
2 mM L-glutamine (Euroclone); 1 mM sodium pyruvate (Euroclone); 1X non-
essential amino acids (from 100X mix, Euroclone); antibiotics (100 U/ml 
penicillin and 100 μg/ml streptomycin) (Euroclone); 50 mM β-
mercaptoethanol (Sigma Aldrich) 
Complete culture medium 
for BMMCs and PDMCs 
 
RPMI 1640 (Euroclone); 20% FBS (Sigma Aldrich); 20 mM Hepes (Euroclone) 
2 mM L-glutamine (Euroclone); 1 mM sodium pyruvate (Euroclone); 1X non-
essential amino acids (from 100X mix, Euroclone); antibiotics (100 U/ml 
penicillin and 100 μg/ml streptomycin) (Euroclone); 50 mM β-
mercaptoethanol (Sigma Aldrich); 20 ng/ml IL-3 (PeproTech); 20 ng/ml SCF 
(PeproTech)*      (*only for PDMCs cultures) 
Complete culture medium 
for MC-38, CT26, B16-F0, 
4T1 cell lines 
DMEM High Glucose (Euroclone); 10% FBS (Sigma Aldrich); 2 mM L-
glutamine (Euroclone); antibiotics (100 U/ml penicillin and 100 μg/ml 
streptomycin) (Euroclone) 
Phosphate Buffered Saline 
(PBS) pH 7.4 
137 mM NaCl (Sigma Aldrich); 27 mM KCl (Sigma Aldrich); 4.3 mM Na2HPO4 
(Sigma Aldrich); 1.4 mM KH2PO4 (Sigma Aldrich)  
MACS buffer  PBS pH 7.4; 2 mM EDTA (Sigma Aldrich); 0.5% BSA (Sigma Aldrich) 
Tyrode’s buffer 
pH 7.4 
10 mM HEPES buffer; 130 mM NaCl; 5 mM KCl; 1.4 mM CaCl2; 1mM MgCl2 
5.6 mM glucose; 0.1% BSA 
 
7.2 ANIMALS, CELL PREPARATION AND CULTURE CONDITIONS 
 
7.2.1 Mice and treatments 
C57BL/6 and BALB/c mice were purchased from Envigo (Netherlands) and maintained at the animal 
facility of the Department of Medical Area, University of Udine (Italy). TNF-α-/-, IL-6-/-, IL-33-/- femurs 
and tibiae were kindly gifted by Dr. Armaka M. (BSRC “Alexander Fleming”, Vari, Greece), Prof. 
Colombo M. (Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy), Prof.  Bulfone-Paus S. 
(University of Manchester, England), respectively. Experiments with BMMCs derived from CCL2-
eGFP transgenic mice and the study of B cells in KitW-sh and RMB mice in physiologic conditions and 
DSS-induced intestinal inflammation were performed in the laboratory of Prof. Blank U. (University 
Paris Diderot, faculty of Medicine, CRI, Paris, France) during the exchange period of my PhD. KitW-sh 
and BMMCs-reconstituted KitW-sh (rec-KitW-sh) MC-38 tumor-bearing mice were done in 
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collaboration with Dr. Jachetti E. (Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy). 
Organs from IκBNS-deficient bumble mice and their wt counterparts were kindly provided by Prof. 
Karlsson Hedestam G. (Karolinska Institutet, Stockholm, Sweden). 
Mice were maintained under pathogen-free conditions and all animal experiments were performed 
in accordance to institutional guidelines and national laws of respective institutes. 
8 weeks-old RMB mice were injected i.p. twice (2 days apart) with 1 μg DT (Merch Millipore) in PBS 
(control RMB mice were injected with PBS), and sacrificed 3 weeks after MC depletion (basophils 
were recovered at day 12 and mice were left one more week in conditions deprived of MCs before 
the sacrifice). Blood, spleen, peritoneum, LNs and colon were recollected and analysed. RMB mice 
were used for DSS-induced colitis experiments. 14 days after DT injections mice were administered 
2% DSS (molecular weight 36,000–50,000; MP BIOMEDICALS) in drinking water for 8 days. Body 
weight was daily monitored to follow disease course and clinical signs of disease (consistency of the 
stools and rectal bleeding) were  checked. At day 8 mice were sacrificed and organs were collected. 
To induce tumors, MC-38 cells (2 × 105) resuspended in sterile PBS were injected i.d. in C57BL/6 wt,  
KitW-sh or rec-KitW-sh mice flanks. Control mice were injected with sterile PBS. Within 4-5 weeks of 
inoculation, when tumors reached the size of 1x2 cm, mice were sacrificed and blood, spleen, 
peritoneum, LNs and tumors were collected for ex vivo analysis. 
 
7.2.2 Bone marrow-derived MCs differentiation, peritoneal-derived MCs expansion 
and reconstitution of KitW-sh mice 
BMMCs were obtained from 5- to 8-week-old female mice by in vitro differentiation of bone marrow 
derived progenitors obtained from mice femurs and tibiae. Precursor cells were cultured in 
complete culture medium for BMMCs at 37°C in 5% CO2 atmosphere. After 5 weeks, BMMCs 
differentiation was confirmed by flow cytometry. 
Peritoneal derived mast cells (PDMCs) were isolated from 5- to 8-week-old female mice and 
expanded in vitro. Ice cold PBS, supplemented with 3% fetal bovine serum (FBS) and antibiotics, was 
injected into mouse peritoneal cavity, the peritoneum was gently massaged to dislodge any 
attached cells into the PBS solution and fluid was collected. Cells suspension was centrifuged twice 
(300g for 10 min at 4°C) then pellet of cells was resuspended in complete culture medium for 
PDMCs. At day 3, non adherent cells were discarded and fresh medium was added to the flask; at 
day 10 suspension cells were analysed for purity by flow cytometry. Anti- FcεRIa and c-Kit 
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conjugated antibodies were used to assess MCs purity. BMMCs and PDMCs cultures were usually  
around 96-98 % c-Kit+ and FcεRIa+ cells as shown in figure 64. 
 
 
Figure 64: Purity of BMMCs and PDMCs. BMMCs and PDMCs are selected on FSC vs SSC plot and their 
positivity for FcԑRIa and c-Kit is shown in the dot plots below. 
 
KitW-sh mice were reconstituted with i.p. injection of 5x106 mature BMMCs resuspended in PBS 4 
weeks before their sacrifice (at the age of 11-12 weeks) for B cells analyses or the injection of MC-
38 cells (see paragraph 6.2.1). 
 
7.2.3. MCs degranulation assay 
Degranulation response was determined as the percentage of β-hexosaminidase released and used 
as a functional test for IgE/Ag-dependent MCs activation. 0.25x106 BMMCs were sensitized in 
complete RPMI medium for 3 hours with 1 µg/ml of dinitrophenol (DNP)-specific IgE, then washed 
twice, resuspended in Tyrode’s buffer with or without an equal amount of B cells and then 
challenged with 50, 10 or 1 ng/ml DNP (Sigma-Aldrich). The enzymatic activity of the released β-
hexosaminidase was assessed by the cleavage of its synthetic substrate (p-nitrophenyl N-acetyl- 
glucosamide, Sigma-Aldrich) in p-nitrophenol, measuring the p-nitrophenol absorbance at 405nm 
96,5% 98,7%
BMMCs PDMCs
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with a plate spectrophotometer. Results are expressed as the percentage of β-hexosaminidase 
released in the supernatant over β-hexosaminidase retained in the cytoplasm. 
Leukotrienes C4, D4 and E4 were measured in the same samples using a commercial detection kit (GE 
Healthcare) according to manufacturer’s instructions. 
 
7.2.4. B cells purification and culture 
Purified splenic and peritoneal cavity B cells were obtained from 8-to-12 week-old mice. Spleens 
were removed and mechanically dissociated in PBS supplemented with 0.0192 M sodium citrate 
through 70 µm-pore-size nylon filters. Splenocyte suspension was depleted of red blood cells (RBCs) 
by hypotonic lysis with ACK lysing buffer (Lonza). Peritoneal cells were collected by injecting ice cold 
PBS, supplemented with 3% FBS, into mouse peritoneal cavity. The peritoneum was gently 
massaged and fluid was collected. Cells pelleted and resuspended in MACS buffer and two different 
strategies of B cell purification were used, both based on magnetic-activated cell sorting.  
In the experiments in which B-2 and B-1 enriched B cell populations were co-cultured with MCs, a 
kit based on positive selection for CD19 marker, the CD19 MicroBeads mouse (Miltenyi, 130-052-
201) was used following manufacturer’s instructions. Purified splenic and peritoneal cavity B cells 
were cultured at the final concentration of 1x106 cell/mL in complete RPMI medium. 
Splenic B cells from KitW-sh, RMB and from MC38-tumor bearing mice were purified by negative 
selection through the use of the B cell isolation kit (Miltenyi, 130-090-862) following  manufacturer’s 
instructions. Purified splenic B cells were cultured at the final concentration of 1x106 cell/mL, in the 
presence or absence of 1 µg/mL anti-mouse CD40 mAb (BD Pharmigen), 10 µg/mL LPS (Sigma-
Aldrich) or 5 µg/mL CpG (Sigma-Aldrich). B cells are about 95-99% pure. 
 
7.2.5. Cell lines 
MC-38 colon adenocarcinoma cell line (C57BL/6 background) was kindly gifted by Prof. Bronte V. 
(University of Verona, Italy), these cells were used for in vitro and in vivo tumor experiments. 
C57BL/6 skin melanoma B16-F0 (ATCCR CRL-6475TM), BALB/c colon cancer CT26 (ATCCR CRL-2638TM), 
mouse breast tumor 4T1 (ATCCR CRL-2539TM) were used for in vitro experiments. All the cell lines 
were cultured in DMEM and Trypsin-EDTA 1x (Euroclone) was used for cell dissociation.  
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7.2.6. Isolation of LNs cells 
Single cell suspensions from LNs were obtained by mechanical dissociation of the organs in cold PBS 
supplemented of antibiotics through 70 µm-pore-size nylon filters. 
 
7.2.7. Isolation of tumor cells 
MC-38 tumors were collected and suspension cells were obtained by digesting the mass with 0.25 
mg/ml Collagenase type IV (Sigma-Aldrich) and 5 U/ml DNase (Roche) in RPMI supplemented with 
L-glutamine and antibiotics at 37°C and 5% CO2. FBS was added to stop the reaction after 30-45min. 
Cells, filtered through 70 µm-pore-size nylon filters, were resuspended in fresh complete RPMI 
medium and used for flow cytometry analysis or plated into cell culture multi-well plates in order to 
have 25% confluence for co-culture experiments. 
 
7.2.8. Co-cultures  
For all co-culture experiments with B cells, MCs were previously starved for 3h in complete RPMI 
medium in resting condition or sensitized with DNP-specific IgE. After 3h cells were washed twice 
and resuspended in fresh medium alone (for resting MCs) or with 100ng/ml DNP to challenge the 
cells. MCs were then put in culture in a 1:1 ratio with freshly purified B cells in cell culture multi-well 
plates (SARSTEDT), each cell type in a concentration of 1x106/ml. B cell conditions alone were 
included among the experimental conditions. Where indicated 2,5 µg/ml E18 Fab anti-CD28 Ab was 
used in the co-culture medium. 
When co-cultured with cancer cells, MCs were previously starved for 1h in complete medium, 
resuspended in fresh medium at 1x106/ml concentration and then added to the cell culture multi-
well plates. All the cancer-cell used, namely MC-38, adherent cells derived from MC-38 tumors, 
CT26, B16 or 4T1, were plated the day before at 25% of confluence. In some conditions 50 ng/ml IL-
33 (ImmunoTools) was added to the culture medium. 
Cells and supernatant were collected and analysed at different time points. 
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7.3. FLOW CYTOMETRIC ANALYSIS AND GATING STRATEGIES 
To assess cell-surface expression of different phenotypic and activation markers or co-stimulatory 
molecules, cultured cells were collected into polystyrene tubes (Sarstedt), washed and resuspended 
with PBS. After the addition of fluorescent mAbs, or Ig isotype-matched controls, cells were 
incubated in darkness for 30 minutes at 4°C. After the incubation, cells were washed with PBS and 
flow cytometry analysis were performed. FACSCalibur or FACSCanto flow cytometers (Becton 
Dickinson) were used for sample acquisitions.  A complete list of the antibodies used in this work 
are shown in table 6. 
 
Table 6. Antibodies used for immunophenotyping and gating strategies 
Specificity of Antibody Isotype Clone Conjugation Manufacturer 
CCR10  Rat IgG2b 248918 PE R&D systems 
CCR4 (CD194)  Armenian Hamster IgG 2G12 PE BioLegend  
CCR6 (CD196) Armenian Hamster IgG 29-2L17 PE BioLegend 
CCR7 (CD197)  Rat IgG2a 4B12 PE eBioscience 
CCR9 (CD199) Mouse IgG2a CW-1.2 PE BioLegend 
CD117 (c-Kit) Rat IgG2b ACK2 
FITC, PE-Cy7, 
APC BioLegend 
CD138 Rat IgG2a 281-2 PE BD Pharmigen 
CD19 Rat IgG2a 6D5 FITC, APC BioLegend 
CD1d Rat IgG2b 1B1 PE eBioscience 
CD21 Rat IgG2b 7G6 APC BD Pharmigen 
CD23 Rat IgG2a B3B4 PE BD Pharmigen 
CD28 Golden Syrian Hamster IgG 37.51 APC eBioscience 
CD30L Rat IgG2b RM153 PE eBioscience 
CD4 Rat IgG2a RM4-5 FITC BD Pharmigen 
CD40L (CD154) Hamster IgG MR-1 PE BioLegend 
CD45R (B220) Rat IgG2a RA3-6B2 APC, PE/Cy7 BioLegend 
CD45R (B220) Rat IgG2a RA3-6B2 PE/Cy7 BD Pharmigen 
CD5 Rat IgG2a 53-7.3 FITC BioLegend 
CD80 A. Hamster IgG 16-10A1 APC BioLegend 
CD86  Rat IgG2b PO3 APC BioLegend 
CXCR4 (CD184) Rat IgG2b L276F12 APC BioLegend 
CXCR5 (CD185) Rat IgG2a SPRCL5 PE eBioscience 
FasL Hamster IgG MFL3 APC eBioscience 
FcεRIa Hamster IgG mar-01 PE BioLegend 
ICAM-I Rat IgG2b YN/1.7.4 FITC eBioscience 
IgA Rat IgG1 C10-3 FITC BD Pharmigen 
IL-6 Rat IgG1 MP5-20F3 PE eBioscience 
LAMP-1 (CD107a)   Rat IgG2a 1D4B APC BioLegend 
MHC-II Rat IgG2b M5/114.15.2 PE BioLegend 
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OX40L Rat IgG2b RM134L PE BioLegend 
PD-1 Rat IgG2a 29F.1A12 PE BioLegend 
PD-L1 Rat IgG2a 10F.9G2 PE eBioscience 
ST2  Rat IgG2a RMST2-2 APC eBioscience 
TLR2 Rat IgG2b 6C2 PE eBioscience 
TLR4 Rat IgG2a MTS510 PE-Cy7 BioLegend 
TNF-α Rat IgG1 MP6-XT22   PE BD Pharmingen 
Isotypes controls   Clone Conjugation Manufacturer 
Rat IgG1   11-430182 FITC eBioscience 
A. Hamster IgG   400907 PE BioLegend 
Mouse IgG1   11-4714-81 FITC eBiosciences 
Rat IgG1   17-4301 APC eBioscience 
Rat IgG2a   400505 FITC BioLegend 
Rat IgG2a   400508 PE BioLegend 
Rat IgG2a   400509 PE-Cy5 BioLegend 
Rat IgG2b   400633 FITC BioLegend 
Rat IgG2b   12 4031 PE eBioscences 
Rat IgG2b   400611 APC BioLegend 




7.3.1. Co-cultures experiments 
Double staining strategies were used to discriminate the two different cell types in MCs-B cells co-
cultures: anti- c-Kit or -CD19 mAbs were used to distinguish MCs and B cells respectively, as shown 
in figure 65. In MCs-cancer cells co-cultures, suspension cells were collected and analyses were 
performed on c-Kit+ cells. 
 




Figure 65: Examples of gating strategies used for flow cytometry analysis in MCs-B cells co-cultures. (A) 
BMMCs were first gated in the FSC vs SSC plot. Cells are further selected for c-Kit positivity (right panels) 
and on these gated cells, second membrane markers were analysed. (B) B cells were gated in the FSC vs 
















                                                                                                                                       Materials and Methods 
148 
 
7.3.2. Splenic B cells subsets 
Murine splenic B cells are heterogeneous and different subsets can be identified by the differential 
expression of membrane markers. The anti- CD19, CD21 and CD23 mAbs staining was used for the 
identification of three main naïve splenic B cells subsets: the newly formed B cells (NF), the follicular 
(FO) and the marginal zone (MZ) B cells325. In addition, transitional 2-marginal zone precursor (T2-
MZP) B cell, that are CD21hiCD23hi, were identified.326. Furthermore MZ B cells are also characterized 
by the high expression of CD1d molecule. The triple staining anti- CD19, CD5 and CD1d mAbs was 
used to better identify other splenic phenotypes such as CD1d+CD5+ B10 cells327. All these subsets 




Figure 66: Examples of gating strategies used for splenic B cell subsets: B cells are first gated as CD19+ 
cells among total splenocytes. Splenic B cells are further gated based on the anti-  CD21 and CD23 staining 
in the following phenotypes: newly formed (NF), CD21low, transitional 2-marginal zone precursor (T2-MZP), 
marginal zone (MZ) and follicular (FO) cells (A); the anti- CD5 and CD1d staining was used to sub-divide B 














































7.3.3. Peritoneal cavity B cell subsets 
Peritoneal cavity B cells can be classified into several phenotypical and functional B cell subsets. The 
CD19+ population contains the minor fraction of B-2 cells that is distinguished from the B-1 subset 
by the expression of CD23. On the contrary, the expression of CD5 by B-1a cells helps to discriminate 
them from  B-1b cells 328.  The gating strategy used in our analyses is shown in the figure 67. 
 
Figure 67: Examples of gating strategies used for peritoneal B cell subsets: B cells are first gated as CD19+ 
cells among total peritoneal cells. B cells are further selected based on the anti-  CD5 and CD23 staining. 
Among the CD23- and CD23+CD5- cells B-1a, B-1b and B-2cells are identified as shown in the panel on the 
right (the analyses reported in result sections are percentages of B-1a, B-1b and B-2 cells and the total of 
the three is 100%). 
 
7.3.4. B cell viability 
Annexin V and Propidium Iodide (PI) staining approach (Annexin V-FITC Apoptosis Detection kit, 
eBiosciences) was used to determine the percentages of viable purified splenic or peritoneal cavity 
B cells at 48h of cultures alone in resting condition, in co-culture with MCs or upon anti-CD40, LPS 
or CpG stimulation. Annexin V marks cells undergoing apoptosis, dead cells instead are permeable 
and highly positive for PI, since they lose membrane integrity. An example of the gating strategy 






















Figure 68: Strategies used for assess B cell viability in co-culture with MCs: 48h cultures between BMMCs 
and splenic (upper panels) or peritoneal cavity (lower panels) B cells were established. Cells were stained 
for anti-CD19 Ab followed by Annexin V/P.I. staining. B cells were first discriminated from MCs by the SSC 
vs CD19 density plot. In selected cells, viable population is determined for double negativity of both P.I. 
and Annexin V staining. 
 
7.3.5. B cell proliferation 
In order to study B cell proliferation, distinct generations of proliferating cells were determined by 
dye dilution. To evaluate the contribution of BMMCs in promoting B cells’ proliferation, freshly 
purified splenic or peritoneal cavity B cells were stained with carboxyfluorescein succinimidyl ester 
(CFSE) (Molecular Probes, Invitrogen) following manufacturer’s instruction, then were resuspended 
in fresh complete medium and cultured alone or with MCs for 72h. To assess the proliferation of 
KitW-sh and RMB mice, freshly purified B lymphocytes were stained with CellTrace Violet Cell 
Proliferation Kit (ThermoFisher) following manufacturer’s instruction and cell  proliferation was 
analyzed by flow cytometry at 72h. The anti-CD19 conjugated Ab was used as additional B cell 





















Figure 69: Strategies used to assess B cell proliferation: (A) after 72h of co-culture between CFSE-stained 
splenic (upper panels) or peritoneal cavity (lower panels) B cells and BMMCs, cells were stained for anti-
CD19 mAb. B cells were first discriminated from MCs in the FCS vs SSC scatter plot and for CD19 positivity. 
Proliferated B cell population is determined by CFSE dilution. (B) Purified splenic B cells from a RMB mouse 
were stained with CellTrace Violet Cell Proliferation dye and cultured in resting condition (//) or stimulated 
with aCD40 mAb, LPS or CpG for 72h. Cells were then stained for anti-CD19 mAb and proliferated cells 
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7.3.6. Intracellular staining (ICS) 
0.25x106 resting or IgE/Ag stimulated BMMCs are stained for intracellular TNF-α after 1 hour of co-
culture with splenic and peritoneal cavity B cells in in the presence of Brefeldin A (eBioscience, 1000x 
solution). In order to discriminate viable from dead cells, the suspensions were stained with 
CellTraceTM Violet Cell Proliferation Kit (ThermoFisher SCIENTIFIC). They were then washed with PBS 
and incubated for 30 minutes with c-Kit mAb. Then cells were washed and fixed with 250 µl of 
Cytofix/Cytoperm cell fixation buffer (BD Biosciences) for 20 minutes and, at the end of the 
incubation, cells were washed two times with the Perm/Wash buffer for cell permeabilization (BD 
Biosciences). Sequentially, Fc Block antibody was added to avoid non-antigen-specific binding. After 
being washed, the cells were stained with Perm/Wash buffer containing anti-TNF-α mAb or Isotype 
control Ab and incubated for 30 minutes. 
Finally, cells were washed twice with Perm/Wash buffer and analysed by flow cytometry.  
For intracellular IL-6 detection in MC-38 cells cultured alone or in the presence of BMMCs, after 1h 
of co-culture, Brefeldin A was added overnight to the culture medium that intracellular staining was 
performed. In these analysis, Live/Dead Fixable Green Dead Cell Stain Probe (Molecular Probes, 
Invitrogen, 1:750) were used to discriminate viable from necrotic cells. A similar procedure has been 
followed with the addition of anti- c-kit and IL-6 mAb respectively as extra-cellular and intra-cellular 
markers. 
 
7.4. QUANTIFICATION OF SECRETED MEDIATORS 
Sera samples or cell supernatants for cytokine and antibody quantification were analysed by 
sandwich-based ELISA techniques for the detection of soluble mediators.  
We used mouse IL-1β, IL-4, IL-5, IL-6, IL-10, IL-13, IL-33 TNF-α, CXCL13 and IgM (eBiosciences), MIP-
3 alpha (CCL20) and SCF (RayBiotech), CCL2 (PeproTech) specific ELISA kits according to 
manufacturer’s instructions.  
For IgG and IgA a home-made sandwich ELISA was developed. 96-well flat-bottom polystyrene 
plates (Corning) were coated with affinity-purified anti-mouse IgA (SouthernBiotech) or anti-mouse 
IgG (Sigma-Aldrich) Abs at the final concentration of 2 mg/mL and 10 mg/mL, respectively. After 1 
h incubation at 37°C, plates were washed with 0.05% Tween-20 in PBS and blocked with 1% bovine 
serum albumin in PBS for 1 h at RT. 100 mL of cell supernatants or of opportunely diluted mouse 
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sera were added to Ab-coated wells. Purified mouse IgA (BD PharMingen) or IgG (Sigma-Aldrich) 
were used as  standards. After o/n incubation at 4°C, the plates were washed and optimal 
concentration of horseradish peroxidase-conjugated goat anti-mouse IgA (SouthernBiotech; 
1:2000) or goat anti-mouse IgG (Pierce; 1:1000) Abs were added. Next, the plates were incubated 
for 1 h at RT and washed before the addition of tetramethylbenzidine (TMB) substrate solution 
(Sigma-Aldrich). The reaction was stopped with 2 mol/L sulfuric acid and absorbance was measured 
at 450 nm. 
 
7.5. RNA EXTRACTION AND RT-QPCR ANALYSES  
Cells were lysed with EUROGOLD TriFast (Euroclone) and total RNA was extracted with the phenol-
chloroform protocol according to manufacturer’s instructions. Total RNA was quantified using a 
NanoDropTM spectrophotometer (ThermoFischer) and 1µg was reverse transcribed with the 
SensiFASTTM  cDNA Synthesis Kit (Bioline). RT-qPCR analyses were performed with SYBR Green 
chemistry (iQTM SYBR Green Super Mix, BioRad) using a BioRad CFX96 real-time PCR detection 
systems. Target genes expression was quantified using G3PDH (glyceraldehyde 3-phosphate 
dehydrogenase) as normalizer gene. Primers (Sigma Aldrich) used for RT-qPCR are listed in the table 
7. 
               Table 7: Primers used in real-time PCR 
 
Target gene Forward primer Reverse primer 
g3pdh TCAACAGCAACTCCCACTCTTCCA ACCCTGTTGCTGTAGCCGTATTCA 
ccl2 AGCAGGTGCCCCAAAGAAGCTGTA AAAGGTGCTGAAGACCTTAGGGCA 
ccl5 TGCTGCCCACGTCAAGGAGTATTT TCTTCTCTGGGTTGGCACACACTT 
cxcl12 GGTAGCTCAGGCTGACTGGT TCCTCTTGCTGTCCAGCTCT 
cxcl13 CATAGATCGGATTCAAGTTACGCC TCTTGGTCCAGATCACAACTTCA 
ccl19 CTGTGGCCTGCCTCAGATTA GTGTGGTGAACACAACAGCA 
ccl20 TGCTATCATCTTTCACACGAAGAA TCATTTCCTCCTTGGGCTGT 
ccl21 ATCCCGGCAATCCTGTTCTC TTCTCTTGCAGCCCTTGGAG 
ccl25 CCGGCATGCTAGGAATTATCA GGCACTCCTCACGCTTGTACT 
ccl28 AGACACCTCAGTGCAACAGC TCACCTGAGTCATTGCCAGA 
il-33 CTACTGCATGAGACTCCGTTCTG AGAATCCCGTGGATAGGCAGAG 
aid AAGTCACGCTGGAGACCGAT AGGTAGGTCTCATGCCGTCC 
 
 
7.6. IMMUNOHISTOCHEMISTRY ANALYSIS  
Histologic analyses were carried out on paraffin-embedded tissues. For immunohistochemical 
analyses four-micrometers-thick tissue sections were deparaffinized and rehydrated.  
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Murine samples from Wt and bumble mice were stained with Hematoxylin & Eosin or with Toluidine 
Blue stain to determine MC distribution and frequency; MCs were counted in five nonoverlapping 
high-power microscopic fields (×400) and results were expressed as average. 
Murine colon samples were incubated with the following primary antibody at room temperature: 
Goat Anti-Mouse IgA alpha chain (HRP-Conjugated), (diluition 1/400, pH9,  ab97235 abcam). The 
binding of the primary antibody was revealed by AEC (Dako 3-amino-9-ethylcarbazole) substrate-
chromogen, following manufacturer’s instruction. 
Double marker immunohistochemistry was performed by two consecutive rounds of single-marker. 
The murine tumor samples were incubated, by sequential immunostaining, with primary antibodies 
against Rat anti-mouse CD45R (RA3-6B2 1/10 pH9, BD Pharmigen) revealed by goat anti-rat IgG 
(H+L) specific secondary antibody (diluition 1/500 Novex by Life Technologies and DAB 3,3'-
Diaminobenzidine Leica Biosystems), substrate-chromogen. After Fc blocking the slides were 
incubated with the second primary antibody Mast Cell Tryptase  (EPR 8476, diluition 1:500, pH6, 
ab134932). The binding of the second primary antibody was revealed by Multilink Alk. Phos. 
Detection System (Biogenex) and Vulcan Fast Red (Biocare Medical) substrate-chromogen kit, 
following manufacturer’s instruction. The slides were counterstained with Harris Hematoxylin 
(Novocastra).  
All the sections were analysed under an AXIO Scope A1 optical microscope (ZEISS) and 
microphotographs were collected using an Axiocam 503 Color digital camera (Zeiss).  
 
7.7. FLUORESCENCE MICROSCOPY  
Resting or 3h IgE-stimulated CCL2-eGFP BMMCs in complete RPMI medium were washed twice with 
PBS, resuspended in fresh medium (0.5x106/ml) supplemented with MnCl2 and plated into 
microscope 8-chamber slides (Lab-TekR) that were coated o/n with 10 µg/ml fibronectin (Sigma 
Aldrich). 15 min later Brefeldin A (BFA) (eBioscience, 1000x solution) was added to the medium and 
the chamber was placed on a 37°C pre-warmed heating plate, and controlled 5% CO2. After 15 
additional minutes, 100ng/ml DNP and an equal number of freshly splenic and peritoneal cavity 
purified B cells were added in the slide. Phase-contrast images were recorded at the indicated time 
points within 5h of co-culture with in an inverted fluorescent microscope (Zeiss). Images were 
analysed by means of the ZEN software. 




7.8. STATISTICAL ANALYSIS  
In all experiments results are expressed as mean (+± SEM) of the indicated numbers of independent 
experiments. According to the number and type of groups in the analyses, 2-tailed paired or 
unpaired Student’s t test, or one-way ANOVA with the Bonferroni correction as post-hoc analysis, 
were done to asses statistical significance with the GraphPad Prism 5 Software. A confidence level 
of 95% was used. *=p<0.05, **=p<0.01, ***=p<0.001. 
 
 





Animal models are used as potent predictors of human responses. However, it is fundamental to 
correlate data derived from animal studies with information about human to corroborate the most 
important elements of the model.  
Using the algorithm CIBERSORT329, relative proportions of 22 immune cells (LM22 signature) were 
determined on two different transcriptional profiles datasets (GSE87211 and GSE107499). Detailed 
information of immune cells are listed in table 8. In figure 70A-B immune cells infiltrating the colon 
of patients suffering from UC are reported: the non-inflamed intestine signature was compared with 
the one of the inflamed tissue. Figure 70C-D analyse CRC patients comparing normal mucosa with 
the cancerous one. The first observation is that resting MCs infiltrating “normal” tissues became 
almost totally activated in inflammation and cancer. Naïve and memory B cells and differentiated 
PCs are also highly represented in the intestinal mucosa. Differently from MCs, these three 
populations are expanded in UC patients while are less depicted in cancer. This last result is in 
accordance with our previous data in which we showed accumulation of IgA+ PCs in areas of low 
grade dysplasia and an extrusion of these cells from the adenoma263. Considering the relative 
relation between MC and PCs cells, in healthy portions of the colon there is an inverted correlation 
between activated MCs density and PCs. In UC tissues instead, the increase of activated MCs 
positively correlates with the increase of PCs. The trend is exactly the opposite in CRC, where the 
increase of MCs is followed by a decrease of PCs. This trend, according to the p value of the 
Spearman correlation, is also strongly statistically significant.  
We can speculate that in patients suffering from acute inflammation, as we observed in our DSS 
mouse model, activated MCs are important for the expansion of IgA+ PCs. In tumor condition, MCs 
expand and became activated and this may reflect in the accumulation of B cells in LNs directly 
draining the tumor where these cells can exert or immune-suppressive functions or promote 
immune-surveillance.  




Figure 70: Relative proportions of 22 immune cell types in UC and CRC. Relative proportions of 22 immune 
cells determined on their gene expression profile in biopsies from UC (A) and CRC (C) patients. The 
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Finally, with the aim of exploring the possibility whether CCL20 and CXCL13 are overexpressed in 
tumor dLNs also in human CRC, we used the GEO2R tool to compare the expression level of two cell 
lines derived from primary and metastatic CRC tumor cells (SW480 and SW620 cell lines). We chose 
this cell line pair as an accepted model for analyses concerning of CRC progression330. Interestingly, 
the expression of the two chemokines is higher in metastatic tumor cells, indicating that these two 
factors increase along with the progress of the tumor (figure71). This data suggests the importance 
of these two chemokines in the CRC setting and indicates that they can be considered important 
factors for the recruitment of B cells in metastatic CRC also in men. 
 
 
Figure 71: CCL20 and CXCL13 are more expressed in LNs metastasis compared to primary CRC tumor. 
CCL20 and CXLC13 expression was determined on GSE89523 dataset by using the GEO2R web tool, 
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Table 8: Methods used for the determination of immune infiltrates 
 
 
LM22 Cells Cell Type 
Description 
Cell Separation Method Markers used Purity 
B cells 
B cells naive 







MACS® CD138 microbeads and CD19 
microbeads, then FACS 
CD19+ CD27+ Not stated 




CD8 T T cells CD8 





CD4 T cells 
T cells CD4 
naive 
Ficoll, then MACS CD4+ T cell isolation kit CD4+ >98% 
T cells CD4 
memory 
resting 
Ficoll, then FACS CD45ROhigh Not stated 
T cells CD4 
memory  
activated 
Ficoll, then FACS, then activated by anti-CD3 
(plate-bound) + anti-CD28 (soluble) 
CD45ROhigh; 






Ficoll, then MACS CD4+ T cell isolation kit, then 
FACS 




Ficoll-Hypaque, then MACS CD4+ T cell 
isolation kit, then FACS 









RosetteSep™ NK-cell enrichment cocktail + 
CD2 Microbeads 
CD56 Not stated 
NK cells 
activated 
RosetteSep™ NK-cell enrichment cocktail + 
CD2 Microbeads + IL2 or IL15 for activation 




Monocytes MACS® CD14 Microbeads, monocyte subset N/A Not stated 
Macrophages 
M0 









Histopaque 1.077, then Miltenyi negative 
selection monocyte isolation kit and LS 
columns, then differentiated with 1% medium 
supplement nutridoma-HU + 100 nM M-CSF, 












Histopaque 1.077, then Miltenyi negative 
selection monocyte isolation kit and LS 
columns, then differentiated with 1% medium 
supplement nutridoma-HU + 100 nM M-CSF, 
then activated with 20 ng/ml IFN-g+ 100 ng/ml 




















Monocytes differentiated with 17 ng/ml IL4, 
and 67 ng/ml GMCSF 




Monocytes differentiated with 17 ng/ml IL4, 
and 67 ng/ml GMCSF, then stimulated with 1 
ug/ml LPS 




Ficoll of cord blood, then 100 ng/ml SCF + 10 




Ficoll of cord blood, then 100 ng/ml SCF + 10 
ng/ml IL-10 + 5 ng/ml IL-6 + IgE receptor 
activation 
N/A   
Eos Eosinophils 
0.6% Dextran T500, then Percoll gradient (70%, 




0.6% Dextran T500, then Percoll gradient (70%, 
80%), then negative selection with MACS anti-
CCR3 + anti-mouse IgG Microbeads 
CD62L >97% 
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